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ABSTRACT 
iNKT cells are a population of T cells with unique characteristics. In contrast to most αβ 
T cells which recognize peptides presented by highly polymorphic MHC molecules, 
iNKT cells are reactive to glycolipids presented by CD1d, a non-polymorphic MHC-I 
like molecule. Moreover, whereas MHC-restricted αβ T cells bear highly variable 
receptors (TCRs) formed after somatic recombination of the V(D)J gene segments, the 
TCR of iNKT cells is formed by an invariant α chain, which always contains the same 
gene segments: AV14 and AJ18; and a β chain of limited BV gene usage: BV8S2, BV7 
or BV2, in the mouse. This invariant α chain is the reason for which these cells are 
named “i” and the NK part of their name refers to the expression of receptors typical of 
natural killer (NK) cells. iNKT cells recognize glycolipids of endogenous and microbial 
origin. After activation they secrete large amounts of very different cytokines such as 
IFN-γ and IL-4 and thus influence immune responses and pathological conditions. One 
of the most potent iNKT cell agonists, recognized by the semi-invariant TCR, is the 
synthetic glycolipid α-Galactosylceramide (α-Gal). iNKT cells can be visualized using 
CD1d-multimeric complexes loaded with α-Gal and flow cytometry, since this reagent 
has enough avidity to stain these cells. Interestingly, mouse iNKT cells can be stained 
with human α-Gal-loaded CD1d oligomers and human iNKT cells can also be 
visualized with mouse α-Gal-loaded CD1d oligomers, indicating a high degree of 
conservation of the recognition of α-Gal presented by CD1d through evolution.  
Previous studies showed that rats have the genes necessary to build semi-invariant 
TCRs: They have a CD1d homologue; one or two BV8S2 homologues and 
interestingly, up to ten AV14 gene segments, which are highly conserved when 
compared to the mouse genes. Importantly, it has been shown at least for two of these 
AV14 gene segments that they can produce invariant TCRα chains which, when co-
expressed with BV8-containing β chains, react to α-Gal presented by rat CD1d. 
Furthermore, ex vivo stimulation of primary splenocytes with α-Gal results in the 
secretion of IL-4 and IFN-γ. Surprisingly, rat semi-invariant TCRs do not recognize α-
Gal presented by mouse CD1d and accordingly, mouse α-Gal-loaded CD1d tetramers 
failed to stain a discrete population of rat iNKT cells. Taking all together, despite that 
strong evidence suggested that iNKT cells are present in the rat, the direct identification 
of such population and the analysis of CD1d-restricted immune responses were still 
pending for this species. Hence the work presented in this doctoral thesis was aimed to 
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identify iNKT cells, to analyze their phenotype and also to study the distribution and 
function of CD1d in the rat. For these purposes, we produced essential reagents which 
were still lacking such as rat specific anti-CD1d monoclonal antibodies and rat CD1d 
oligomers. 
Importantly, two of three anti-rat CD1d monoclonal antibodies (all of them generated in 
our laboratory before this thesis was initiated) also recognized mouse CD1d and 
therefore allowed a direct comparison of CD1d expression between rat and mouse. 
Whereas CD1d distribution in the hematopoietic system was found to be extremely 
similar between these two species; in non-lymphatic tissues important differences were 
observed. Interestingly, CD1d protein was detected at not yet described sites such as the 
rat exocrine pancreas and rat and mouse Paneth cells. These monoclonal antibodies did 
not only allowed the analysis of CD1d expression, but also the first demonstration of the 
function of rat CD1d as an antigen presenting molecule, since cytokine release in 
response to α-Gal was blocked when they were added to ex vivo cultures of rat primary 
cells.  
Staining of primary rat iNKT cells (possible now with the newly generated rat CD1d 
oligomers) revealed interesting similarities with human iNKT cells. First, we observed 
that rat iNKT cells are only a minority among all NKR-P1A/B positive T cells. Human 
iNKT cells constitute also a very small proportion of NKR-P1A (CD161) expressing T 
cells, whereas in mice inbred strains which express NKR-P1C (NK1.1), most of NKR-
P1C expressing T cells are iNKT cells. Second, the majority of rat iNKT cells are either 
CD4 or DN and only a small proportion expresses CD8β. These findings are similar to 
humans and different to mice which lack CD8+ iNKT cells. Third, analysis of various 
inbred rat strains demonstrated different iNKT cell frequencies which correlated with 
cytokine secretion after α-Gal stimulation of primary cells. In comparison to mice, 
iNKT cell numbers are markedly reduced in rats. In F344 rats, inbred rat strain which 
released the highest cytokine amounts after α-Gal stimulation, approximately 0.25% and 
0.1% of total liver and spleen lymphocytes, respectively, are iNKT cells. In contrast, in 
LEW rats iNKT cells were practically absent and neither IL-4 nor IFN-γ were detected 
after stimulation of primary cells with α-Gal. Once more, these frequencies are very 
close to those observed in humans. Last, as reported for human peripheral blood cells, 
rat iNKT cells could be easily expanded in vitro by adding α-Gal to cultures of 
intrahepatic lymphocytes, whereas the expansion of mouse iNKT cells was not possible 
using the same protocol.    
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The presence of a multimember AV14 gene segment family in the rat is an intriguing 
characteristic. These AV14 gene segments are extremely homologous except in the 
CDR2α region. Based on the amino acid sequence of this region they have been divided 
into two different types: Type I and II. A specific tissue distribution of the different 
types was proposed in the first study where the presence of several AV14 gene 
segments was described. We also analyzed the AV14 gene segment usage in F344 and 
LEW inbred rat strains. In F344 rats we found no preferential usage of either AV14 
gene segment type in the spleen and the liver but type II AV14 gene segments appeared 
more frequently in the thymus. In contrast, LEW rats show a preferential usage of type I 
AV14 gene segments in all three compartments analyzed: Thymus, spleen and liver.  
Taken all together, the usage of newly generated reagents allowed to gain novel insights 
into CD1d expression in the rat and in the mouse and to directly identify rat iNKT cells 
for the first time. The phenotypic and functional analysis of rat iNKT cells revealed 
numerous similarities with human iNKT cells. These are of special interest, since rats 
serve to investigate several pathological conditions including models for autoimmune 
diseases. The possibility now to analyze iNKT cells and CD1d-restricted T cell 
responses in the rat might help to understand the pathogenesis of such diseases. In 
addition, the uncomplicated in vitro expansion and culture of rat iNKT cells should 
facilitate the analysis of the immunomoldulatory capacities of these cells.  
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ZUSAMMENFASSUNG 
iNKT Zellen sind eine Population von T Zellen mit einigen Besonderheiten. Anders als 
die meisten αβ T Zellen, deren T Zell Rezeptoren (TZRs) für von hochpolymorphen 
MHC Molekülen präsentierte Peptide spezifisch sind, erkennen iNKT Zellen 
Glycolipide die von CD1d, einem nicht polymorphem MHC-I artigen Moleküle, 
präsentiert werden. Während MHC-restringierte αβ T Zellen sehr unterschiedliche 
TZRs haben, die nach somatischer Rekombination der V(D)J Gensegmente generiert 
werden, besteht der TZR der iNKT Zellen aus einer invarianten α Kette und einer β 
Kette mit einem limitierten BV Gen Repertoire (BV8S2, BV7 und BV2 in Maus). Die 
invariante α Kette, auf die das i im Namen der iNKT Zellen verweist, enthält in der 
Maus immer AV14 und AJ18 kodierte V-Regionen. Das NK in ihrem Namen verweist 
darauf, dass sie häufig NK-Zell typische Oberflächenmoleküle exprimieren. iNKT 
Zellen erkennen Glycolipide endogenen und mikrobiellen Ursprungs und sezernieren 
nach Aktivierung große Mengen verschiedener Zytokine wie zum Beispiel IL-4 und 
IFN-γ. Auf diese Weise beeinflussen sie Immunantwort und pathologische Zustände. 
Eine der potentesten iNKT-Zell-TZR Agonisten ist das α-Galactosylceramid (α-Gal) 
und α-Gal beladene CD1d-Multimere ermöglichen es iNKT Zellen zu färben und 
mittels Durchflusszytometrie sichtbar zu machen. Die hohe Konservierung der iNKT 
TZR-CD1d Interaktion ermöglicht es sogar, Maus iNKT Zellen mittels α-Gal beladenen 
humanen CD1d-Multimere zu färben. 
Vorhergehende Studien zeigten, dass Ratten die notwendigen Gene für die Generierung 
der semi-invarianten TZR haben: Sie besitzen ein CD1d Homolog, ein oder zwei 
BV8S2 Homologe und bis zu zehn AV14 Gensegmente, die im Vergleich zu den Maus-
AV14 Genen hoch konserviert sind. Mehrere dieser AV14 Gensegmenten wurden mit 
AJ18 zusammen rearrangiert gefunden und für mindestens zwei dieser invarianten α 
Ketten wurde gezeigt, dass sie zusammen mit BV8 enthaltenden β Ketten TZR bilden, 
die von CD1d präsentiertes α-Gal erkennen. Weiterhin wurde gezeigt, dass primäre 
Ratten- Milzzellen und intrahepatische Lymphozyten nach Kultur mit α-Gal IL-4 und 
IFN-γ sezernieren. Auf Grund dieser Befunde und der starken Konservierung der CD1d 
Gene und der Gene, die die semi-invarianten TZR kodieren, überrascht es, dass keine 
definierte Zellpopulation von intrahepatischen Rattenlymphozyten mittels α-Gal 
beladenen Maus CD1d-Tetrameren gefärbt wurde. Zusammengefasst kann gesagt 
werden, dass die direkte Identifizierung der Zellen und die Analyse der CD1d-
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restringierten Immunantworten in der Ratten noch austand, obwohl es starke Hinweise 
für die Existenz der iNKT Zellen in dieser Art gab. Infolgedessen sind die Ziele dieser 
Arbeit: die Identifizierung der Ratten iNKT Zellen, die Analyse ihres Phänotyps und die 
Untersuchung der CD1d-restringierten Immunantworten. Um diese Ziele zu erreichen, 
wurden noch fehlende essentielle Reagenzien hergestellt, wie die ersten Ratten-CD1d 
spezifischen monoklonalen Antikörper und Ratten CD1d Oligomere.  
Zwei der drei charakterisierten monoklonalen Antikörpern erkennen sowohl Ratten 
CD1d als auch Maus CD1d. Dies ermöglichte den direkten Vergleich der CD1d 
Expression zwischen beiden Spezies (diese Antikörper wurden in unserem Labor vor 
dem Anfang dieser Doktorarbeit hergestellt). Während die CD1d Verteilung im 
hämatopoetischen System beider Arten äußerst ähnlich ist, wurden in nicht 
lymphatischen Geweben sehr starke Unterschiede gefunden. Interessanterweise wurde 
das CD1d Protein auch an noch nicht beschriebenen Stellen wie im exokrinen Pankreas 
der Ratte und in Paneth Zellen von Maus und Ratte beobachtet. Die monoklonalen 
Antikörper erlaubten nicht nur die Analyse der CD1d Verteilung, sondern auch den 
Beweis der Funktion von CD1d als Antigen präsentierendes Molekül, weil die Zugabe 
der Antikörper zu ex vivo Kulturen von primären Zellen die Sekretion von Zytokinen 
bei der Stimulation mit α-Gal hemmt.   
Färbungen von primären Ratten iNKT Zellen, jetzt möglich durch die neu generierte 
Ratten CD1d-Dimere, zeigten interessante Gemeinsamkeiten mit humanen iNKT 
Zellen. Es wurde erstens beobachtet, dass Ratten iNKT Zellen nur eine Minderheit unter 
allen NKR-P1A/B positiven T Zellen sind. Dies ähnelt den humanen iNKT Zellen, die 
ebenfalls auch nur ein sehr kleinen Teil der NKR-P1A (CD161) exprimierenden T 
Zellen stellen, während in Mausstämmen, die NKR-P1C (NK1.1) exprimieren, die 
Mehrheit der NKR-P1C positiven T Zellen iNKT Zellen sind. Zweitens sind die meisten 
Ratten iNKT Zellen CD4 positiv oder doppelt negativ während nur ein kleiner Anteil 
CD8β exprimiert. Diese Befunde gleichen denen mit humanen iNKTs und 
unterscheiden sich von Maus iNKTs, die immer CD8β negativ sind. Drittens zeigt die 
Analyse von verschiedenen Rattenstämmen, ähnlich wie beim Menschen, 10-100 fach 
geringere Frequenzen von iNKT Zellen als in der Maus. In F344 Ratten sind etwa 
0.25% aller Lymphozyten in der Leber und etwa 0.1% aller Milzzellen iNKT Zellen. 
Wobei dies der Rattenstamm ist, der die größte Mengen an Zytokinen nach α-Gal 
Stimulation produziert. In LEW Ratten, die keine Zytokine nach α-Gal Stimulation 
produzierten, konnten iNKT Zellen praktisch nicht gefärbt werden. Schließlich konnten, 
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wie bei humanen peripherischen Blutzellen beobachtet, Ratten iNKT Zellen durch 
alleinige Zugabe von α-Gal in vitro expandiert werden, während dies mit Maus iNKT 
Zellen nicht möglich war. 
Eine faszinierende bislang nur in der Ratte gemachte Beobachtung ist die Existenz einer 
AV14 Multigenfamilie, deren Mitglieder bis auf die CDR2 kodierende Region 
hochhomolog sind. Basiert auf der Aminosäuresequenz dieser Region wurde diese 
Familie in zwei Gruppen aufgeteilt: Typ I und II. Die erste Studie, in der diese zwei 
verschiedenen Typen beschrieben wurden, schlug eine spezifische Gewebsverteilung 
von AV14 positiven TCR vor. Wir haben ebenfalls die Benutzung dieser AV14 Gene in 
F344 und LEW Inzuchtrattenstämmen analysiert und gefunden, dass es in F344 Leber 
und Milz keine Präferenz für einen bestimmten AV14 Typ gibt. Jedoch wurde der Typ 
II häufiger in F344 Thymus gefunden. Im Vergleich zeigen LEW Ratten eine 
bevorzugte Benutzung des Typ I in allen analysierten Geweben (Thymus, Milz und 
Leber).  
Zusammengefasst kann gesagt werden, dass diese Studie mit Hilfe neu generierter 
Reaganzien neue Erkenntnisse zur CD1d Expression in Ratte und Maus gewonnen 
wurden und erstmals eine direkte phänotypische und funktionelle Analyse von iNKT 
Zellen der Ratte durchgeführt wurde. Es wurden eine Reihe von Gemeinsamkeiten 
zwischen iNKT Zellen von Ratte und Mensch gefunden. Diese sind vor allem deshalb 
von Interesse, da das Versuchstier Ratte für eine Reihe von Autoimmunkrankheiten und 
andere pathologische Zustände als Modellorganismus dient. Es ist zu erwarten, dass 
weitere Untersuchungen von CD1d-restringierten Zellen der Ratte neue Einsichten in 
die Genese dieser Krankheiten ermöglicht. Darüberhinaus sollte die in der Ratte 
beobachtete einfach durchzuführende in vitro Kultur und Expansion von iNKT Zellen 
eine Analyse ihrer immunmodulatorischen Eigenschaften deutlich erleichtern.  
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1 INTRODUCTION 
The immune system protects an organism from infections via many different 
mechanisms. Immune responses have typically been divided into two types: innate and 
adaptive, based on the need of a previous exposure to the microorganism and the time 
required to elicit a response. Innate immune responses are very fast and are generally 
triggered after recognition of typical structures shared by many microorganisms such as 
cell-wall components like lipopolysaccharide. In contrast, adaptive immunity needs a 
certain time to develop and has an exquisite capacity to distinguish between very similar 
microbes and molecules. One additional characteristic of adaptive immune responses is 
the development of memory responses, which imply a much more rapid and efficient 
response in the subsequent occasions in which the organism encounters the same 
infectious agent. 
Both, innate and adaptive immune responses have cellular and soluble components. 
Typical cells of the innate immune system are natural killer cells, which after sensing 
various alterations of the host cells elicit strong cytolytic signals which “kill” them and 
phagocytes such as macrophages and neutrophils, which ingest and eliminate 
pathogens. The exquisite specificity of the adaptive immune responses is achieved with 
receptors and soluble molecules (antibodies) of enormous variability encoded by DNA 
sequences which are not present in the germline DNA but which are produced after 
somatic recombination. Basically, there are two different cell types capable of 
generating such non-germline encoded molecules: B and T cells, which differ 
considerably in their modes of action. B cells produce antibodies which are secreted 
forms of their surface receptors. Once secreted, antibodies recognize structures of the 
pathogens (antigens) and after binding can neutralize the infectivity of the microbes or 
target (opsonize) them for elimination by various mechanisms. Immunity mediated by 
antibodies is known as humoral immunity. In contrast, the responses elicited by T cells 
are regarded as cellular immunity. T cells eliminate or help to eliminate pathogens such 
as virus which survive and proliferate inside the host cells. 
The division between innate and adaptive immunity has also helped to study the 
complex immune system. Nonetheless, the same cells, molecules and mechanisms very 
often have functions in both responses. One example are natural killer (NK) cells, which 
are a main component of the innate immune system but also exert effector functions in 
adaptive immune responses such as in antibody-dependent cell-mediated cytotoxicity. 
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Moreover, some cells which by definition belong to the adaptive branch because they 
express non-germline encoded receptors, such as iNKT cells or B1-B cells may have 
innate-like modes of action as described later in more detail.  
 
1.1 MHC-restricted and non-MHC-restricted T cells 
The antigen receptors of T cells are formed by two chains. Based on the molecules 
which form these T cell receptors (TCR) there are two types of T cells: αβ T cells, 
which bear a TCR formed by an α and a β chain, and γδ T cells, which bear a TCR 
formed by a γ and a δ chain. The enormous variability of these receptors is achieved 
after somatic recombination of various gene segments: variable (V), diversity (D) and 
joint (J), which encode the domains which will contact the antigen, namely, the variable 
domains. These variable domains of the α and γ chains are formed by VJ 
rearrangements and of β and δ by VDJ. The potential variability of these receptors is 
enormous since there are multiple copies of each gene segment which encode different 
amino acid sequences and in addition, non-germline encoded nucleotides are introduced 
during somatic recombination in the junctional regions of these rearranged genes. The 
most different amino acid residues of the different gene segments are localized in 
specific regions named complementarity-determining region (CDR). There are three 
CDRs in each TCR chain: CDRs 1 and 2 are encoded by the V gene segment and the 
CDR3 is the result of VJ or VDJ recombination.  
In contrast to B cells whose receptors can directly recognize antigens, αβ T cells 
recognize antigens which have previously been processed and which are presented by 
specialized molecules called antigen presenting molecules. Since TCRs are products of 
non-germline encoded DNA sequences, T cells bearing newly generated TCRs have to 
be selected in such a way that they will recognize self-antigen presenting molecules 
(positive selection and restriction) but will not react against self-derived molecules 
(negative selection). Although the mechanisms behind are not as well understood as for 
T cells, B cells also undergo negative selection.  
The restriction elements of T cells can be encoded or not in the major histocompatibility 
complex (MHC) and depending on which is their restriction element T cells can be 
further subdivided. These different subtypes also have very different functions which 
are reflected in very different phenotypes. The first division that can be made is between 
MHC-restricted and non-MHC-restricted T cells, meaning T cells which are restricted 
by an element which is encoded in the MHC (MHC-restricted) or which is not (non-
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MHC-restricted). The first antigen presenting molecules which were identified are 
classical major complex histocompatibility (MHC) molecules (Zinkernagel and 
Doherty, 1974), but in the last two decades, other molecules capable of presenting 
antigens such as CD1, HLA-E (H2-Qa1 in the mouse), or MR1 have also been reported 
(Rodgers and Cook, 2005).  
Classical MHC molecules present peptides to T cells. There are two different types of 
these classical MHC molecules: class I and class II (henceforth referred simply as 
MHC-I and MHC-II). In addition, there are several molecules of each class which are in 
general encoded by highly polymorphic genes. These molecules are codominantly 
expressed, resulting in a very high variety of molecules expressed at the cell surface 
which present many different peptides. MHC-I molecules present cytoplasm-derived 
peptides to CD8+ T cells, which mainly exert cytolytic functions and are therefore 
commonly referred as cytotoxic T lymphocytes (CTLs). In contrast, MHC-II present 
peptides derived from extracellular compartments which enter the endocytic-lysosomal 
route to CD4+ T cells. CD4+ T cells are also known as T helper (Th) cells, because they 
“help” other cells to elicit their effector functions by releasing soluble products or by 
direct interaction of their cell-surface molecules with cell-surface molecules on the 
antigen presenting cell. One example among many of this help is the IFN-γ secreted by 
Th cells which stimulates macrophages to eliminate ingested pathogens. CD4+ T cells as 
well as CD8+ T cells can be further subdivided into more subsets depending on the 
products they release and the effector functions they have. 
There are other αβ T cells which are restricted to other MHC molecules (non-classical) 
encoded in the MHC such as HLA-E in humans and H2-M3 in mice. These MHC- 
molecules are regarded as non-classical MHC molecules and present peptides of very 
particular sources, such as signal peptides from MHC-I molecules (Rodgers and Cook, 
2005). Interestingly, HLA-E is also recognized by CD94/NKG2 receptors and is 
involved in regulating NK-cell-mediated cytotoxicity (Braud et al., 1998). 
Under the definition of non-MHC-restricted T cells falls any T cell which is not 
restricted to antigen presenting molecules encoded in the major histocompatibility 
complex and therefore this group is enormously heterogeneous, containing γδ T cells, 
MR1-restricted mucosal-associated invariant T cells (MAIT cells) and CD1-restricted T 
cells. Interestingly, despite heterogeneity of this group these T lymphocytes share some 
important characteristics which can be regarded as typical of innate responses: i) in 
contrast to MHC-restricted T cells, which as result from somatic recombination and 
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positive and negative selection the TCR repertoires are expected to contain ~2*106 and 
~2*107 different specificities in mice and humans, respectively (Arstila et al., 1999; 
Casrouge et al., 2000), non-MHC-restricted T cells bear invariant or semi-invariant 
TCRs formed by particular gene segments and often also invariant joining regions, 
making these receptors similar to pattern recognition receptors. ii) non-MHC-restricted 
T cells are activated very rapidly within hours after first antigen encounter, in contrast 
to MHC-restricted T cells which first undergo clonal expansion, a process which takes 
days and iii) these cells home to particular tissues, which are the first line of defense 
against pathogens such as the skin and the intestinal mucosa.  
 
1.2 CD1d 
1.2.1 CD1 family 
Similar to MHC-I, CD1 molecules are glycoproteins expressed at the cell surface, 
which are non-covalently associated with β2-microglobulin and possess an antigen 
binding groove formed by two of their three extracellular domains: α1 and α2. Despite 
these structural similarities with MHC class I molecules, they considerably differ in 
other aspects (Brigl and Brenner, 2004; Kasmar et al., 2009; Silk et al., 2008): i) CD1d 
molecules are rather non-polymorphic whereas classical MHC class I molecules are 
highly polymorphic, ii) CD1d proteins bind and present antigens containing a lipid or 
other hydrophobic moieties while MHC class I molecules accommodate and present 
peptides, iii) so far, CD1 genes have only been identified in mammals and chicken, 
while MHC class I genes are present in all jawed vertebrates and iv) whereas MHC-I 
molecules are rather similar to each other with respect to function and expression, CD1 
genes and molecules differ remarkably between each other and between species in 
number, expression pattern, type of presented antigens and mode of antigen loading.  
In humans, the CD1 gene family is composed of five members (CD1A, -B, -C, -D and -
E) which are subdivided into two groups based on the amino acid sequence similarity of 
the α1 and α2 domains of the encoded proteins (Calabi et al., 1989). CD1a, -b, and -c 
belong to group 1; CD1d is the only member of group 2 and CD1e cannot clearly be 
assigned to either group. In contrast, mice and rats possess only representatives of group 
2: mice have two CD1d orthologues (CD1d1 and CD1d2) (Bradbury et al., 1988) and 
rats have one (Ichimiya et al., 1994; Kasmar et al., 2009; Katabami et al., 1998). During 
the past ten years, the role of CD1 proteins, except for CD1e, as molecules presenting 
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lipid antigens to T cells has been well established (Brigl and Brenner, 2004; de la Salle 
et al., 2005; Kasmar et al., 2009; Silk et al., 2008). 
 
1.2.2 Expression of CD1d 
CD1d is expressed in the hematopoietic system but also in non-lymphatic tissues such 
as the liver. Interestingly, its distribution varies between different species (Brigl and 
Brenner, 2004). In humans its expression in the hematopoietic system is more restricted 
than in mice. Monocytes and circulating B cells express low levels of CD1d at the cell 
surface, whereas among resting mature T cells CD1d is hardly detectable at the cell 
surface although it seems to be intracellularly-stored after stimulation with 
phytohemagglutinin (PHA) (Exley et al., 2000; Salamone et al., 2001). Nonetheless, the 
low levels of CD1d detected on monocytes seem to be sufficient to present α-
galactosylceramide (α-Gal) and promote proliferation of a T cell line (Spada et al., 
2000). In contrast to mature T cells, human cortical thymocytes express high levels of 
CD1d (Exley et al., 2000). In the mouse hematopoietic system CD1d1 is constitutively 
expressed although surface expression levels vary among different cell types: Dendritic 
cells, macrophages and marginal zone (MZ) B cells are the cells with highest levels, 
followed by B cells and cortical thymocytes and subsequently, by mature T cells 
(Brossay et al., 1997; Park et al., 1998; Roark et al., 1998). Of the two CD1d genes 
present in mice, CD1d2 is only expressed on thymocytes and is of limited functionality 
with respect to antigen presentation and T cell selection (Chen et al., 1999). Notably, in 
C57BL/6 mice a frame shift mutation prevents CD1d2 surface expression (Park et al., 
1998). Thus the functional orthologue is CD1d1.  
In humans, CD1d expression outside the hematopoietic system has been detected in 
parenchymal cells, vascular smooth muscle cells and epithelial cells in organs such as 
the liver, kidney and gut (Canchis et al., 1993). Moreover, it also has been detected in 
Schwann cells of the peripheral nervous system (Im et al., 2006) and in the skin (Bonish 
et al., 2000). Interestingly, CD1d levels are increased under some pathological 
conditions such as psoriasis and atherosclerosis (Bonish et al., 2000; Melian et al., 
1999). In mice, the expression in non-lymphatic organs such as liver and lung has also 
been reported (Bradbury et al., 1988; Brossay et al., 1997; Mosser et al., 1991). 
However, in other tissues like the intestine, the precise localization of CD1d molecules 
is still a matter of debate (Brigl and Brenner, 2004). In spite of this, a recent study by 
Blumberg and colleagues has demonstrated the importance of CD1d expression for gut 
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function since pathogenic and non-pathogenic bacterial intestinal colonization of CD1d-
deficient mice was increased in comparison to wild type mice (Nieuwenhuis et al., 
2009). Paneth cells, in which CD1d mRNA has been detected by in situ hybridization 
(Lacasse and Martin, 1992), play a crucial role in controlling intestinal homeostasis. 
Localized at the bottom of the crypts of Lieberkühn, these specialized cells control the 
microbiota content by secreting antimicrobial peptides (defensins) into the intestinal 
lumen. Interestingly, Blumberg and colleagues also showed that in CD1d knockout 
mice, compared to wild type mice, the morphology and content of the secretory 
granules of Paneth cells were altered, and more importantly, that degranulation of these 
cells was defective.  
The actual knowledge about rat CD1d expression is based on experiments using reverse 
transcription-polymerase chain reaction (RT-PCR), in situ hybridization or polyclonal 
antiserum. These studies found CD1d to be widely distributed within and outside the 
hematopoietic system and, as in mice, high levels of CD1d mRNA were detected in 
Paneth cells (Ichimiya et al., 1994; Kasai et al., 1997). In two additional studies mAbs 
originally generated against mouse CD1d have been reported to cross-react with rat 
CD1d. In the first study, the rat IgMs 1H1 and 3C11 (Bleicher et al., 1990) were shown 
to bind a CD1d-like molecule which was detected in the liver but not in the thymus 
(Burke et al., 1994). In the second study, reactivity of mAb 3H3 with rat thymocytes 
and splenocytes was reported but not further investigated (Mandal et al., 1998). Hence, 
prior to our study, appropriate monoclonal antibodies for the analysis of CD1d 
expression and function in this species were still missing. 
 
1.2.3 CD1d function: lipid antigen presenting molecule 
As mentioned, CD1d function is to present lipids to T cells. CD1d-restricted T cells 
often, but not always, express receptors shared with natural killer (NK) cells and are 
therefore named NKT cells (Godfrey et al., 2004). As described in more detail in the 
introduction section 1.3, NKT cells are divided into type I and II depending on the 
genes used for the generation of the TCR α chain and the reactivity of the TCR to α-Gal. 
In this study and also in most of the publications what is commonly referred as α-
galactosylceramide (α-Gal) is actually a synthetic analogue (termed KRN7000) of the 
natural α-galactosylceramide isolated from the marine sponge Agelas mauritianus in a 
screening of natural anticancer medicines (Morita et al., 1995). α-Gal is the first 
glycolipid antigen described to be presented by CD1d and is recognized by NKT cells 
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with an invariant TCRα chain rearrangement (type I NKT cells or iNKT cells, 
introduction section 1.3) (Kawano et al., 1997). Due to its marine origin, it is difficult to 
assign a physiological role for α-Gal. Nonetheless, its very potent capacity to activate 
iNKT cells makes α-Gal an indispensable tool to study and to “exploit” this T cell 
population. Moreover, the peculiar α-linkage of the sugar (most mammalian ceramide 
glycosphingolipids contain sugars in the β-anomeric form) has helped to identify other 
antigens presented by CD1d and numerous synthetic analogues, recently reviewed by 
Venkataswamy and Porcelli (Venkataswamy and Porcelli, 2010). 
Since α-Gal was found, other lipid antigens from endogenous and microbial origin have 
been identified to be presented by CD1d and recognized by iNKT cells. Glycolipid 
antigens have been found in pathogen microorganisms such as α-glucuronosylceramide 
(GSL-1) form the ubiquitous bacterium Sphingomonas (Kinjo et al., 2005; Mattner et 
al., 2005) and diacylglycerols containing an α-linked galactose (BbGI-II) from Borrelia 
burgdorferi, which is a Gram negative species causative of Lyme disease. Furthermore 
lipids derived from protozoa pathogens which activate mouse iNKT cells have also 
been reported: Lipophosphoglycan (LPG or LD1S) from Leishmania donovani and a 
phosphatidylinositol (EhPIa) from Entamoeba histolytica (Amprey et al., 2004; Lotter 
et al., 2009). 
Although the identity of endogenous lipids which are presented by CD1d and 
recognized by NKT cells remains largely unresolved, several functional and 
biochemical analyses have provided essential information. The recognition of 
endogenous antigens was evident with the finding that NKT cells are autoreactive when 
cultured in vitro with antigen presenting cells expressing CD1d without the addition of 
any exogenous antigen (Bendelac et al., 1995; Exley et al., 1997). The deficiency to 
stimulate iNKT cells of a cell line with a mutant β-glucosylceramide synthase indicated 
that the endogenous NKT cell ligands might include lysosomal glycosphingolipids 
(Stanic et al., 2003). Moreover, the fact that mice deficient for β-hexosaminidase B 
(enzyme which processes isoglobotetrahexosylceramide (iGb4) into 
isoglobotrihexosylceramide (iGb3)) have a severely impaired iNKT cell development 
together with the finding that purified and synthetic iGb3 can stimulate human and 
mouse iNKT cells (Zhou et al., 2004b), lead to the hypothesis that iGb3 is a major 
selecting ligand of iNKT cells in vivo (Zhou et al., 2004b). Nonetheless, later reports 
showed that alterations in other enzymes distinct from β-hexosaminidase B which cause 
accumulation of lysosomal glycosphingolipids also result in defective iNKT cell 
 21 
development (Gadola et al., 2006b) and more importantly, that iNKT cell numbers are 
normal in mice lacking iGb3 synthase (Porubsky et al., 2007). Thus, although iGb3 is 
an endogenous ligand for iNKT cells, it is probably not the most important selecting 
lipid. Nonetheless and although the exact molecular structures are not known yet, three 
studies have clearly shown that after stimulation with TLR agonists or during infection 
the lipids bound to CD1d are altered, and strongly activate iNKT cells (Darmoise et al., 
2010; Paget et al., 2007; Salio et al., 2007). This illustrates how the antigen presenting 
cells can sense the presence of pathogens and can “alert” the immune system also by 
presenting endogenous glycolipids to iNKT cells. Moreover, sulfatides are other 
endogenous lipids which have been shown to activate a distinct CD1d-restricted T cell 
population (type II NKT cells) (Jahng et al., 2004; Roy et al., 2008).  
Taken all together, it is clear that CD1d functions as an antigen presenting molecule 
specialized in presenting lipids to CD1d-restricted T cells. Nonetheless, an additional 
function for CD1d distinct from that of antigen presenting molecule appears also 
possible since Nieuwenhuis and colleagues recently found intrinsic defects in the 
granular content and morphology of Paneth cells in CD1d-deficient mice (Introduction 
section 1.2.2 and (Nieuwenhuis et al., 2009)). 
 
1.3 CD1d-restricted T cells 
As previously mentioned, CD1d-restricted T cells have been named NKT cells due to 
the expression of receptors typically found in NK cells (Godfrey et al., 2004). Also as 
previously alluded, these cells can be categorized into two groups depending on the 
gene segments used to form their TCR and their reactivity to α-Gal. Type I NKT cells, 
also designated as invariant NKT cells (iNKT cells) or Vα14 NKT cells, express an 
invariant TCRα chain characterized by AV14-AJ18 (Vα14-Jα18) rearrangements in 
mice and by the homologous AV24-AJ18 rearrangements in humans (TRAV10-
TRAJ18 and TRAV11-TRAJ18 according to the IGMT nomenclature for human and 
mice, respectively). Apart from the invariant α chain, the β chains of iNKT cells also 
show a limited BV (Vβ) repertoire with highly variable CDR3β regions. In humans, 
most iNKT cells bear a BV11 (TRBV10 based on the IMGT gene nomenclature) 
comprising β chain and in mice more than 80% of these cells have BV8S2, BV7 or BV2 
β chains (TRBV13, TRBV29 and TRBV1, based on IMGT nomenclature, respectively) 
(Benlagha et al., 2000; Lee et al., 2002a; Matsuda et al., 2000). 
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Neither all iNKT cells express receptors typical of NK cells such as NK1.1 (NKR-P1C) 
in mice or CD161 (NKR-P1A) in humans nor all NK1.1+/CD161+ T cells are iNKT 
cells, therefore unequivocal identification of iNKT cells should be carried out with α-
Gal-loaded CD1d oligomers, which are reagents that exploit the specificity and high 
affinity of the semi-invariant TCR-α-Gal-CD1d interactions (Godfrey et al., 2004; 
Gumperz et al., 2002; Hammond et al., 2001; Matsuda et al., 2000). 
The type II category includes all CD1d-restricted T cells which do not express the 
canonical α chain. Although the specificities of this diverse group remain largely 
unclear, as already pointed out, it has been demonstrated that some cells react to 
endogenous sulfatides and, similarly as iNKT cells, they can be identified with 
sulfatide-loaded CD1d tetramers (Behar and Cardell, 2000; Cardell et al., 1995; Jahng et 
al., 2004). A recent study has shown that these sulfatide-reactive T cells have an 
oligoclonal TCR repertoire with a predominant use of AV3/AV1-AJ7/AJ9 and 
BV8S1/BV3S1-BJ2S7 gene segments (Arrenberg et al., 2010).  
 
1.4 Recognition of α-Gal-CD1d by semi-invariant TCRs  
Crystal structures of human and mouse iTCR-α-Gal-CD1d complexes have provided a 
clear insight into the structural basis of the AV14 and AJ18 requirement to form the 
invariant TCRα chain (Borg et al., 2007; Pellicci et al., 2009). The recognition mode of 
α-Gal-CD1d by the semi-invariant TCR is very different from how other TCRs 
recognize peptide-MHC complexes. First, in contrast to MHC class I-peptide-TCR 
interactions, where α and β chains contribute more or less to the same extent, adopting a 
diagonal footprint with respect to the axis of the antigen binding groove of the MHC 
molecule; in the recognition of α-Gal-CD1d complexes by the semi-invariant TCR, the 
α chain makes many more contacts than the β chain and the foot print over α-Gal-CD1d 
is parallel to the antigen binding groove. Second, the docking mode of the TCR when it 
is bound to peptide-MHC complexes is perpendicular to the plane drawn by the α1 and 
α2 helices of the MHC molecule but the semi-invariant TCR adopts a very acute 
docking mode lying only above the F’ pocket when it binds to α-Gal-CD1d and third, 
whereas all CDRs of both α and β chains make important interactions in the recognition 
of peptides presented by MHC molecules, there are big differences in the contributions 
of the CDRs of the semi-invariant TCR. The CDR3 loop of the α chain of the semi-
invariant TCR, mainly formed by AJ18, spreads broadly over the α-Gal/CD1d complex 
making contacts with the protruding galactose head of α-Gal and the α1 and α2 helices 
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of CD1d. In contrast, the CDR1α loop makes a few contacts only with α-Gal and the 
CDR2α makes no evident interactions with CD1d or α-Gal. In the structures resolved to 
date with human BV11 and mouse BV8S2 and BV7 TCRs, the only contributions of the 
β chain are made with the CDR2β loop which makes contacts with CD1d but not with 
the antigen. In addition to these crystallographic analyses, mutagenesis studies carried 
out by our and other laboratories have also demonstrated the important role of the 
CDR2β region in α-Gal-CD1d recognition by the semi-invariant TCR (Borg et al., 
2007; Mallevaey et al., 2009; Pellicci et al., 2009; Pyz et al., 2006; Scott-Browne et al., 
2007; Wun et al., 2008).  
 
1.5 iNKT cell development 
iNKT cells as well as MHC-restricted T cells develop in the thymus from the same 
precursors, namely double positive (CD4+ and CD8+) thymocytes. The most important 
selecting factor driving iNKT cell development is the generation of the semi-invariant 
CD1d-restricted TCR. Thus mice lacking the AJ18 gene segment or CD1d lack iNKT 
cells (Cui et al., 1997; Mendiratta et al., 1997). Moreover, although V (D in the β chain) 
J gene segments are randomly recombined, the size of the excised DNA is limited and 
therefore, it is necessary to undergo multiple excisions in order to recombine distal gene 
segments such as AV14 and AJ18 (Guo et al., 2002). To be able to go through multiple 
excisions, thymocytes must have a prolonged lifespan. Consequently, mice which lack 
factors involved in prolonging survival such as ROR-γt and BCL-XL have reduced 
iNKT cell frequencies (Bezbradica et al., 2005; Egawa et al., 2005). After 
recombination and expression at the cell surface of the semi-invariant TCR, iNKT cells 
are positively selected but, in contrast to MHC-restricted T cells which are selected by 
cortical thymic epithelial cells (cTECs), iNKT cells are selected by cortical DP 
thymocytes (Bendelac, 1995). These homotypic interactions result in a distinct cell 
programming in comparison to MHC-restricted T cells since the costimulatory signals 
provided by thymocytes differ considerably from those provided by cTECs (Godfrey et 
al., 2010). In particular, it has been shown as iNKT cell development is dependent on 
signaling via SLAM molecules (Griewank et al., 2007; Jordan et al., 2007). SLAM 
proteins are cell surface receptors which signal through the SLAM adaptor protein 
(SAP). Mice lacking SAP or SLAM1 and SLAM6, which are the SLAM family 
members expressed by thymocytes, lack iNKT cells but have normal MHC-restricted T 
cells numbers (Chung et al., 2005; Griewank et al., 2007; Nichols et al., 2005; Pasquier 
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et al., 2005). Although demonstration of negative selection is a complicated task, the 
impaired iNKT cell development in the presence of α-Gal or of CD1d-overexpressing 
dendritic cells (Chun et al., 2003; Pellicci et al., 2003) suggests that iNKT cells also 
might undergo apoptosis if during development their semi-invariant TCR recognizes 
ligands with a very high affinity.  
After positive and probably negative selection, iNKT cells undergo several maturation 
steps, which can be distinguished by differently-expressed cell surface molecules 
(Godfrey et al., 2010). Many factors are involved in this maturation process and have 
been extensively reviewed elsewhere (Godfrey and Berzins, 2007; Godfrey et al., 2010; 
Matsuda and Gapin, 2005). Several of them are also important for MHC-restricted T 
cell maturation. A lot of efforts have been made to identify a master regulator specific 
of the iNKT cell lineage. In two recent studies it has been shown that the transcription 
factor PLZF is expressed by iNKT cells but not by T cells restricted by classical MHC 
molecules (Kovalovsky et al., 2008; Savage et al., 2008). Although PLZF is also 
expressed by a subset of γδ T cells and by human, but not mouse, MAIT cells, at least 
PLZF is limited to non-conventional T lymphocytes (non-classical MHC-restricted T 
cells). Accordingly, mice deficient for PLZF have much lower numbers of iNKT cells, 
and those iNKT cells which reach maturation, do not have the characteristic activated 
phenotype of normal iNKT cells. Once iNKT cells have maturated, they home to tissues 
different from those where MHC-restricted T cells migrate and some of them stay in the 
thymus. iNKT cells are especially abundant in the liver (in mouse inbred strains such as 
C57BL/6 constitute a 30% of all intrahepatic lymphocytes) and whereas they are present 
at considerable amounts in the spleen (1% of total lymphocytes), they are hardly 
detectable in lymph nodes (Hammond et al., 2001; Matsuda et al., 2000). 
 
1.6 iNKT cell function 
During the last ten years, many studies have shown the in vivo role of iNKT cells at the 
interface between innate and adaptive immune responses. As mentioned, iNKT cells 
display an activated phenotype and respond very rapidly by secreting large amounts of 
cytokines within a few hours after activation. iNKT activation can occur in different 
ways referred as direct and indirect activation pathways (Brigl and Brenner, 2010). In 
the direct activation pathway iNKT cells are activated by the recognition of exogenous 
microbial lipid antigens such as BbGI-II or GSL-1 by their semi-invariant TCR 
(Introduction section 1.2.3). In contrast, in the indirect pathway in order to secrete large 
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amounts of cytokines, iNKT cells need two stimulatory signals: One is the recognition 
of endogenous ligands with their semi-invariant TCR and the other one is the binding of 
stimulatory cytokines released by the antigen presenting cells (such as IL-12 or type I 
IFNs) (Paget et al., 2007; Salio et al., 2007). Furthermore, two studies have 
demonstrated that iNKT cells release IFN-γ in response to recombinant innate cytokines 
such as IL-12 and IL-18 independently of TCR stimulation (Hou et al., 2003; Leite-De-
Moraes et al., 1999).  
Activation of iNKT cells often results in the activation or maturation of the antigen 
presenting cell (DC or B cells). This activation feedback is mainly dependent on 
cytokines released by iNKT cells and on CD40 ligation (Hermans et al., 2003; Lantz 
and Bendelac, 1994). In such a way, iNKT cell adjuvant activity enhances B and T cell 
responses (Cerundolo et al., 2009; Fujii et al., 2010). Additionally, also a cytolytic 
potential of iNKT cells has been shown, although this is probably not one of their main 
effector functions (Smyth et al., 2002).  
The outcomes after iNKT cell activation are diverse: On the one hand they can enhance 
immune responses such as anti-tumor T cell activity but on the other hand, they are also 
able to inhibit the immune system resulting in an amelioration of autoimmune diseases 
(Bendelac et al., 2007; Godfrey and Kronenberg, 2004). How iNKT cells manage to 
exert these contradictory and most of the times beneficial roles for the host is being 
intensively investigated (Godfrey et al., 2010).  
 
1.7 iNKT cells in the rat 
Rats have the genes necessary for the generation and selection of semi-invariant TCRs: 
First, as mentioned in the introduction section 1.2.1, they have one CD1d gene which is 
highly homologous to its mouse counterpart (Katabami et al., 1998); second, they have 
several AV14 homologues which have been shown to rearrange with AJ18 (Matsuura et 
al., 2000) and third, they have two homologues of the mouse BV8S2 gene segment: 
BV8S2 and BV8S4 (Asmuss et al., 1996).  
The presence of several AV14 gene segments in the rat (Kinebuchi and Matsuura, 2004; 
Matsuura et al., 2000; Pyz et al., 2006) is intriguing since humans contain one single 
AV14 gene segment and mice one or two (Koseki et al., 1991; Lefranc, 2001). These 
AV14 gene segments are highly similar except in the CDR2α region, where two very 
different amino acid sequences are found. Based on the amino acid sequence of this 
region, these AV14 genes have been divided into two groups: Type I and type II 
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(Kinebuchi and Matsuura, 2004; Matsuura et al., 2000). Interestingly, the studies carried 
out by Matsuura and colleagues suggested a specific tissue distribution of these two 
different types: Invariant TCRα chains using type I AV14 gene segments were slightly 
more abundant among hepatic lymphocytes whereas in the spleen, type II invariant 
TCRα chains were expressed more frequently (Matsuura et al., 2000). 
Up to date, two different Tcrb (loci encoding TCRβ chains) haplotypes have been 
described in the rat which contain different alleles of each BV8S2 and BV8S4 gene 
segments. In the Tcrba haplotype, present in DA and F344 inbred rat strains, both gene 
segments encode functional BV8 polypeptides, in contrast, in inbred rat strains 
containing a Tcrbl haplotype such LEW, BN and PVG, BV8S4 is predicted to be non-
functional due to the deletion of one nucleotide which results in a frame shift. BV8S2a 
and BV8S4a differ in six amino acids located in the CDR2 and CDR4 regions. In 
contrast, the predicted amino acid sequences of the a and l BV8S2 alleles differ in three 
residues localized outside of the CDR regions (Asmuss et al., 1996). The mAb R78, 
often used in this study, binds to BV8S4a but not to BV8S2a, whereas in inbred rat 
strains of the l haplotype, it binds to BV8S2l (Asmuss et al., 1996; Torres-Nagel et al., 
1993). In addition, other BV8 family members have been described in rats such as 
BV8S3 (detected by the mAb B73 (Torres-Nagel et al., 1993)) and BV8S1 (Hashim et 
al., 1991; Smith et al., 1991). The predicted amino acid sequences of these BV8 gene 
segments differ considerably from BV8S2 and BV8S4, especially the CDR2 of BV8S3 
(Asmuss et al., 1996).   
E. Pyz et al. demonstrated that these gene segments can produce semi-invariant TCRs 
which are reactive to α-Gal presented by rat CD1d and that rat primary cells respond to 
α-Gal stimulation by secreting IFN-γ and IL-4. Nonetheless, despite these functional 
and genetic data, all attempts carried out to identify iNKT cells in the rat had been based 
on the one hand, on co-staining of NKR-P1 receptors on T cells detected by the mAbs 
3.2.3 or 10/78 (which detect two NKR-P1 isoforms: A and B (Li et al., 2003)) together 
with mAbs specific for TCRβ chains formed by certain BV gene segments (Knudsen et 
al., 1997; Li et al., 2003; Matsuura et al., 2000; Pyz et al., 2006; Ru and Peijie, 2009); 
and on the other hand on the usage of mouse α-Gal-loaded CD1d oligomers (Pyz et al., 
2006). First, although it can be expected that rat iNKT cells are contained among NKR-
P1+ T cells (as in mice and humans), it is possible that not all these cells bear the semi-
invariant TCR and second, surprisingly, mouse α-Gal-loaded CD1d oligomers failed to 
identify a discrete rat iNKT cell population despite the high homology between rat and 
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mouse CD1d molecules. Since E. Pyz et al. also showed that cell lines bearing rat semi-
invariant TCRs did not respond to α-Gal presented by mouse CD1d, the failure of the 
identification of a reliable rat iNKT cell population with mouse CD1d oligomers could 
be explained by the lack of binding of mouse CD1d by rat iNKT cells (Pyz et al., 2006).  
Taken all together, although strong evidence suggested that rats have iNKT cells the 
direct identification and phenotypical characterization of this particular T cell 
population in the rat was still pending. Therefore, the principal aims of this doctoral 
thesis were first, to develop appropriate reagents which allow the direct staining of rat 
iNKT cells and second, the analysis of these cells among different inbred rat strains.   
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemical reagents 
Agar-agar    Applichem (Darmstadt, Germany) 
Acetic acid Applichem (Darmstadt, Germany) 
α-Gal (α-Galactosylceramide)   Alexis Biochemicals, Enzo Lifesciences 
(New York, USA) 
Agarose      Roth (Karlsruhe, Germany) 
Ammonium chloride    Roth (Karlsruhe, Germany) 
Ampicillin     Gibco BLR (Eggenstein, Germany) 
APS       Roth (Karlsruhe, Germany) 
β-mercaptoethanol     Gibco BLR (Eggenstein, Germany) 
Boric acid      Roth (Karlsruhe, Germany) 
Bromophenol blue    Sigma (St. Louis, USA) 
BSA      Roth (Karlsruhe, Germany) 
Calcium Chloride     Roth (Karlsruhe, Germany) 
Concanavalin A    ICN (Meckenheim, Germany) 
Coomassie R250    Sigma (St. Louis, USA) 
Diethylamine      Sigma (St. Louis, USA) 
DMSO (Dimethyl sulfoxide)   Applichem (Darmstadt, Germany) 
DMP Pierce (Rocford, USA) 
dNTP Set   Peqlab Biotechnologie (Erlangen, 
Germany) 
EDTA   Applichem (Darmstadt, Germany) 
Ethanol      Applichem (Darmstadt, Germany) 
Ethidium bromide     Roth (Karlsruhe, Germany) 
FCS       Sigma (St. Louis, USA) 
Ficoll-Paque      GE Healthcare (Uppsala, Sweden) 
Formaldehyde     Roth (Karlsruhe, Germany) 
Formamide      Roth (Karlsruhe, Germany) 
G418 (Geneticin solution)    Biochrom (Berlin, Germany) 
Glycerol     Applichem (Darmstadt, Germany) 
Glycine      Roth (Karlsruhe, Germany) 
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HEPES for cell culture   Applichem (Darmstadt, Germany) 
Hydrogen peroxide 35%   Applichem (Darmstadt, Germany) 
Isopropanol      Applichem (Darmstadt, Germany) 
LB (Broth Base medium)   Applichem (Darmstadt, Germany) 
Luminol      Applichem (Darmstadt, Germany) 
Magnesium Chloride     Roth (Karlsruhe, Germany) 
MEM (Non-essential amino acids)  Gibco BLR (Eggenstein, Germany) 
Non fat dried milk powder    Applichem (Darmstadt, Germany) 
NONIDET P-40    Sigma (St. Louis, USA) 
p-Coumaric Acid    Merck (Darmstadt, Germany) 
Penicillin      Grünenthal (Aachen, Germany) 
Percoll      GE Healthcare (Uppsala, Sweden) 
Acrylamide      Applichem (Darmstadt, Germany) 
Polybrene (Hexadimthrinbromide)   Sigma (Deisenhofen, Germany) 
Protein A Sepharose Fast Flow  GE Healthcare (Uppsala, Sweden) 
Protein G Sepharose 4 Fast Flow  GE Healthcare (Uppsala, Sweden) 
SDS (Sodium dodecyl sulphate)  Sigma (Deisenhofen, Germany) 
Sodium Azide     Merck (Darmstadt, Germany) 
Sodium Chloride     Roth (Karlsruhe, Germany) 
Sodium Butyrate     Sigma (Deisenhofen, Germany) 
Sodium Hydroxide    Applichem (Darmstadt, Germany) 
Streptomycin     Riemser (Greifswald, Germany) 
Sulfo-NHS-LC-Biotin    Pierce (Rocford, USA) 
TEMED     Roth (Karlsruhe, Germany) 
Tris      Applichem (Darmstadt, Germany) 
TRITON X-100    Sigma (St Louis, USA) 
Trypan blue      Sigma (Deisenhofen, Germany) 
Tween 20      Sigma (Deisenhofen, Germany) 
Zeocin      Invivogen (Toulouse, France) 
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2.1.2 Media, buffers, solutions 
• Culture medias of eukaryotic cells 
- DMEM-: DMEM with Glucose and L-Glutamine (Gibco Invitrogen, Darmstadt, 
Germany)), supplemented with 10% FCS and antibiotics (Penicillin and 
Streptomycin). 
- DMEM+: DMEM + GlutaMAXTM-I (with Glucose and 25mM HEPES, Gibco 
Invitrogen, Darmstadt, Germany)) supplemented with 10% FCS and antibiotics 
(Penicillin and Streptomycin). 
- RPMI+: RPMI 1640 with L-Glutamine (Gibco Invitrogen, Darmstadt, Germany) 
supplemented with 10 % of SC (supplement complete) 
- RPMI++: RPMI+ supplemented additionally with 5% FCS and 25 mM HEPES 
(pH 7.5) 
- ISF-1 media (Biochrom, Berlin, Germany) supplemented with antibiotics 
(Penicillin and Streptomycin). 
- SFM4MAb media supplemented with antibiotics (Penicillin and Streptomycin) 
(Fisher Scientific, Schwerte, Germany).  
- Freezing media (40% RPMI 1640, 50% FCS and 10% DMSO). 
• SC-supplement (50 ml of SC per 500 ml of RPMI-): 500 ml heat-deactivated FCS, 
100 ml Na puryvate 100 mM, 100 ml non-essential amino acids, 100 ml Penicillin-
Streptomycin (10000U/ml) and 5 ml β-Mercaptoethanol 50 mM. 
• ATV: 0.05% Trypsin, 0.02% EDTA in PBS. 
• BSS (Hanks balanced salt solution): to prepare BSS 125 ml of BSS I was mixed 
with 125 ml of BSS II add filled with water to 1 L. 
- BSS I: 50 g Glucose, 3 g KH2PO4, 11.9 g NaH2PO4, 0.4 g Phenylred and water 
to 5 L. 
- BSS II: 9.25 g CaCl2, 20 g KCl, 320 g NaCl, 10 g MgCl2, 10 g MgSO4 and water 
to 5 L. 
• BSS/BSA: BSS supplemented with 0.2% of BSA.  
• 2xHBS: 50 mM HEPES pH 7.05 (different pHs were prepared and tested), 10 mM 
KCl, 12 mM Glucose, 280 mM NaCl and 1.5 mM NaH2PO4. 
• PBS (Phosphate buffered saline): 4 mM KH2PO4, 16 mM Na2HPO4 and 115 mM 
NaCl with a pH of 7.3. 
• FACS buffer: PBS with 0.1% BSA and 0.05% NaN3. 
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• TAC (Tris-Ammoniumchlorid) buffer: 20 mM Tris pH 7.2 and 0.82% NH4Cl. 
• LB-medium: 20 g LB and water to 1 L, autoclaved and stored at 4°C 
• Low salt LB media: 10 g Tryptone, 5 g NaCl and 5 g Yeast Extract 
• Bio-Rad Protein Assay, Bio-Rad (Munich, Germany) 
• Coating buffer: 8.4 g NaHCO3, 3.56 g Na2CO3 in 1 L H2O, pH 9.5     
• ECL-solutions (self made) 
- Solution I: 2.5 mM Luminol, 400 µM p-coumaric acid in 0.1 M Tris pH 8.5 (1% 
DMSO, dissolvent of Luminol and p-coumaric acid) 
- Solution II: 5.4 mM H2O2 in 0.1 M Tris pH 8.5 (prepared the same day in which 
it is used) 
Equal volumes of solutions I and II were mixed and added to the blotted 
membrane.  
• ECL solution, if not self-made was purchased from GE Healthcare (Uppsala, 
Sweden). 
• BDTM ELISPOT AEC Substrate Set (BD Biosciences Pharmingen; San Diego, 
USA) 
• BD OptEIATM TMB Substrate Reagent Set (BD Biosciences Pharmingen; San 
Diego, USA) 
• 10xTBE (Agarose electrophoresis buffer): 890 mM Tris, 890 mM Boric Acid and 
20 mM EDTA 
• 5xTGS (SDS-PAGE buffer): 15.1 g Tris, 94 g Glycine, 50 ml 10% SDS and water 
to 1 L.  
• SDS-PAGE gel staining solution: 12.5% isopropanol, 10% acetic acid 0.25% 
Coomassie Brilliant Blue R250. 
• SDS-PAGE gel destain solution: 12.5% isopropanol and 10% acetic acid 
• Stripping buffer: 62 mM Tris, 2% SDS and 100 µM Tris HCl pH 6.7  
• Buffers for semi-dry protein transfer into a PVDF membrane: 
- Anode Buffer I: 0.3 M Tris, pH 10.4, 10% methanol 
- Anode Buffer II: 25 mM Tris, pH 10.4, 10% methanol 
- Cathode Buffer: 25 mM Tris, 40 mM glycine, 10% methanol, pH 9.4 
• IP loading buffer: 2% SDS, 62.5 mM Tris pH 6.8, 10% glycerol, 770 mM β-
mercaptoethanol and 0.04% bromophenol blue 
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• IP Lysis buffer: 50 mM Tris, pH 7.4, 150 mM NaCl, 0.25% Na-deoxycholate, 1 mM 
EDTA, 1% NP40 and protease inhibitors.  
• WB reducing loading buffer is the same as the IP loading buffer but 4x 
concentrated. 
• WB non-reducing loading is the same as the WB reducing loading buffer but 
without β-mercaptoethanol. 
 
2.1.3 Cell lines 
293T Highly transfectable derivative of the 293 cell line into which the 
temperature sensitive gene for SV40 T-antigen was inserted 
(ATCC# CRL-11268). 
 
58C (BW58) Do-11.10.7 hybridoma derived AKR/J mouse αβ TCR-negative cell 
lymphoma; ATCC#TIB-233. Kindly provided by Dr. Palmer (Basel 
Institute, Switzerland). 
 
BW58 r/mCD28 BW58 cells transduced with r/mCD28 (Luhder et al., 2003). 
 
BW58 rAV14S6 + CDR2+4 BW58 cells transduced with r/mCD28 and a rat semi-
invariant TCR generated by E. Pyz and described elsewhere (Pyz et 
al., 2006). The TCRα chain contains the AV14S6 gene segment 
(previously named AV14S1).  
 
J558L  J558L is a spontaneous heavy chain-loss-variant myeloma cell 
line obtained from the J558 cell line (Oi et al., 1983). 
 
P80rCD1d P815 mouse (DBA/2) cell mastocytoma (ATCC# TIB-64) 
transduced with rat CD80 and CD1d generated by E. Pyz (Pyz et 
al., 2006). 
 
Raji rCD1d  Raji human Burkitt's lymphoma cell line (ATCC# CCL-86) 
transduced with rat CD1d (Pyz et al., 2006). 
 
Raji mCD1d Raji human Burkitt's lymphoma (ATCC #CCL-86) transduced 
with mouse CD1d (Pyz et al., 2006). 
 
SC2  Drosophila melanogaster cells. 
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2.1.4 Animals 
Animals were used at 6 – 16 weeks of age. C57BL/6J, BALB/c, C57BL/6, CD1d-/- and 
BALB/c CD1d-/- mice, as well as LEW/Crl and F344/Crl rats were bred in the animal 
facilities of the Institute for Virology and Immunbiology Virology and Immunobiology, 
University of Würzburg, Würzburg, Germany. Breeding pairs for CD1d-/- mice, 
previously bred on a BALB/c background were a kind gift of Heidrun Moll, Institute for 
Infection Biology, Würzburg University. C57BL/6 CD1d-/- (Mendiratta et al., 1997) 
were kindly provided by Mandfred Lutz, Institute for Virology and Immunobiology, 
University of Würzburg, Würzburg, Germany. BN/SsNOlaHsd, DA/OlaHsd, 
PVG/OlaHsd, BUF/SimRijHsd, AGUS/OlaHsd, AUG/OlaHsD and WF/NHsd rats were 
purchased from Harlan laboratories. BH/Ztm rats and CBA/N mice were provided by 
Kurt Wonigeit, Medical School Hannover, Hannover, Germany. 
 
2.1.5 Vectors 
 
pczVSV-G  Encodes the env protein from Vesicular Stomatitis Virus  
(Pietschmann et al., 1999). 
 
pHIT 60  pHIT60-CMV-MLV-gag-pol-SV40ori; containing gag and pol from 
Moloney Murine Leukemia Virus (MoMLV) under the control of 
human Cytomegalovirus (CMV) promoter (Soneoka et al., 1995). 
 
pczCFG5 IZ Retroviral vector for the MuLV driven constitutive expression of 
a gene of interest and through IRES mediated expression the 
protein which confers Zeocin resistance. This vector was kindly 
provided by I. Berberich, Institute for Virology and 
Immunobiology, University of Würzburg, Würzurg, Germany.  
 
pczCFG5 IEGN Retroviral vector for the MuLV driven constitutive expression of 
a gene of interest and through IRES mediated expression the 
EGFP-Neo fusion protein which serves as reporter and confers 
neomycin resistance (Knodel et al., 1999). This vector was kindly 
provided by I. Berberich, Institute for Virology and 
Immunobiology, University of Würzburg, Würzurg, Germany.  
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pXIg Vector containing MluI and XhoI unique restriction sites. The 
vector encodes the signal sequence of the IgG1 heavy chain 5’ of 
the MluI site and the IgG1 heavy chain starting from the intact 
variable domain after the XhoI restriction site (Dal Porto et al., 
1993). This plasmid was derived from the pSN-RCR2, a plasmid 
which contains the gene encoding an IgG1 heavy chain specific 
for the hapten NP (Hebell et al., 1991).   
 
pFUSE-hIgG1-Fc2  Commercially available vector containing the IL-2 signal 
sequence and the CH2 and CH3 domains and the hinge region of 
the human IgG1. Invivogen, San Diego, USA.   
 
pMT/BioHis-IAbα Vector containing the metallothionein promoter, necessary for 
expression of proteins in the Drosophila cells, the BiP signal 
sequence, a mouse MHC-II α chain, the specific biotinylation site 
(Schatz, 1993) recognized by the BirA enzyme and a 
polyhistidine tag (Schiemann, 2005). This vector was kindly 
provided by D. Busch, Institute of Medical Microbiology, Dept. 
of Medicine, Technical University Munich.  
 
pcDNA3.1/V5HiABio  Vector containing the CMV promoter, a multiple cloning site and 
encoding the specific biotinylation site recognized by the BirA 
enzyme and Polyhistidine tag. This vector was kindly provided by 
I. Müller, Dept. of General Paediatrics, Hematology and 
Oncology, University Children's Hospital, Tübingen.   
 
pMT/BiP/His/StrepTagIII-IAbα  Vector containing the metallothionein promoter, 
necessary for expression of proteins in the Drosophila cells and 
DNA sequences encoding the BiP signal sequence, a mouse 
MHC-II α chain, a thrombin cleavage site, an acidic leucine 
zipper domain and after the KpN2I restriction site the Strep-Tag 
III amino acid sequence (Neudorfer et al., 2007). This vector was 
kindly provided by D. Busch, Institute of Medical Microbiology, 
Dept. of Medicine, Technical University Munich.  
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2.1.6 Oligonucleotides 
The orientation of all oligonucleotides is 5’ to 3’. Restriction sites contained in the 
oligonucleotides appear underlined. All oligonubleotides were synthesized by MWG- 
Biotech AG (Ebersberg, Germany) or Sigma (Taufkirchen, Germany). 
 
- Primers used for the amplification and direct sequencing of rat CD1d genomic DNA 
sequences: 
gCD1d fo 77: CAAGGGGAGTTGGCTTTGTA  
gCD1d re 78: GTGGAGAACCAGGGTGAAAA  
 
- Primers used for IgG heavy chain and kappa light chain RT-PCR and direct 
sequencing. These oligonucleotides were adapted from Wang et al. (Wang et al., 
2000): 
MH2_82: SARGTNMAGCTGSAGSAGTCWGG 
IgGrev 2_ 101: CAGACTGCAGGAGAGCTGG  
 
Mk_84: GAY ATT GTG MTS ACM CAR WCT MCA  
Igk rev 1_103: CACTTGACATTGATGTCTTTGG  
Igk rev 2_104: TTTGCTGTCCTGATCAGTCC  
 
- Primers used for RT-PCR of rat β-actin. The forward and reverse primers are 
complemetary to the exon 4 and 5, respectively (designed by R. Rudolf): 
RNBetaActFwd17: CACCACCACAGCTGAGAGG  
RNBetaActRev18: AGACAGCACTGTGTTGGCATAG  
 
- Primers used for RT-PCR and sequencing of AV14-containing TCRα mRNAs: 
rVa14lead gDNA f (50): CTTCTGCAGAAAAACCATGGGGAAG  
rJa18lead gDNA r(51): AGGTGTGACAGTCAGCTGAGTTCC               
rCa_seq2nd_118: AGTCGGTGAACAGGCAGAGGG  
rAV14int_124: CCTTCAATGCAATTACACTGTG 
 
- Primers used for RT-PCR of BV8-containing TCRβ mRNAs: 
rVb8_seq_fow_122: TGGGCTCCAGGTTCCTCTTAGTG  
rVb8_seq_rev_123: GCCAAGCACACGAGGGTAGC 
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- Oligonucleotides used for real time PCR: 
rVa14_Bendef 79: CTAAGCACAGCACCCTGCACA  
rJ281_Bende 80: CAGGTGTGACAGTCAGCTGAGTTC  
rt_rCaE1_fo 71: AAGCTTCAGCTGCAAAGACG   
rt_rCaE3_re 72: GATTCGGAGTCCCATGACTG  
 
- Primers used for cloning of Mus musculus CD1d2 and Mus spretus CD1d1 into 
pczCFG5 IEGN retroviral expression vector: 
mCD1d_fo EcoRI: GGGGAGAATTCCGGCGCTATGCGGTACCTACC  
msCD1d_BamHIrev_113: GCATGGATCCTCACCGGATGTCTTGATAG  
 
- Primers used for cloning of rat CD1d into pczCFG5 IZ retroviral expression vector: 
rCD1d_EcoRI_f62: CTTCGAATTCGACCGCCGGCACTATGCTGT 
rCD1d_BamHI_r63: GTTGGGATCCCTCACATGATGTCTTGATAGG 
 
- Primers used for rat β2-microglobulin cloning into pczCFG5 IZ retroviral 
expression vector: 
MfeI b2 fow P3:  TGCCAATTGGCCGCCACCATGGCTCGCTCGGTGACC 
rb2m BamHI re P2: TGAGGATCCTTACATGTCTCGGTCCCAGG 
 
- Primers used for cloning mouse CD1d and rat CD1d into the pXIg vector were 
based in the work of MacDonald and colleagues (Schumann et al., 2003): 
mCD1d-MD-MluI-F: 
GTCCACGCGTCGCAGCAAAAGAATTACACCTTCCGC  
mCD1d-MD-XhoI-Rev: 
GTCACTCGAGCCAGTAGAGGATGATATCCTGTC 
rCD1d-MD-MluI-F: GTCCACGCGTCGCAGCAGAATTACACCTTCGGC 
rCD1d-MD-XhoI-R: GTCACTCGAGCCAGTAGAGGATGATGTCCTGCC 
 
- Primers used for cloning of rat CD1d into the pFUSE-hIgG1-Fc2 vector: 
rCD1dEcoRI Fc2_88: CTCAGAATTCGGTCCAGCAGAATTACACCTTC 
rCD1dBamHI Fc_86: CTACGGATCCCCAGTAGAGGATGATGTC   
 
- Primers used for cloning of rat β2-microglobulin and the glycine-serine polylinker 
into the rat CD1d-pFUSE-hIgG1-Fc2: 
rb2 MunI fo_105: CCCCAATTGTCAGAAAACTCCCCAAATTCAAG 
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rb2m MunI rev_106: 
CCCCAATTGCTTCCACTTCCACTTCCACTTCCACTTCCACTTCCCATGT
CTCGGTCCCAGGTG 
 
- Primers used for cloning of rat CD1d into pMT/BioHis-IAbα vector once the 
Kpn2I restriction site had been inserted: 
Ok CD1d SacII For: AATTGGCCGCGGGGTCCAGCAGAATTACACCT   
CD1d Kpn2I Rev: AGTAATCCGGACCAGTAGAGGATGATGTC 
 
- Primers used for the insertion of the Kpn2I site into the pMT/BioHis-IAbα vector: 
Kpn2I Forward: 
GGAAAAGGAACTGGCTCAGTCCGGACTTAATGACATTTTCGAGG  
Kpn2I  Reverse: 
CCTCGAAAATGTCATTAAGTCCGGACTGAGCCAGTTCCT 
 
- Primers used for cloning of rat β2-microglobulin-CD1d into the pcDNA3.1/V5 
His A Bio vector (Methods section 2.2.2.8): 
IL2ko EcoRV_111: TAGAGATATCGAAGGAGGGCCACCATGTA 
rCD1drev XhoI_112/3: TACACTCGAGCCAGTAGAGGATGATGTCCT 
  
- Primers used for cloning of rat β2-microglobulin-CD1d into the pMT/BiP/His-
IAbα StrepTag III vector (Methods section 2.2.2.9):  
rb2mSacII_114: TGCACCGCGGACAGAAAACTCCCCAAATTCAAG 
CD1d Kpn2I Rev: AGTAATCCGGACCAGTAGAGGATGATGTC 
 
- Primers used for cloning of AV14-containing TCRα chains into the retroviral 
expression vector (designed by E. Pyz): 
rVa14EcoRI-Fow: GGGCTAGAATTCTGCAGAAAAACCATGGGGAAG    
Ca end BamH1 antisense: 
ATGCGGATCCTCAACTGGACCACAGCCTTAGCGTCATGAG    
TTTCC 
 
 
- Primers used for sequencing of pczCFG5 IZ and pczCFG5 IEGN vectors: 
PSI:  CACGTGAAGGCTGCCGACC 
IRE II seq: TGGAAAATAACATATAGA 
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- Primers used for sequencing of pXIg/CD1d-pXIg vectors (designed by E. Pyz and 
I. Müller): 
pX/Ig fow: CAG GTC CAA CTG CAC GCG 
N4 (fow): TGGGTGATGTGGATGCGGGGT 
r/mCD1-alpha1-Re: GTCTTCTTTAGGTGACATCATTTTGAC 
pX/Ig rev: GAC CTG GCT CAC CTC GAG 
 
- Primers used for sequencing of pFUSE-hIgG1-Fc2 vectors: 
pFUSE Fc fow_90: TTGCTCAACTCTACGTCTTTG  
pFUSE Fc rev_91: GGTGTCCTTGGGTTTTGG      
 
- Primers used for sequencing of pMT/BiP/BioHis vectors: 
MT Forward: CATCTCAGTGCAACTAAA  
BGH Reverse: TAGAAGGCACAGTCGAGG  
 
- Primers used for sequencing of rat pcDNA3.1/V5 His A Bio vector: 
pcDNA3 fo_107: GAGCTCTCTGGCTAACTAGAG 
pcDNA3 rev_108: GGCAAACAACAGATGGCTGG 
 
- Primers used for sequencing of pMT/BiP/His/StrepTagIII vectors: 
OpIE2 Forward_59: CGCAACGATCTGGTAAACAC 
OpIE2 Reverse_60: GACAATACAAACTAAGATTTAGTCAG 
rCD1d seq_61: GCAGATACTCCTGAACGACA 
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2.1.7 Antibodies and secondary reagents 
• Primary antibodies 
Antigen Clone Conjugation Isotype Purchased from 
m TCRβ  H57-597 APCy or FITC hamster IgG2, λ1 BD Pharmingen 
m CD4 RM4-5 APCy or PE-Cy5 rat IgG2a, κ BD Pharmingen 
m CD21 (CR2/CR1) 7G6 FITC rat IgG2b, κ BD Pharmingen 
m CD23 (FcεRII) B3B4 PE rat IgG2a, κ BD Pharmingen 
m CD19  1D3 APCy rat IgG2a, κ BD Pharmingen 
m CD8  53-6.7 APCy rat IgG2a, κ BD Pharmingen 
m NK1.1 PK136 FITC or PE mouse IgG2a, κ BD Pharmingen 
r TCRβ  R73 FITC, PE or bio mouse IgG1, κ BD Pharmingen 
r CD4  OX-35 PE, PE-Cy5 or APCy mouse IgG2a, κ BD Pharmingen 
r CD4 OX-38 PE mouse IgG2a, κ BD Pharmingen 
r CD8β  341 bio mouse IgG1, κ BD Pharmingen 
r CD8α  OX-8 PerCP mouse IgG1, κ BD Pharmingen 
r dendritic cell 
marker OX-62 unconjugated mouse IgG1, κ BD Pharmingen 
r CD11b/c  OX-42 PE mouse IgG2a, κ BD Pharmingen 
r CD45RA  OX-33 FITC or bio mouse IgG1, κ BD Pharmingen 
r MZ B cell marker HIS57 bio mouse IgG1, κ BD Pharmingen 
r IgM  G53-238 FITC mouse IgG1, κ BD Pharmingen 
r IgD  MARD-3 bio mouse IgG1 AbD Serotec 
r BV8 TCRβ R78 bio or unconjugated   
BD Pharmingen or 
purified in our 
laboratory 
r BV16 TCRβ HIS42 unconjugated mouse IgG1, κ Hybridoma 
supernatant 
r NKR-P1A/B 10/78 bio or PE mouse IgG1, κ BD Pharmingen 
m CD1d 1B1 PE  rat IgG2b, κ BD Pharmingen 
h CD1d CD1d42 PE  
Kind of gift of 
Ekkehard Kämpgen, 
Dermatology Dept. 
University of 
Erlangen. 
r/m CD1d 233 (WTH-1) 
bio, FITC or 
unconjugated mouse IgG2a, κ 
purified and 
conjugated in our 
laboratory 
r/m CD1d 35  (WTH-2) 
bio, FITC or 
unconjugated 
purified and 
conjugated in our 
laboratory 
purified and 
conjugated in our 
laboratory 
r CD1d  58 bio, FITC or 
unconjugated 
purified and 
conjugated in our 
laboratory 
purified and 
conjugated in our 
laboratory 
ERK2   
C-14, sc-154, 
polyclonal rabbit 
antiserum 
Santa Cruz  
Biotechnology 
 
Table 1. Antibodies used in FACS stainings or Westernblot. Abbreviations: m, mouse; r, rat and h, 
human.  
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• Secondary antibodies 
Antigen Antibody Conjugation Purchased from 
Mouse IgG (H+L) 
Donkey F(ab’)2 fragment with minimal 
cross-reaction to rat and other species 
serum proteins 
FITC or PE 
Jackson 
Immunoresearch 
Laboratories 
Human IgG, Fcγ 
Fragment Specific 
Goat AffiniPure F(ab’)2 fragment  with 
minimal cross-reaction to bovine, mouse 
and rabbit serum proteins 
PE 
Jackson 
Immunoresearch 
Laboratories 
Mouse IgG1 Rabbit serum unconjugated ICN Biochemicals  
Mouse Goat secondary antibody HRP Santa Cruz  Biotechnology 
Rabbit  Goat secondary antibody HRP Santa Cruz  Biotechnology 
 
Table 2. Secondary antibodies used in FACS stainings or Westernblot analyses.  
 
• Secondary Reagents 
Reagent Binds to Conjugation Purchased from 
Streptavidin Biotin HRP BD Pharmingen 
Streptavidin Biotin APCy, PE or PE-Cy5  BD Pharmingen 
Strep-Tactin®   Strep-tag PE IBA (Göttingen, Germany) 
 
Table 3. Reagents used for the detection of biotin/Strep-tag conjugated antibodies or molecules.  
 
2.1.8 Enzymes and inhibitors 
T4-DNA-Ligase     Fermentas (St.Leon-Rot, Germany) 
Pfu-DNA Polymerase    Finnzymes (Espoo, Finnland) 
Restriction Enzymes: BamHI, EcoRI, EcoRV, MfeI (MunI), MluI, XhoI, Cfr42I (SacII), 
Kpn2I (BspEI) and PvuI    Fermentas (St.Leon-Rot, Germany) 
Trypsin  BD Biosciences Pharmingen (San Diego, 
USA) 
Biotin-protein ligase BIRA500   Avidity (Colorado, USA) 
Complete Mini    Roche (Mannheim, Germany) 
 
2.1.9 Commercially available kits and mixtures 
Big Dye 3.1  AB applied biosystems (California, USA) 
ELISA kits: rat IFN-γ and IL-4 and IL-10; mouse IFN-γ and IL-4  BD Biosciences     
GeneJET Plasmid Miniprep Kit   Fermentas (St.Leon-Rot, Germany) 
JET quick DNA clean Up Spin Kit  Genomed (Löhne, Germany) 
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MESA GREEN qPCR MasterMix   Eurogentec (Seraign, Belgium) 
Midi and Maxi JETSTAR Kits   Genomed (Löhne, Germany) 
Mini Elute Gel Extraction Kit  Qiagen (Hilden, Germany) 
Mouse monoclonal antibody isotyping test kit AbD Serotec (Kidlington, UK) 
PCR Master Mix containing Taq-DNA Fermentas (St.Leon-Rot, Germany) 
QIAamp DNA Mini Kit   Qiagen (Hilden, Germany) 
QuikChange II Site-Directed Mutagenesis Kit  Qiagen (Hilden, Germany) 
Rat IL-4 ELISPOT Set   BD Biosciences Pharmingen (San Diego, 
USA) 
RNAeasy Mini Kit    Qiagen (Hilden, Germany) 
QIAshredder     Qiagen (Hilden, Germany) 
 
2.1.10 Consumables 
6 well flat bottom culture plates   Greiner Bio-One (Germany) 
12 well flat bottom culture plates   Greiner Bio-One (Germany) 
24 well flat bottom culture plates   Greiner Bio-One (Germany) 
48 well flat bottom culture plates   Greiner Bio-One (Germany) 
96 well U bottom culture plates    Greiner Bio-One (Germany)  
6 cm tissue culture dish    Greiner Bio-One (Germany)  
50 ml cell culture flask    Greiner Bio-One (Germany) 
5, 15 and 25 ml single use pipettes  Greiner Bio-One (Germany) 
1.5 ml Eppendorf centrifuge tube   Eppendorf (Eppendorf, Germany) 
15 ml centrifuge tube 50 ml centrifuge tube  Greiner Bio-One (Germany) 
Cuvette      Bio-Rad (Munich, Germany) 
10 µl tips      Molecular Bioproducts (USA) 
200 µl yellow tips     Roth (Karlsruhe, Germany) 
1000 µl blue tips     Roth (Karlsruhe, Germany) 
2 ml and 5ml single-use syringe   BD Biosciences Pharmingen (San Diego, 
USA)  
60 ml single-use syringe   Dispomed (Gelnhausen, Germany) 
Cell strainer 70 µm     BD Biosciences Pharmingen (USA) 
Needles (of different sizes) for single use Dispomed (Gelnhausen, Germany) 
Polystyrene half area 96 well plates   Corning Incorporated (New York, USA) 
Absorbent paper for Western-Blot   Schleicher & Schuell (Dassel, Germany) 
 42 
Poly-Prep Colums     Bio-Rad (Munich, Germany) 
Roti-PVDF membrane for Western-Blot  Roth (Karlsruhe, Germany) 
 
2.2 Methods 
2.2.1 Routine molecular biology methods 
• Spectrophotometric determination of RNA and DNA amounts 
Quantification of RNA and DNA was performed at wavelengths of 260 and 280 nm 
using the Ultrospec 2000 spectrophotometer (Pharmacia Biotech) following the 
instructions provided by the manufacturer.  
 
• Genomic DNA isolation 
Genomic DNA from thymocytes or ears was purified using the QIAamp DNA Mini 
Kit from Qiagen following the instructions provided by the manufacturer.  
   
• RNA isolation 
RNA isolation was carried out with the RNAeasy Mini Kit following the 
instructions of the manufacturer and using QIAshredder to disrupt the cells. 4-5*106 
and 1-2*106 cells were used to isolate RNA from primary cells (thymocytes, 
splenocytes and IHLs prepared as described in the methods section 2.2.7.3) and 
from hybridomas, respectively.  
 
• cDNA synthesis 
cDNA synthesis was carried out using the First Strand cDNA Synthesis Kit from 
Fermentas. 500 ng RNA and oligo(dT)18 primers were used for cDNA synthesis. 
cDNA was generally directly used as template for PCR except in real time PCR 
where cDNA was cleaned using the DNA Clean and ConcentratorTM-5 Kit and 
eluted in water.  
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• Polymerase chain reactions (PCRs) 
Various PCR protocols were followed depending on the aim of the experiment: 
- Amplification of IgG heavy and light chain cDNA from the hybridomas 
232, 233, 244, 35 and 58  
To asses the V(D)J gene segment usage of Ig genes of anti-CD1d mAb secreting 
hybridomas, heavy and light chain mRNAs were amplified by RT-PCR. After 
purification from agarose gels PCR products were directly sequenced.  
PCR mixture (50 µl) contained: 
2.5 µl cDNA  
5 µl primer mix (10µM) 
17.5 µl H2O 
25 µl PCR Master Mix 2x containing Taq DNA polymerase, MgCl2, and dNTPs 
 
The primer pairs used for the amplification of the heavy and light chains were 
MH2_82/IgGrev 2_101 and Mk_84/Igk rev 2_104, respectively. Forward 
degenerate primers were slightly modified from (Wang et al., 2000).  
PCR was carried out in an Eppendorf Mastercycler thermocycler as follows:  
1 min at 94 ºC 
1 min at 45 ºC  
2 min at 72 ºC  
Repeated 30 times 
 
Sequencing of the heavy chain was carried out with the IgGrev 2_ 101 primer 
and of the light chains with the Igk rev 1_103 and Igk rev 2_104 primers.  
 
- 1.5.2 Analysis of rat CD1d alleles by PCR amplification of genomic DNA 
Genomic DNA from 10 different inbreed rat strains (see animals) containing the 
exons 1 to 3 and the respective introns was amplified by PCR and directly 
sequenced after purification on agarose gels.  
The PCR mixture contained: 
500 ng of genomic DNA as template 
2.5 µl primer mix (10µM) 
10 µl 5x HB buffer (containing 7.5 mM MgCl2) 
1 µl dNTPs (10mM) 
0.5 µl Phusion DNA polymerase  
H2O until a final volume of 50 µl was obtained 
 
The primers used for PCR amplification and also direct sequencing were gCD1d 
fo 77 and gCD1d re 78.  
 44 
The PCR program repeated 30 times was: 
10 sec at 98 ºC 
30 sec at 60 ºC 
45 sec at 72 ºC 
 
- RT-PCR and direct sequencing of AV14- and BV8-containing TCRs 
In order to asses the presence of AV14+ TCRα and BV8+ TCRβ chains, AV14-
AJ18 rearrangements and β-actin transcripts among thymocytes, splenocytes and 
IHLs RT-PCR was performed as follows:  
PCR Mixture (20 µl) contained: 
1 µl cDNA template 
1 µl primer mix (10µM) 
8 µl H2O 
10 µl PCR Master Mix 2x containing Taq DNA polymerase, MgCl2, and dNTPs 
The primer pairs used were: 
Amplified product Primers 
β-actin RNBetaActFwd17 and RNBetaActRev18 
AV14-AJ18 (Fig. 20) rVa14lead gDNA f (50) and rJa18lead gDNA r(51) 
AV14-AC (Fig. 20) rVa14lead gDNA f (50) and rCa_seq2nd_118 
BV8-BC rVb8_seq_fow_122 and rVb8_seq_rev_123 
 
Table 4. Primers used in RT-PCR analyses of AV14- and AV14-AJ18-containing TCRs.  
 
The program followed in the Eppendorf Mastercycler, repeated 28 and 35 times 
for β-actin and for the other PCR products, respectively, was: 
10 sec at 98 ºC 
30 sec at 66 ºC 
30 sec at 72 ºC 
13µl of PCR products were mixed with 3µl of 6×loading buffer and were loaded 
onto 1% agarose gels containing 1 µg/ml ethidium bromide. After 
electrophoresis DNA amounts were visualized and imaged using a UV 
transilluminator (Intas UV System) equipped with a camera. 
 
In order to asses AV14 and AJ gene segment usage in AV14 and AV14-JA18 
comprising TCRs by direct sequencing, the primers used were the same as in the 
RT-PCR described above (Table 4) but the PCR mixture differed. 
 PCR mixture (50 µl):   
1-3.5 µl cDNA template 
2.5 µl primer mix (10µM) 
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10 µl 5x HB buffer (containing 7.5 mM MgCl2) 
1 µl dNTPs (10mM) 
0.5 µl Phusion DNA polymerase  
32.5-35 µl H2O 
 
The program followed in the Mastercycler (Eppendorf) and repeated 35-40 times 
was: 
10 sec at 98 ºC 
30 sec at 66 ºC 
30 sec at 72 ºC 
After purification on agarose gels, the PCR products were directly sequenced 
using the same forward and reverse primers as in the RT-PCR and the 
rAV14int_124 primer. 
 
- Insert preparation by PCR.  
Inserts for cloning were generated by PCR with primers containing the desired 
modifications such as restriction sites or the nucleotide sequences needed for the 
creation of fusion proteins.  
The PCR mixture generally contained:  
2-3 µl of cDNA or 50 ng of cloned template 
2.5 µl primer mix (10µM) 
10 µl 5x HB buffer (containing 7.5 mM MgCl2) 
1 µl dNTPs (10mM) 
0.5 µl Phusion DNA polymerase  
and H2O until a final volume of 50 µl 
 
The program followed in the thermocycler and repeated 25 to 35 times 
depending on the nature of the template was: 
10 sec at 98 ºC 
30 sec at 66 ºC 
30 sec at 72 ºC 
 
• Real time PCR 
Real time PCR was conducted running triplicates. The PCR mixture (25 µl) 
contained: 
1 µl cDNA (previously cleaned with the DNA Clean and ConcentratorTM-5 Kit 
1 µl primers (7.5 µM AC primer mix or 2.5 µM iTCR primer mix) 
10.5 µl H2O 
12.5 µl 2x MESA GREEN including: dNTPs, Meteor Taq DNA polymerase, MgCl2 
8 mM, SYBR Green I and stabilizers.  
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The primer-pairs used were rVa14_Bendef 79/rJ281_Bende 80 and rt_rCaE1_fo 
71/rt_rCaE3_re 72 for amplification of AV14-AJ18 rearrangements (iTCR) and the 
constant region of the TCRα chain (AC), respectively (Fig. 21).    
The protocol followed in the thermocycler iCycler (Bio-Rad) was:  
Cycle 1 (1 repetition): 5 minutes at 95 ºC 
Cycle 2 (40 repetitions): 15 sec at 95 ºC, 20 sec at 65 ºC and 40 sec at 72 ºC. Data 
collection 
Cycle 3 (1 repetition): 1 minute at 95 ºC  
Cycle 4 (1 repetition): 1 minute at 52 ºC 
Cycle 5 (86 repetitions): 10 sec at 52 ºC and then increase set point temperature 
after repetition 2 by 0.5 ºC. Data collection.  
Cycle 6 (1 repetition): Hold at 15 ºC.  
 
• Sequencing 
Amplification of DNA was carried out in a 5 µl mixture containing: 
3 µl template DNA (750 ng if the amplified template was contained in an expression 
vector) 
0.5 µl sequencing primer (10 µM) 
0.5 µl sequencing buffer 
1 µl Big Dye terminator v3.1 containing DNA polymerase and fluorescently-labelled 
ddNTPs  
 
 25 amplification cycles were performed in the thermocycler: 
30 sec 96 ºC 
15 sec 50 ºC 
4 min 60 ºC 
Sequences were analyzed in an ABI sequencer. 
 
• Preparation and ligation of inserts and vectors 
Inserts and vectors were prepared by digestion with restriction enzymes. The 
digestion was performed following the manufacturer’s indications. Purification of 
digested DNA was carried out on agarose gels. After purification small aliquots of 
vector and insert were loaded on an agarose gel and electrophoresis was performed 
in order to assess purity and relative quantity of each component. Ligation was 
carried out at a 3:1 insert:vector ratio with DNA T4 ligase following the 
manufacturer’s instructions.  
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• DNA purification from agarose gels 
After electrophoresis, the fragment of the agarose gel containing the desired DNA 
was cut out from the gel and DNA was extracted with two different kits depending 
on whether the purified DNA was going to be sequenced or not. The Mini Elute Gel 
Extraction Kit (Qiagen) was used to purify PCR products which were subsequently 
sequenced and the JET quick DNA clean Up Spin Kit (Genomed) was used to 
purify vectors and inserts after digestion. 
 
• Transformation  
1-10 µl of the ligation product were added to 50 or 100 µl of competent cells contained 
in a 1.5 ml plastic tube and incubated for 5 minutes on ice. Subsequently the tubes were 
placed for 90 seconds in a water bath preheated at 42 ºC and the tubes were returned 
to ice where they were incubated for 2 minutes. After the addition of 150 µl of LB-
SOC media, the bacteria were incubated for 1 hour with agitation at 37 ºC. Then the 
bacteria were spread on 1 or 2 agar plates containing selecting antibiotics and were 
incubated over night at 37 ºC.  
 
• Bacteria cultures 
Most of the vectors used in this study contained ampicillin resistance. Thus, cultures 
in agar plates and LB media were carried out with in the presence of 100 µg/ml 
ampicillin, unless the cultured bacteria contained pFUSE-hIgG1vectors, in which 
case, 50 µg/ml Zeocin were added to low-salt LB-agar plates and liquid cultures. 
 
• Mini, midi and maxi preparations of DNA vectors  
Different volumes of bacteria cultures, depending on the type of desired DNA 
amounts were incubated overnight at 37ºC with rotation (180 rpm): 5 ml for mini- 
50 ml for midi- and 250 ml for maxi-preparations. All the DNA-preparations were 
carried out with commercial kits following the indications of the manufacturer. The 
kits used were: GeneJET Plasmid Miniprep Kit (Fermentas), and Midi and Maxi 
JETSTAR Kits (Genomed). After purification of midi- and maxi-preparations, DNA 
concentration measured by spectrophotometry (Methods section 2.2.1) and 
generally, an aliquot (250 ng) was digested analyzed by electrophoresis to assess the 
quality of the DNA sample.  
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2.2.2 Cloning 
2.2.2.1 Cloning of Mus musculus CD1d2 and Mus spretus CD1d1 into pczCFG5 
IEGN 
Mus musculus CD1d2 and Mus spretus CD1d1 cDNA sequences were cloned into the 
EcoRI and BamHI sites of pczCFG5 IEGN. Vectors containing the CD1d cDNA 
sequences amplified by PCR to use as inserts, were kindly provided by Wang, C.R and 
are described elsewhere (Chen et al., 1999; Zimmer et al., 2009). PCR was performed 
using the mCD1d_fo EcoRI and msCD1d_BamHIrev_113 primers in order to introduce 
the EcoRI and BamHI restriction sites at the 5’ and 3’ ends of the CD1d cDNA 
sequences.  
 
2.2.2.2 Cloning of rat CD1d cDNA into pczCFG5 IZ 
CD1d cDNA sequences derived from LEW, DA, BN and PVG thymocytes were cloned 
into the EcoRI and BamHI sites of pczCFG5 IZ after PCR amplification of thymus-
derived cDNA with the primers: rCD1d_EcoRI_f62 and rCD1d_BamHI_r63 and 
subsequent double digestion.  
 
2.2.2.3 Cloning of rat β2-microglobulin into the retroviral expression vector 
pczCFG5 IZ (Carried out by P. Neuhöfer)  
Rat β2-microglobulin was amplified from LEW splenocytes cDNA by PCR using the 
MfeI b2 fow P3 and rb2m BamHI re P2 primers, with which the restriction sites MfeI 
and BamHI were introduced at the 5’ and 3’ ends of β2-microglobulin, respectively. 
After double digestion with MfeI and BamHI, the resulting product was inserted into 
the EcoRI and BamHI restriction sites of the retroviral expression vector pczCFG5 IZ. 
The sequence of the cloned β2-microglobulin was identical to the sequence published in 
the GenBank under the accession number NM_012512.  
 
2.2.2.4 Cloning of mouse CD1d into pXIg (Carried out by E. Pyz and I. Müller)  
As previously described by others (Schumann et al., 2003), the α1-α3 domains of mouse 
CD1d cDNA were cloned into MluI and XhoI restriction sites of the pIXg vector. For 
this purpose, the insert was prepared by introducing MluI and XhoI restriction sites by 
PCR using mouse CD1d cDNA cloned into pczCFG5 IZ  (Pyz et al., 2006) as template 
and the mCD1d-MD-MluI-Fow and mCD1d-MD-XhoI-Rev primers. To assure the 
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correct sequence of the mouse CD1d-IgG1 fusion molecule, sequencing was carried out 
with the primers: pX/Ig fow, N4 (fow), r/mCD1-alpha1-Re and pX/Ig rev.  
 
2.2.2.5 Cloning of rat CD1d into pXIg (Carried out by E. Pyz and I. Müller).  
As mouse CD1d, the cDNA encoding the α1-α3 domains of rat CD1d was cloned into 
the MluI and XhoI restriction sites of the pXIg vector. By PCR, CD1d cDNA was 
amplified from rat CD1d cloned into pczCFG5 IEGZ (Pyz et al., 2006) and restriction 
sites were introduced. rCD1d-MD-MluI-F and rCD1d-MD-XhoI-R are the primers 
which were used. The signal sequence of CD1d was not included, because the pXIg 
vector contains the signal sequence of the IgG1 heavy chain. In order to prove the 
correct insertion of rat CD1d into the pXIg vector, pX/Ig fow, N4 (fow) and pX/Ig rev 
primers were used for sequencing.  
 
2.2.2.6 Cloning of rat β2-microglobulin-CD1d fusion protein into the pFUSE-
hIgG1-Fc2 vector 
First of all, rat CD1d was cloned into the pFUSE-hIgG1-Fc2 plasmid, creating a fusion 
protein with the rat CD1d extracellular domains (α1- α3) inserted between the IL-2 
signal sequence and the human IgG1 Fc portion. The CD1d insert was produced by 
PCR from previously cloned rat CD1d cDNA (Pyz et al., 2006) using the primers 
rCD1dEcoRI Fc2_88 and rCD1dBamHI Fc_86. The PCR product contained the EcoRI 
and BamHI restriction sites, and after double digestion it was inserted into the EcoRI 
and BglII sites of the pFUSE-hIgG1-Fc2 vector. Subsequently, rat β2-microglobulin 
was attached to this fusion protein-construct. To this end, rat β2-microglobulin cDNA 
was amplified from a retroviral expression vector (see methods section 2.2.2.3) using 
rb2 MunI fo_105 and rb2m MunI rev_106 primers, which did not amplify the rat β2-
microglobulin signal sequence. These primers allowed not only to insert the MunI 
restriction site at both, 5’ and 3’ ends of the β2-microglobulin cDNA, but also to include 
a glycine-serine linker at the 3’ end. The resulting product was digested with MunI and 
inserted into the EcoRI site of the previously cloned rat CD1d pFUSE-hIgG1-Fc2 
plasmid. Sequencing was carried out with the pFUSE Fc fow_90 and pFUSE Fc rev_91 
primers to assure that the final fusion protein consists of the IL-2 signal sequence, rat 
β2-microglobulin linked to rat CD1d by a glycine-serine linker and, at the 3’ end of 
CD1d, the human IgG1Fc portion.  
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2.2.2.7 Cloning of rat CD1d into the pMT/BioHis-IAbα vector 
In the first place, in order to allow the insertion of rat CD1d between the BiP signal 
sequence and the biotinylation site contained in the pMT/BioHis-IAbα vector produced 
by M. Schiemann, Institute of Medical Microbiology, Dept. of Medicine, Technical 
University Munich (Schiemann, 2005), the Kpn2I restriction site was included before 
the specific biotinylation sequence by site directed mutagenesis with the QuikChange II 
Site Directed Mutagenesis Kit. The primers used were Kpn2I Forward and Kpn2I 
Reverse. This vector contains a metallothionein promoter and a BiP signal sequence 
which are necessary for protein production in SC2 cells. After addition of the Kpn2I 
restriction site, the insert (an MHC II α chain) was excised by double digestion with 
SacII and Kpn2I and replaced by the extracellular domains of rat CD1d. The rat CD1d 
insert was prepared by PCR using rat CD1d cDNA (Pyz et al., 2006) as template and 
the Ok CD1d SacII For and CD1d Kpn2I Rev primers, followed by double digestion 
with the SacII and Kpn2I restriction enzymes. Sequencing of the final plasmid was 
carried out with the MT Forward and BGH Reverse primers.  
 
2.2.2.8 Cloning of rat β2-microglobulin-CD1d into the pcDNA3.1/V5 His A Bio 
vector  
The fusion protein containing the IL-2 signal sequence, rat β2-microglobulin and rat 
CD1d (see methods section 2.2.2.6), previously constructed for the production of the 
human Fc dimers, was amplified by PCR with the IL2ko EcoRV_111 and rCD1drev 
XhoI_112/3 primers. After double digestion it was inserted into the EcoRV and XhoI 
sites of the pcDNA3.1/V5 His A Bio vector 5’ to the biotinylation sequence and the 
polyhistidine tag. Sequencing of the final construct was carried out with the pcDNA3 
fo_107 and pcDNA3 rev_108 primers. 
 
2.2.2.9 Cloning of rat β2-microglobulin-CD1d into the pMT/BiP/His/Strep TagIII-
IAbα vector  
To produce the rat CD1d strep-tag fusion construct, the cDNA encoding the rat β2m-
CD1d fusion protein (described in the methods section 2.2.2.6), was cloned into the 
pMT/BiP/His-IAbα StrepTag III. This vector contains the BiP signal sequence necessary 
for secretion in SC2 cells. Therefore, the rat β2-microglobulin CD1d construct was 
cloned into the SacII and Kpn2I restriction sites without the IL-2 signal sequence. The 
vector was linearized by double digestion with SacII and Kpn2I and the insert (a mouse 
 51 
MHC class II α chain) was replaced by the rat β2m-CD1d construct. The SacII and 
Kpn2I restriction sites in the rat β2m-CD1d insert were introduced by PCR 
amplification using the rb2mSacII_114 and CD1d Kpn2I Rev primers. Sequencing of 
the final construct was carried out with the MT Forward priming site and rCD1d seq_61 
primers to assure that it contained the BiP signal sequence, rat β2-microglobulin fused 
to CD1d by a glycine-serine linker and the strep-tag.  
 
2.2.2.10 Cloning of AV14-containing TCRα chains  
AV14-containing TCRα chain cDNAs were cloned into the EcoRI and BamHI of the 
retroviral expression vector pczCFG5 IZ after RT-PCR amplification of splenocytes or 
intrahepatic lymphocytes-derived RNA using the primers rVa14EcoRI-Fow and Ca end 
BamH1 antisense. 
 
2.2.3 Production and purification of CD1d oligomers 
2.2.3.1 Mouse and rat CD1d-IgG dimers 
Plasmids encoding CD1d-IgG proteins were transfected by electroporation (after 
linearization with PvuI) into the endogenously λ light chain expressing J558L murine 
plasmocytoma cell line, as previously described (Schneck, 2000). After G-418 selection 
and single cell cloning, screening of clones secreting high CD1d-Ig levels was carried 
out with the CD1d Sandwich ELISA described in the methods section 2.2.6. 
Subsequently, J558L cells producing rat CD1d-IgG dimers were retrovirally transduced 
with rat β2-microglobulin. Dimers were purified from large-scale serum-free cultures 
(ISF-1 media) by protein G affinity chromatography (Methods section 2.2.3.6). Protein 
purity of the different eluted fractions was monitored by SDS-PAGE and Coomassie 
Blue R250 staining (Fig. 14). Fractions containing CD1d dimers were collected and 
concentrated using Centriprep YM-30 columns or Vivaspin 6 (50.000 MWCO) at the 
same time as the elution buffer was exchanged for PBS. Final protein concentration was 
determined by photometry.  
 
2.2.3.2 Rat β2-microglobulin CD1d human Fc dimers 
293T cells were transfected using calcium chloride, selected with Zeocin, and cloned by 
limiting dilution. Clones were screened for protein secretion by CD1d Sandwich ELISA 
(see methods section 2.2.6) and the clone expressing the highest levels of rat β2-
microglobulin CD1d human Fc (rat β2m-CD1d-hFc) dimers was expanded with serum 
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containing media (DMEM). Prior to protein purification, culture media was exchanged 
by serum free media (ISF-1) and 48 hours later, the supernatant was harvested. Protein 
was purified by protein G affinity chromatography (Methods section 2.2.3.6). Purity of 
the different eluted fractions was controlled by SDS-PAGE followed by Coomassie 
Blue R250 staining (Fig. 14). As described for the mouse CD1d-IgG dimers, the 
fractions containing the rat β2m-CD1d-hFc dimers were collected, concentrated and the 
elution buffer was exchanged for PBS using a Centriprep YM-30 column. Since other 
proteins were present in the preparation (Fig. 14), only half of the protein concentration 
obtained by photometry was considered to be rat β2m-CD1d-hFc dimers.  
 
2.2.3.3 Rat CD1d production in SC2 drosophila cells  
Rat CD1d fused to a specific biotinylation sequence followed by a polyhistidine tag (rat 
CD1d-biotag) was constructed as described in the methods section 2.2.2.7. Plasmid 
transfection into SC2 cells, selection and isolation of CD1d producing clones, protein 
purification and biotinylation was performed by M. Schiemann, Institute of Medical 
Microbiology, Dept. of Medicine, Technical University Munich as previously described 
by A. Bendelac and colleagues (Benlagha et al., 2000). Protein purity was monitored by 
SDS-PAGE and Coomassie Blue R250 staining (Fig. 14). 
  
2.2.3.4 Rat β2-microglobulin-CD1d production in 293T human cells 
293T cells were transfected with the vector described in the methods section 2.2.9 using 
calcium chloride and selected with G-418. After single cell cloning, the clone producing 
the highest amounts of soluble rat CD1d protein, identified by analyzing the 
supernatants using CD1d Sandwich ELISA (Methods section 2.2.6), was expanded with 
serum containing media (DMEM). 72 hours prior harvesting, media was exchanged by 
serum free media (HyQ). S. Saremba, Julius von Sachs Institute, Dept. of Biology, 
University of Würzburg, purified the CD1d soluble protein by Ni-NTA 
chromatography. Protein purity was assessed by SDS-PAGE and Coomassie Blue R250 
staining (Fig. 14). Concentration was determined by photometry, taking in consideration 
the molar absorptivity of the final rat β2m-CD1d fusion protein.  
 
 
 
 53 
2.2.3.5 Rat β2-microglobulin-CD1d linked to a streptag production by SC2 
drosophila cells 
Transfection with the plasmid encoding the fusion protein described in the methods 
section 2.2.2.9 into SC2 drosophila cells, selection of the clones producing CD1d and 
protein purification using the strep-tag was carried out by M. Schiemann, Institute of 
Medical Microbiology, Dept. of Medicine, Technical University Munich. Protein purity 
was assessed by SDS-PAGE and Coomassie Blue R250 staining (Fig. 14). 
 
2.2.3.6 Protein G affinity chromatography 
1 ml of Protein G sepharose 4 Fast Flow stored with PBS containing 0.9% of sodium 
azide at 4 ºC was placed in a Poly-Prep 9 cm column and washed firstly with 5 ml of 50 
mM diethylamine (pH 11) at 1 ml/min and secondly with 10 ml PBS. The supernatant 
of 1.5 l of J558L cultures (in serum free media) was loaded at 1ml/min. The column 
was washed with 10 ml of PBS and with 5 ml of PBS containing 1M NaCl. Elution was 
carried out with 5 ml 50 mM diethylamine (pH 11) and protein was collected in 1.5 ml 
plastic tubes containing Tris buffer (2M at pH 6.0, 300 µl Tris for 5 ml eluted proteins).      
After elution, the column was washed with 20 ml of PBS and further purifications were 
carried out until the concentration of the dimers contained in the supernatant had dropt 
at least to one fifth of the initial concentration (monitored by CD1d Sandwich ELISA, 
methods section 2.2.6).  
 
2.2.3.7 Photometric determination of protein concentration  
Monoclonal antibody and dimer concentrations were measured by photometry using the 
Ultrospec 2000 spectrophotometer and calculated using the formula A280*1.46 - 
A260*0.74 = c (mg/ml), where A is absorbance and c is concentration. The concentration 
of monomeric rat β2m-CD1d-biotag (Methods section 2.2.3.4) was measured 
considering the molar absorptivity of the final fusion protein with the formula: c = A280 / 
ε L, where L is 1 cm; A the absorbance at 280 nm and ε the molar absorption coefficient 
which can be calculated with the formula:  ε = (nW*5500) + (nY*1490) + (nC*125), 
where n is the number of each amino acid residue and the stated values are the amino 
acid molar absorptivities at 280 nm (W, tryptophan; Y, tyrosine and C, cysteine).  
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2.2.3.8 Coomassie Blue staining 
After proteins were separated by SDS-PAGE and stacking gel was removed, 
polyacrylamide gels were submerged for 4 to 16 hours in Coomassie Blue staining 
solution. Subsequently, several incubations were carried out with destainig solution 
until the polyacrylamide gel appeared transparent and proteins could be visualized 
stained in blue.  
 
2.2.3.9 Specific biotinylation 
Specific biotinylation of the soluble CD1d-purified protein (150 µg) from 293T cells  
supernatants (Methods section 2.2.3.4) was carried out with BirA (3 µg) enzyme during 
2 hours and 45 minutes at 30 ºC and in a final volume of 279.5 µl, conditions which are 
recommended by the manufacturer. Specific biotinylation was assessed by incubating 
the biotinylated samples during 2 hours at room temperature in Polystyrene 96 well 
plates which had been pre-coated overnight with 50 µl of unconjugated 233 mAb 
diluted in coating buffer (100 ng/ml). After 5 washing steps with PBS containing 0.05% 
Tween, SA-HRP was added, incubated 1 hour at room temperature. Plates were washed 
5 more times (30 sec to 1 min incubations) and substrate solution was added for 30 
minutes. Reaction was stopped by addition of 25 µl of 2M H2SO4 solution and plates 
were read at 450 nm in the Vmax Kinetic Microplate Reader (Molecular Devices).  
 
2.2.3.10 Lipid loading into CD1d molecules 
α-Gal and β-Gal loading into CD1d recombinant proteins (rat and mouse CD1d-IgG 
dimers, rat β2m-CD1d-hFc dimers and of rat β2m-CD1d-streptag) was carried out at 37 
ºC during 24 hours in the presence of 0.05% TRITON X-100. Rat and mouse CD1d-IgG 
dimers were loaded with 40x molar excess of α-Gal or β-Gal at a final concentration of 
250 µg/ml. The rat β2m-CD1d-hFc dimers were also loaded with a 40x molar excess of 
α-Gal or β-Gal but at a final concentration of 138 µg/ml. Rat β2m-CD1d-streptag 
monomers were loaded with 20x molar excess of α-Gal or β-Gal at a final concentration 
of 100 µg/ml. 
 
2.2.3.11 Oligomerization of rat β2-microglobulin-CD1d linked to a streptag 
Rat β2m-CD1d-streptag monomers loaded with α-Gal or β-Gal as described in the 
methods section 2.2.3.10, and thus containing 0.05% TRITON X-100, were incubated 
with Strep-Tactin-PE for 45 min on ice. For each microgram of rat β2-m-CD1d-streptag 
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monomers, 5 µl Strep-Tactin-PE were added in a final volume of 50 µl achieved with 
the addition of FACS buffer.  
 
2.2.4 Immunoprecipitation 
Thymocytes and transduced cell lines were biotinylated with 2 mg/ml Sulfo-NHS-LC-
Biotin in PBS for 15 min on a rotating platform at 4 ºC and washed twice with RPMI 
(supplemented as for cultures) followed by two additional washing steps with 
BSS/BSA. After biotinylation, 106 transductants or 5*107 thymocytes were lysed in 1 ml 
of IP lysis buffer for 30 min on ice. Nuclei were removed by centrifugation immediately 
after lysis. Subsequently, the lysate was pre-absorbed one hour on Protein A Sepharose 
at 4 ºC. For specific immunoprecipitation, Protein A Sepharose beads were pre-coated 
with rabbit anti-mouse IgG before the addition of monoclonal antibodies. Then, the 
matrices were covalently linked as previously described (Schneider et al., 1982). Pre-
absorbed lysates were incubated overnight with specific immunomatrices. Precipitates 
were then washed four times with IP lysis buffer and were resuspended in IP loading 
buffer and boiled for 5 min before loading onto SDS-PAGE. The molecular weight 
marker used, PageRuler™ Prestained Protein Ladder, was purchased from Fermentas. 
After SDS-PAGE and blotting, membranes were incubated with streptavidin-HRP 
diluted 1:10000 in PBS containing 0.1% Tween during two hours at room temperature. 
After four washing steps with PBS containing 0.1% Tween detection was carried out 
using commercially available ECL reagents.  
 
2.2.5 Western blot analysis 
2.2.5.1 Binding capacities of anti-CD1d mAbs under reducing and non-reducing 
conditions 
In order to asses the binding capacities of the 233, 35 and 58 mAbs under reducing and 
non-reducing conditions, 250 µl of whole cell lysate-proteins from P80 cells transduced 
with rat CD1d  (2*107 P80rCD1d cells were lysed in 1 ml of lysis buffer) were mixed 
with reducing and non-reducing WB loading buffer and were separated by SDS-PAGE. 
In this case the stacking gel was casted with a comb containing one large sample well 
and one reference well. Proteins were transferred to a Roti-polyvinylidene difluoride 
membrane. Protein-free sites of the membranes were blocked with PBS containing 0.1% 
BSA and 5% non-fat dried milk was carried out during one hour at room temperature. 
After washing five times with PBS containing 0.1% Tween, membranes were placed 
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into a multiscreen apparatus which allowed the incubation of the membranes with at 
least 20 different antibodies solutions (specific antibodies and final concentrations are 
specified in the legend of Fig. 2). After overnight incubation at 4 ºC with the different 
antibody solutions, the membranes were washed and bound antibody was detected with 
a secondary HRP-conjugated Goat anti-mouse secondary antibody diluted in PBS 
containing 0.1% of Tween and 2.5% of non-fat dried milk during one hour at room 
temperature. After four washing steps with PBS containing 0.1% Tween, detection was 
carried out with commercially available ECL reagents.  
 
2.2.5.2 Binding of 233 and 35 mAbs to mouse and rat CD1d  
For the analysis of cell lines expressing rat and mouse CD1d, whole cell lysates (2*107 
cells in 1 ml WB lysis buffer) were mixed with WB non-reducing loading buffer and 18 
µl were separated by 10% SDS-PAGE. The molecular weight marker used, 
PageRuler™ Prestained Protein Ladder, was purchased from Fermentas. Proteins were 
transferred to a Roti-polyvinylidene difluoride membrane. For CD1d detection, 233 and 
35 mAbs were used at a final concentration of 0.75 µg/ml. Protein loading control anti-
ERK2 rabbit polyclonal antibody was used at a final concentration of 2 µg/ml. Primary 
antibodies were detected with HRP-conjugated goat anti-mouse antibody. All antibodies 
were diluted in PBS, 0.1% Tween and 2.5% non-fat dried milk. Films were developed 
by chemiluminescence using self-made or commercially available ECL reagents.  
 
2.2.5.3 Western blot of proteins derived from rat tissues  
Protein preparation from rat tissues was performed by disrupting the tissues with a 
rotor-stator homogenizer directly into WB lysis buffer supplemented with protease 
inhibitors. After protein concentrations had been determined by using the Bio-Rad 
protein assay, 20 µg of protein were mixed with WB non-reducing loading buffer, 
boiled, and separated by 10% SDS-PAGE. For detection of CD1d, only the 233 mAb 
was used. The protocol followed was the same as described in the previous section 
including the anti-ERK loading control (Methods section 2.2.5.2). 
 
2.2.6 CD1d Sandwich ELISA 
A CD1d Sandwich ELISA was established with the 233 and 35 mAbs and carried out in 
Polystyrene 96 well plates. Proteins derived from rat CD1d transduced P80 cells 
(complete cell lysate, 2*106 cells /ml) were used as standard.  
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• Coating was carried out overnight with the unconjugated 233 mAb diluted in 
coating buffer at a final concentration of 100 ng/ml (50 µl).  
• Plates were washed five times with PBS-T (0.05% Tween) (200 µl).  
• Non-specific binding sites were blocked with PBS containing 10% FCS (100 µl) 1 
hour at room temperature.  
• Plates were washed five times with PBS-T (0.05% Tween) (200 µl). 
• Samples (50 µl) were incubated for two hours at room temperature.  
• Plates were washed five times with PBS-T (0.05% Tween) (200 µl). 
• Biotinylated 35 mAb (50 µl) diluted in PBS containing 10% FCS, at a final 
concentration of 176 ng/ml, was incubated for one hour at room temperature.  
•  Plates were washed five times with PBS-T (0.05% Tween) (200 µl), with 1 min to 
30 sec soaks. 
• Substrate solution (50 µl) was added and incubated from 10 to 30 min depending on 
the velocity of the reaction 
• 25 µl stop solution (2M H2SO4) was added to each well. 
Plates were read at 450 nm within 30 minutes of stopping reaction in the Vmax Kinetic 
Microplate Reader (Molecular Devices).  
 
2.2.7 Routine cell culture methods 
2.2.7.1 Cell culture  
Cells were cultured in sterile conditions at 37 ºC with 5% CO2 and H2O-saturated 
atmosphere. Unless otherwise indicated, cell lines were cultured with RPMI 1640 
supplemented with 5% FCS, 1 mM sodium pyruvate, 2.05 mM glutamine, 0.1 mM 
nonessential amino acids, 5 mM β-mercaptoethanol and Penicillin-Streptomycin 100 
U/ml. J558L cells and primary cells, unless otherwise specified, were cultured with 
RPMI 1640 supplemented additionally with 10 mM HEPES and 10% FCS. 293T cells 
were cultured with DMEM containing pyruvate supplemented with 10% FCS and 
Penicillin-Streptomycin 100 U/ml. For adherent cells ATV was used to detach cells 
from the plates. 
 
2.2.7.2 Freezing and thawing  
Cell lines were cryopreserved at -140 ºC. For this purpose cells were harvested and 
resuspended in 1 ml of freezing media. Before transferring them to -140 ºC, cells were 
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frozen at -70 ºC. When cells were again cultured, vials were thawed at room 
temperature and immediately washed with complete media twice. After washing, the 
pelleted cells were resuspended in fresh media and incubated at 37 ºC.  
 
2.2.7.3 Preparation of primary single cell suspensions   
Animals were sacrificed by asphyxia with CO2. When PBCs were analyzed, heart 
puncture was firstly performed and heparin was added to the collected blood in order to 
avoid coagulation. After dissection, organs were removed and kept in BSS/BSA at 4ºC 
until tissue disruption.  
 
2.2.7.3.1 Single cell suspension from thymus and spleen 
Organs were homogenized by passing them through a metal mesh, cells were 
transferred to a 15 ml tube in 14 ml BSS/BSA and were let stand for 10 min to allow 
that tissue debris settle at the bottom of the tube. Supernatant containing the cells was 
transferred to a fresh 15 ml tube and centrifuged at 1600 rpm for 5 min at 4 ºC. Then, 
always in spleen preparations and if desired in thymus preparations, erythrocytes were 
lysed by incubating the cell pellet with 3 ml TAC buffer for 10 minutes at room 
temperature. Subsequently, 10 ml of BSS/BSA were added and cells were centrifuged at 
1600 rpm for 5 min at 4 ºC. Cells were washed one additional time with BSS/SBA, 
resuspended into BSS/BSA or complete media and counted.  
 
2.2.7.3.2 Intrahepatic lymphocytes preparation  
Mouse and rat intrahepatic lymphocytes were isolated as previously described by E. Pyz 
et al. (Pyz, 2004; Pyz et al., 2006) with slight modifications. 100% Percoll was prepared 
with 90 ml Percoll and 10 ml 10x PBS. Different concentrations of Percoll were 
prepared with this 100% Percoll and RPMI 1640 containing 5% FCS. Percoll solutions 
were used at room temperature to avoid gradient perturbations. 
- After excision of any other organ which also was going to be analyzed, heart 
puncture was performed in order to reduce the blood flowing in the animal. 
- Blood was flushed of the liver by perfusing it with BSS/BSA (100 to 180 ml in rats 
and 10 ml in mice) through the portal vein with a syringe until the liver became 
pale. 
- Once all the blood had been eliminated from the liver, this organ was removed and 
placed in a 10 cm dish containing BSS/BSA and kept at 4 ºC until homogenization. 
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- Liver was cut into small pieces and homogenized in a Glass/Teflon Potter Elvehjem 
homogenizer.   
- Liver homogenate was then passed through a stainless steel mesh adding BSS/BSA 
up to a final volume of 50 ml and cells were transferred into a 50 ml tube, in case of 
rats and into a 15 ml tube in case of mice.  
- Cell suspension was centrifuged at 1600 rpm at 4ºC.  
- Pellet containing cells was resuspended into 40% Percoll (28 ml with rat livers and 
7 ml with mouse livers) and layered over of 80% Percoll (12 and 4 ml, with rat and 
mouse livers, respectively). 
- Centrifugation was carried out at 2500 g (rcf) with no brake for 20 minutes at room 
temperature. 
- The supernatant containing liver tissue was aspirated to facilitate the collection of 
the lymphocytes from the interface. Some erythrocytes appeared at the bottom of the 
tube.  
- Lymphocytes were harvested from the interface (12 ml for rats and 2 ml for mice 
approximately), transferred to a fresh 50 ml tube and washed with 35 ml BSS/BSA 
(10 min 1600 rpm at 4 ºC).  
- Pellet was washed an additional time with BSS/BSA 
- Cells were resuspended in 5 or 10 ml BSS/BSA or complete RPMI media and 
filtered through a 70 µm mesh.  
- Cells were counted and kept on ice until further use.  
 
2.2.7.3.3 Isolation of peripheral blood cells 
Heparin treated blood was isolated by heart puncture and transferred to a 15 ml plastic 
tube. After washing 2 ml of blood with 50 ml BSS/BSA by centrifuging at 1600 rpm for 
10 minutes, erythrocytes were lysed by 3 to 4 incubations with 10 ml TAC buffer. After 
each lysis-incubation, cells were washed by adding 40 ml BSS/BSA directly to the cells 
contained in TAC buffer and centrifugation for 10 min at 1600 rpm. After lysis of 
erythrocytes, the pelleted cells were resuspended into BSS/BSA or complete RPMI 
1640 media and counted.  
 
2.2.7.3.4 Isolation of peripheral mononuclear blood cells 
2-4 ml blood were collected by heart puncture and treated with heparin and diluted with 
an equal volume of phosphate buffered saline (PBS). Blood samples were carefully 
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layered over 3 ml of Ficoll-Hypaque in a 15 ml tube and centrifuged at 400 rcf for 30 
minutes at 20 °C with no brake. The PBMCs at the interface were aspirated with a 
Pasteur pipette and washed twice with BSS/BSA. The PBMCs were finally resuspended 
in 1 ml of RPMI medium or BSS/BSA and counted.  
 
2.2.8 Primary cell cultures 
2.2.8.1 Stimulation assays and analysis of cytokine release  
Primary cells harvested as described in the methods section 2.2.7.3 were cultured for 24 
hours in 96 well plates (U bottom) with different stimuli: α-Gal, β-Gal, ConA or only 
media. The final concentrations of these stimuli in each experiment are specified in the 
legends of the figures. Cell numbers added to each well were 2*106 thymocytes, 2*106 
splenocytes and 5*105 IHLs, unless otherwise indicated in the figure legends. In CD1d-
blocking experiments, purified antibodies or isotype-specific controls were added to the 
culture at a final concentration of 3.6 µg/ml. After harvesting the supernatants cytokine 
production was quantified using commercial ELISA kits from BD Biosciences (rat and 
mouse IFN-γ and IL-4). 
 
2.2.8.2 Seven-days intrahepatic lymphocytes cultures   
106 intrahepatic lymphocytes were incubated for seven days with 1ml RPMI++ per well 
in 48-well plates with α-Gal (20 ng/ml), β-Gal (20 ng/ml), ConA (3 µg/ml), or only 
media.  
 
2.2.8.3 Rat IL-4 ELISPOT assay 
Rat IL-4 ELISPOT assay from BD Biosciences was carried out following the 
manufacturer’s instructions using 250.000 IHLs, 106 splenocytes or1.5*106 thymocytes 
per ELISPOT well. In CD1d-blocking experiments, purified antibodies or isotype-
specific controls were added to the culture at a final concentration of 3.6 and 7.2 µg/ml 
in splenocytes and IHLs cultures, respectively. The substrate used was BDTM AEC 
Reagent. Spots were automatically enumerated and analyzed using the CTL-
ImmunoSpot S5 Versa analyzer ELISPOT reader and ImmunoSpot 4.0 Software (CTL).   
 
2.2.9 Transfection of 293T cells 
Calcium chloride transfection of 293T cells was carried out with two different purposes: 
First, to produce retrovirus for transduction of a gene of interest into other cells as 
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previously described by Soneoka et al. (Soneoka et al., 1995) or second, to obtain 293T 
cells which produced and secreted CD1d recombinant proteins. The same protocol was 
used for both aims, only the plasmids which were transfected were different. 293T cells 
were cultured in DMEM+ (containing HEPES) except during the transfection step.   
- Day 1 
1.5*106 293T cells were plated into a 6 cm tissue culture dish with 5 ml DMEM+. 
DNA was precipitated with 500 µl iso-propanol in a 1.5 ml tube at maximum speed 
(13.000 rpm) precipitation. Once iso-propanol had been discarded, DNA was 
sterilized by adding 500 µl of ethanol (70%) and inverting the tube several times. 
After 30 min centrifugation at maximum speed for 30 minutes at 4°C, ethanol was 
discarded and the tubes were dried in the laminar flow hood to maintain sterile 
conditions. Once all ethanol had been evaporated, DNA was resuspended into 100 
µl of sterile H2O and was kept at 4 °C, if used the next day or at -20°C if used at a 
later time point.   
The total amount of DNA transfected in each culture dish was 15 µg. For production 
of retrovirus; 5 µg of pHIT 60, 5 µg of pVSV and 5 µg of the retroviral expression 
vector containing the gene of interest were precipitated together. For CD1d-
recombinant protein expression; 15 µg of the desired vector (see methods sections 
2.2.2.6 and 2.2.2.8) were precipitated. 
  
- Day 2: Transfections 
After aspiration of the media in which the 293T cells had been cultured, 4 ml of 
fresh DMEM without HEPES were gently added. Culture dishes were incubated one 
hour at 37°C, 5% CO2, in order to equilibrate the pH of the media. 
The transfection mixture was prepared as follows: 338 µl of sterile H2O and 62 µl of 
CaCl2 2M were added to the 100 µl of H2O containing the DNA previously 
prepared, obtaining a final volume of 500 µl. Then, 500 µl of 2X HBS were pipetted 
into a fresh sterile 1.5 ml tube and the mixture of DNA and CaCl2 was added to the 
2x HBS while “bubbling” with a Pasteur pipette and a pipette helper. The mixture 
was incubated for 15-20 minutes at room temperature and added drop wise to the 
culture plates. Dishes were carefully shacked in order to distribute the precipitate 
evenly. Dishes were incubated 6 to 8 hours at 37°C, 5% CO2. Subsequently media 
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was aspirated and replaced by 5 ml of fresh DMEM+. Cells were incubated over 
night at 37 ºC with 5% CO2. 
 
- Day 3 (only carried out if the aim of the transfection was the production of 
retrovirus) 
Media was replaced with 5 ml D-MEM+ containing 10 mM Na-Butyrate and cells 
were incubated for six to seven hours at 37 °C with 5% CO2. Subsequently Na-
Butyrate containing media was aspirated and replaced with 5 ml of fresh DMEM+ 
media and cells were incubated overnight at 37 °C with 5% CO2. 
 
2.2.10 Retroviral transduction 
At day four of the tranfection procedure, target cell lines were tranduced with the 
supernatant derived form the transfected 293T cells (containing the retroviral particles). 
The viral supernatant was aspirated with a syringe and passed through a 0.45 µm filter. 
105 target cells were infected with 3 ml of viral supernatant containing 4 µg/ml 
Polybren. Infection was carried out 30 minutes at 37 ºC in the cell culture incubator, 3 
hours centrifuging at 2000 rcf at 37 ºC and 30 further minutes again at 37 ºC in the cell 
culture incubator. Finally, viral supernatant was exchanged by fresh culture media (for 
example, RPMI 1640).  
 
2.2.11 Immunofluorescence and flow cytometry 
Flow cytometry was carried out using a FACSCalibur (BD Biosciences) and data were 
analyzed with CellQuest (BD Biosciences) or FlowJo software (Tree Star). 
For the analysis rat and mouse primary cells, 1-2*106 cells were diluted in 100 µl FACS 
buffer. When mouse primary cells were stained, unspecific binding to Fc receptor was 
blocked using the 2.4G2 mAb. Combinations of antibodies and/or CD1d oligomers used 
in each staining are specified in the figure legends. When mouse-derived unconjugated 
antibodies or CD1d-IgG dimers were used in multicolor stainings, samples were first 
incubated only with the unconjugated reagent, washed, and bound antibody was 
detected by incubation with a FITC or PE labeled donkey F(ab’)2 fragment anti-mouse 
IgG (H+L) with minimal crossreaction to rat and other species serum proteins. After a 
further washing step, unspecific binding to the donkey anti-mouse reagent during 
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subsequent stainings was blocked by adding substantial amounts of serum mouse IgG 
for 15 min.  
Staining of BW cells expressing a rat semi-invariant TCR (rAV14S6 + CDR2+4, (Pyz 
et al., 2006)) with various CD1d oligomers was carried out as specified in the legend of 
the figures 15 and 16.  
 
2.2.12 Statistical analysis 
Statistical differences between various cell populations were analyzed by conducting 
two-tailed paired Student’s t test: see results section 3.8. All analyses were performed 
with the statistical software GraphPad Prism. 
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3 RESULTS 
3.1 Further characterization of rat CD1d specific mAbs 
The lack of monoclonal antibodies had impaired the study of CD1d and its function in 
the rat. Therefore, five different hybridomas: 232, 233, 244, 35 and 58, which secreted 
anti-rat CD1d mAbs had previously been generated in our laboratory (Pyz, 2004) and 
were further characterized in this thesis. All the antibodies bound to rat CD1d on 
primary thymocytes or transduced cell lines. Importantly, the mAbs 232, 233 and 35 
recognized mouse CD1d1 on transduced cells or thymocytes with the same efficacy as 
rat CD1d while, mAbs 244 and 58 only showed such cross-reactivity for mouse CD1d1 
expressed by transduced cells but not for CD1d1 positive primary mouse cells.  
Titrations and cross-competition flow cytometric analyses using primary as well as 
CD1d-transduced cells revealed indistinguishable binding properties of 232 and 233 on 
the one hand, and of 244 and 58 mAbs on the other hand. The antibody with the highest 
avidity for CD1d was 35, followed by 232 or 233 and by 58 or 244. Moreover, the 
mAbs 35 and 232 or 232 do not cross-compete while 58 and 244 partially compete with 
35 and with 233 or 232.  
Part of the results presented in this doctoral thesis obtained with two of these 
monoclonal antibodies (233 and 35) has already been reported by us in a recent 
publication (Monzon-Casanova et al., 2010). In this published work the 233 and 35 
mAbs were renamed as WTH-1 and WTH-2, respectively, in order to give to the mAbs 
a more distinctive name than only numbers.  
 
3.1.1 Determination of V (D) J gene segment usage 
In order to analyze which V-(D)-J gene segments form the variable regions of the heavy 
and light chains of each hybridoma, both chains were amplified by RT-PCR and 
sequenced. RT-PCR was carried out according to (Wang et al., 2000) but using slightly 
modified degenerate forward primers. The isotype of all mAbs was IgG2a,κ, therefore 
the same primers were used for PCR amplification of all heavy chains. Sequencing of 
the heavy chain was successful for all the hybridomas, whereas it was only possible to 
sequence the light chain of 244, 35 and 58. Identification of which V-(D)-J segments 
were used was accomplished using IMGT/V-QUEST at the international 
ImMunoGeneTics information system (Brochet et al., 2008). This and the direct 
comparison between the sequences obtained for the chains of the different hybridomas 
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revealed on the one hand, identical heavy chains of the 232 and 233 hybridomas and on 
the other hand, that also the 244 and 58 heavy and light chains were the same. In 
contrast, the variable regions of the heavy and light chains of the hybridoma 35 are 
distinct from all the other mAbs (Table 5).  
 
 
Table 5. Gene segment usage of the heavy and light chains of the five studied hybridomas. 
Identification of the gene segments was carried out using the V-QUEST integrated alignment tool under 
the IMGT information system (http://imgt.cines.fr/IMGT_vquest/share/textes/imgtvquest.html)  
 
3.1.2 mAb reactivity in immunoprecipitation and Western blot analyses 
Immunoprecipitation and Western blot experiments were performed in order to further 
confirm CD1d specificity of the mAbs, as well as to study their reactivities under 
denaturating conditions. As shown in figure 1 the three mAbs (233, 35 and 58) 
precipitated two chains from primary rat thymocytes as well as from rat CD1d 
transduced cells. Under reducing conditions the apparent molecular size of the heavy 
chain was between 50 and 60 kDa, corresponding to the heavily glycosylated CD1d and 
the light chain run at the expected weight of β2-microglobulin (12 kDa). Precipitation 
by 58 mAb was less efficient than by 35 or 233. Furthermore, the ratio of precipitated 
β2-microglobulin to CD1d heavy chain was lower than for the other two mAbs. 
Densitometric analysis of material precipitated from primary rat cells revealed ratios of 
0.15, 0.65 and 0.63 for 58, 35 and 233, respectively. The equivalent ratios for rat CD1d 
transductants were: 0.07, 0.62, and 0.87.  
233 and 35 precipitated the corresponding heavy and light chains from mouse 
thymocytes and from mouse CD1d1-transduced cells, while mAb 58 precipitated only 
very weakly the heavy chain from lysates of mouse CD1d transductants but not from 
mouse primary thymocytes (Fig. 1). These results are also in line with the data obtained 
Hybridoma Heavy chain Light chain 
232 
IGHV12-1-1*01  
IGHJ4*01  
IGHD1-14*01 in reading frame 2 
no PCR product was obtained 
233 
IGHV12-1-1*01  
IGHJ4*01  
IGHD1-14*01 in reading frame 2 
no PCR product was obtained 
244 
IGHV3S1*01 
IGHJ3*01 
various IGHD 
IGKV6-25*01 
IGKJ2*01 
35 
IGHV1-77*01 
IGHJ4*01 
IGHD1-1*01 in reading frame 3 
IGKV19-93*01 
IGKJ2*01 
58 
IGHV3S1*01 
IGHJ3*01 
various IGHD 
IGKV6-25*01 
IGKJ2*01 
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by flow cytometry. The apparent molecular weight after SDS-PAGE of the precipitated 
proteins was the same regardless of the species origin or the cell source.  
 
 
Figure 1. Immunoprecipitation of biotinylated surface proteins with 233, 35, 58 or isotype control 
antibodies. Immunoprecipitated material was size separated under reducing conditions on a 15% SDS-
PAGE, blotted to a membrane and detected by addition of streptavidin-HRP. The two blots on the left 
show precipitates from rat (r) CD1d or mouse (m) CD1d1 transductants. The blots on the right show 
precipitates derived from thymocytes.  
 
 
Figure 2. Western blot analyses with 233, 35 and 58 mAbs. a Proteins derived from rat CD1d-
transduced P80 cells were separated by SDS-PAGE on 15 and 10% polyacrylamide gels, for reducing and 
non-reducing conditions, respectively, and blotted to a membrane. Detection of CD1d was carried out 
with decreasing concentrations of the antibodies in a multiscreen apparatus. The final concentrations used 
were: 17.28, 3.45 and 0.69 µg/ml for 233 mAb; 24.48, 4.89 and 0.979 µg/ml for 35 mAb and 6, 1.2 and 
0.240 µg/ml for the mAb 54. b Western blot analysis of proteins derived from rat CD1d (r) or mouse 
CD1d1 (m) transduced cells. Proteins were separated on a 10% polyacrylamide gel under non-reducing 
conditions and blotted to a membrane. CD1d was detected with the 233 or 35 mAbs. Film exposure 
duration for the CD1d blots is indicated under the names of the mAb. After CD1d detection, the blots 
were stripped and re-probed with a polyclonal anti-ERK2 antibody as protein loading control (lower 
blots). c Western blot analysis of proteins derived from LEW tissues: spleen (spl), thymus (thy) and 
pancreas (pan). SDS-PAGE and blotting conditions were the same as in b. 
 
Western blot analysis of protein extracts derived from rat CD1d transductants after 
SDS-PAGE run under reducing and non-reducing conditions revealed the loss of the 
reactivity of the 58 mAb in immunoblots but the conservation of 233 and 35 and 
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mapped their bound epitopes to the heavy chain of CD1d. A remarkable contrast to the 
flow cytometry data was the better binding of 233 mAb in comparison to 35 in both, 
reducing and non-reducing conditions (Fig. 2 a, b and data not shown). Moreover, and 
also in contrast to the results observed by flow cytometry, in immunoblots both mAbs 
bound mouse CD1d much less efficiently than rat CD1d (Fig. 2 b), since both, rat and 
mouse CD1d transduced cell lines are expected to express very similar levels of cell 
surface CD1d due to the nearly identical expression of the reporter gene EGFP observed 
by flow cytometry (Fig. 3 b).  
The 233 mAb was also used to analyze rat CD1d in protein extracts derived from rat 
thymus, spleen and pancreas. Pancreas was included in the study because outstanding 
levels of CD1d had been detected in immunohistological analyses carried out in 
collaboration with Prof. Steiniger, Institute of Anatomy and Cell Biology, Philipps-
University of Marburg, Marburg, (Fig. 12). As shown in figure 2 c, CD1d was detected 
in all three tissues, being the pancreas the organ with the highest levels of CD1d (Ratios 
between CD1d and ERK2 signals obtained by densitometric evaluation of the films 
were: spleen, 0.8 ; thymus, 1.2 and pancreas, 1.7). Interestingly, CD1d isolated from 
pancreatic lysates had a slightly higher mobility in SDS-PAGE than CD1d from thymus 
or spleen protein extracts. 
 
3.1.3 Epitope mapping 
Cross-competiton experiments had demonstrated that the 233 and 35 mAbs recognize 
non-overlaping epitopes on rat CD1d (rCD1d) and mouse CD1d1 (mCD1d1). In order 
to define more precisely the binding sites of these mAbs, firstly, Raji cells were also 
transduced with mouse CD1d2 (mCD1d2) and CD1d1 from Mus spretus (sCD1d) and 
were tested for mAb reactivity by flow cytometry. Figure 3 a shows the high 
conservation of the predicted amino acidic sequences of these different CD1d 
molecules. The observed loss of 233 mAb binding to sCD1d and the massive reduction 
in its reactivity to mCD1d2 (Fig. 3 c) facilitated the mapping of its epitope since only 
three amino acidic residues were unique for sCD1d when compared to rCD1d and to 
mCD1d1: alanine (A), isoleucine (I) and threonine (T) at positions 93, 118 and 162, 
respectively. The residue at position 118 is located in the antigen-binding groove (side 
chains are depicted in gray in Fig. 3 c) and is probably not accessible to the mAb 233 in 
contrast to position 93 at the border of the α1-helix and position 162 which lies in the α2 
helix on the top of the molecule (red and green spheres, respectively, in Fig. 3 c). To 
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test whether any of these last two residues was responsible for the lack of reactivity of 
the 233 mAb against sCD1d, the aspartic acid at position 93 and the methionine 162 of 
mCD1d1 were exchanged by their sCD1d counterparts: Alanine and threonine, and 
named as: mCD1d1D93A and mCD1d1M162T (Fig. 3). In addition, chimeras of mouse 
and human CD1d were generated, expressed in Raji cells and analyzed by flow 
cytometry (Fig. 3 b). The generation of these cells lines, performed by Stefanie 
Schweigle in the course of her diploma thesis and described in our published work 
(Monzon-Casanova et al., 2010), allowed the mapping of the aspartic acid at positions 
92 and 93 of rat CD1d and mouse CD1d1, respectively, as part of the 233 epitope, 
because cells expressing mCD1d1D93A were not stained by this mAb. The arrow in 
figure 3 a points out the position where the regions of mouse CD1d1 and human CD1d 
were exchanged. The structure models shown in figure 3 illustrate with green and gray 
ribbon diagrams, which parts of the α1 and α2 domains of the chimeric CD1d molecules 
correspond to one or the other species. These chimeras confirmed the results obtained 
with the mCD1d1 mutants and the 233 mAb and in addition, restricted the α1 domain 
and the 23 following amino acids of the α2 domain as crucial for formation of the 35 
epitope, since the 35 mAb did not stain the h/mCD1d chimera.  
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Figure 3. Epitope mapping of anti-CD1d mAbs. a Alignment of amino acid sequences of the 
extracellular domains of the CD1d molecules used in this study. α-helical regions are illustrated in bold. 
The open triangle points out the localization of rat CD1d allelism. Mutations in mouse CD1d1 are 
highlighted with closed triangles. The arrow indicates where mouse/human chimeras were joined. 
Numbers show rat CD1d amino acid positions. Accession numbers for the amino acid sequences can be 
found in GenBank: rCD1d (Rattus norvegicus CD1d), BAA82323; mCD1d1 (Mus musculus CD1d1), 
NP_031665; sCD1d1 (Mus spretus CD1d1), ACM45455; hCD1d1 (Homo sapiens CD1d), NP_001757. 
The mCD1d2 (Mus musculus CD1d2) amino acidic sequence differs in one amino acid in the signal 
peptide (tryptophan, position -13) from the sequence published under the accession number: P11610. b 
Binding capacity of mAbs to different CD1d molecules. Raji cells were transduced with CD1d molecules 
using a retroviral expression system. Bicistronic EGFP in the CD1d expression vectors served as reporter 
gene. Cells were stained with unconjugated 233 or 35 mAbs followed by PE-labeled donkey anti-mouse 
IgG or PE-labeled 1B1 mAb and were analyzed by flow cytometry. All primary antibodies were used at a 
final concentration of 250 ng/ml. c Localization of relevant amino acids in the CD1d tertiary structure. 
The model depicts part of the co-crystal of the PBS25 glycolipid and mouse CD1d (PDB: 3GMP) and it 
was visualized using PDB Swiss Viewer Deep View v4.0 (Guex and Peitsch, 1997) 
(http://www.expasy.org/spdbv/). The α1 and α2 domains are shown. Gray and green ribbon diagrams 
highlight the regions constituting the N- and C-terminal parts, respectively, of the chimeric molecules. 
Discussed amino acids are depicted as spheres: aspartic acid (D) 93 in red, methionine (M) 162 in green, 
valine (V) 118 in gray and arginine (R) 21 in blue.     
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3.1.4 CD1d ELISA  
The lack of competition between mAbs 233 and 35 permitted the establishment of a 
CD1d Sandwich ELISA, which allows the detection of CD1d in fluid samples as cell or 
tissue protein extracts, serum or recombinant CD1d molecules purified or in culture 
supernatants. Standardization of the ELISA was carried out with soluble rat β2m-CD1d-
biotag recombinant proteins purified as described in the results section 3.4.1.3 (Fig. 4 
a). The detection levels reached 0.5 to 1 ng of CD1d per ml. The rat β2m-CD1d-biotag 
recombinant protein was used to determine the amounts of rat CD1d contained in the 
cell-lysate from P80 cells transduced with rat CD1d, which was then further used as 
standard in all CD1d Sandwich ELISAs (Fig. 4 a). Figure 4 b shows the amounts of 
CD1d detected in protein extracts derived from thymus, spleen and pancreas of LEW 
rats. In line with immunohistochemistry and Western blot analyses, CD1d levels are 
increased in pancreas compared to spleen, whereas with this technique no big 
differences were observed between thymus and pancreas. The presence of CD1d in the 
serum derived from various rat strains was also addressed by ELISA. Analysis of single 
samples from the following inbred rat strains led to the subsequent results: F344: 2.5 
±0.18, BN: 10.01 ±0.46, DA: 7.3 ±0.56, LEW: 3.6 ±0.3 and PVG 14.5 ±8.3 ng/ml ±SD 
for duplicate samples.  
Similar to Western blot analyses, the reactivity of the 233 and 35 mAbs in ELISA 
against mouse CD1d1 was lower than for rat CD1d (Fig. 2 b and 4 c). The signal given 
by mouse CD1d-IgG dimers was 2 to 3 fold lower than rat CD1d-IgG dimers. 
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Figure 4. CD1d ELISA. a Standarization of rat CD1d-transduced P80 cell lysate with soluble 
recombinant rat β2m-CD1d-biotag purified protein. Shown are the optical density values obtained in 1:2 
dilutions of the analyzed samples. Shown is the mean value of duplicated samples. b CD1d quantification 
in LEW protein extracts derived from thymus (thy), spleen (spl) and pancreas (pan). Shown are the mean 
values obtained from three rats independently analyzed +SD. c Optical density (OD) obtained after 
analysis of the same amounts of rat CD1d-IgG or mouse CD1d-IgG dimers (X axis). The mean value 
obtained for duplicated samples ±SD is shown.  
 
3.2 Analysis of CD1d expression using mAbs 233 and 35 
Up to date, a detailed analysis of CD1d protein expression in the rat has been hampered 
by the lack of suitable mAbs. The widely used and commercially available mouse CD1d 
specific mAb, 1B1, does not recognize rat CD1d (figure 3) and although in two 
additional publications mAbs originally generated against mouse CD1d were reported 
to cross-react with rat CD1d, the investigation of rat CD1d in these studies was rather 
limited. In the first case, the rat IgMs 1H1 and 3C11 (Bleicher et al., 1990) were shown 
to bind a CD1d-like molecule, which was detected in rat liver but not in thymus (Burke 
et al., 1994) and in the second case, reactivity of the mAb 3H3 with rat thymocytes and 
splenocytes was reported but not further investigated (Mandal et al., 1998). Therefore, 
the following data obtained with 233 and 35 mAbs provide the first detailed analysis on 
CD1d expression in the rat and the unique possibility of direct comparison of rat and 
mouse.  
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3.2.1 CD1d in different inbred rat strains  
3.2.1.1 Identification of two rat CD1d alleles   
Two allelic variants of rat CD1d protein coding sequence have been reported and 
defined by an alanine to valine substitution at position 101 of the mature polypeptide 
sequence, which is located in the antigen binding groove. The alanine 101 allele was 
reported for F344, BN and five other rat strains, whereas the valine should be present in 
LEW, Wistar, TO, WKAH and W (Katabami et al., 1998). This reported allelism could 
be of special significance since position 101 is localized in the antigen binding groove 
and consequently could influence the orientation of α-Gal and/or other lipids contained 
in this pocket. Therefore, we analyzed the sequences encoding CD1d in the inbred rat 
strains tested here for α-Gal responsiveness (and of five additional strains (BUF, BH, 
AGUS, AUG and WF) by amplifying genomic DNA by PCR and subsequent 
sequencing of the region covering the exons one to three. Furthermore, the complete 
coding region of CD1d was cloned from splenocytes cDNA derived from BN, LEW, 
PVG and DA. CD1d cDNA from F344 rats had previously been cloned by E. Pyz (Pyz 
et al., 2006). These analyses confirmed the sequence of F344 inbred rats published by 
Katabami et al. (Katabami et al., 1998), but the proposed valine substitution could 
neither be confirmed in LEW nor was it found in any other strain tested by us. In 
contrast, we found a single nucleotide substitution in the signal peptide replacing the 
phenylalanine at position -4 of the F344 allele by a valine (Fig. 5). The CD1d sequences 
obtained (except for F344 rats) were identical to the BN-derived rat genomic sequence. 
Interestingly, the valine at position -4 is also encoded in both mouse CD1d genes (Fig. 3 
a). 
 
 
 
 
F344 atgctgtacctaccgtgcctgttgctgtgggcattcccacagttctggggacaa 
      M  L  Y  L  P  C  L  L  L  W  A  F  P  Q  F  W  G  Q   
 
LEW  atgctgtacctaccgtgcctgttgctgtgggcattcccacaggtctggggacaa 
      M  L  Y  L  P  C  L  L  L  W  A  F  P  Q  V  W  G  Q   
 
Figure 5. Nucleotide and amino acid sequences of the two rat CD1d alleles identified in this 
study. Since the only difference among the complete CD1d coding sequence was found in the signal 
peptide, only this part is shown. The substitution resulting in the phenylalanine to valine change is 
highlighted in bold. The F344 allele was only found in F344 inbred rats, whereas the LEW allele, 
apart from LEW inbred rats was also found in BN, LEW, PVG, DA, BUF, BH, AGUS, AUG and WF 
inbred rats 
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3.2.1.2 Analysis of CD1d expression among different rat strains 
In order to investigate whether the phenylalanine to valine substitution in the signal 
peptide affected CD1d surface expression; thymocytes, splenocytes, intrahepatic 
lymphocytes and PBMCs from the five inbred rat strains tested for α-Gal 
responsiveness in this study (F344, BN, DA, LEW and PVG, results section 3.7.1) were 
stained with the 233 mAb and analyzed by flow cytometry (Fig. 6). Thymocytes, 
splenocytes and PBMCs showed no strain-specific differences in CD1d expression. 
Based on FCS/SCC characteristics the negative/low population, which appears in DA 
PBMCs, are contaminating erythrocytes. Only among IHLs some differences could be 
observed: In DA and PVG inbred rat strains there are more cells expressing high CD1d 
levels. CD1d expression by different cell types of the thymus and spleen is described in 
more detail in the following section of the results.  
 
 
3.2.1.3 CD1d expression in hematopoietic cells: Direct comparison between rat and 
mouse  
The 233 and 35 mAbs allowed us to directly compare CD1d surface expression on 
mouse and rat hematopoietic cells by immuno flurorescence flow cytometry. The results 
obtained with the two mAbs were nearly the same, therefore, only stainings performed 
with the 35 mAb are shown. In the analysis, LEW rats and C57BL/6 mice were used. 
The staining intensity was very similar for both species and between thymocytes and 
most splenocytes (Fig. 7). The only striking difference was the higher proportion of 
CD1d high cells in rat, which, as shown later, can be accounted to MZ B cells (Roark et 
al., 1998). This is consistent with the very broad marginal zone and large number of 
Figure 6. CD1d cell surface expression in different inbred rat strains. CD1d cell surface 
expression was analyzed by flow cytometry using the biotinylated 233 mAb visualized with SA-
APCy in various primary cells: thymocytes, splenocytes, intrahepatic lymphocytes (IHLs) and 
peripheral blood mononuclear cells (PBMCs) derived from PVG, BN, DA, LEW and F344 
inbred rat strains. One experiment is shown for each compartment and each strain except for 
LEW thymocytes, where two independent experiments are shown: light and dark green.  
 74 
these cells found in rats (Kroese et al., 1990; Kumararatne et al., 1981; Steiniger et al., 
2006). 
Co-staining of CD1d and TCR in thymocytes revealed that in rats, as in mice (Park et 
al., 1998), TCR low cells, which are double positive thymocytes, express higher levels 
of CD1d than TCR high cells, which are single positive thymocytes (Fig. 8). 
 
 
 
 
 
Figure 7. Comparison of CD1d expression by rat and 
mouse primary cells. Representative data from one out 
of three experiments are shown. Staining of total 
thymocytes or splenocytes with biotinylated 35 or isotype 
control antibodies and SA-PE. Gray and black lines 
correspond to C57BL/6 and LEW cells, respectively. 
Filled histograms are control stainings.  
 
 
 
 
 
 
Figure 8. Comparison of CD1d expression by rat and 
mouse thymocytes. Representative data from one out of 
three experiments are shown. Co-expression of CD1d and 
TCR on thymocytes was analyzed by two-color flow 
cytometry. CD1d was stained using the unconjugated 35 
mAb and PE-labeled donkey anti-mouse IgG. For staining 
of mouse and rat TCRs, H57-597-APCy and R73-bio + SA-
APCy were used, respectively. Numbers indicate the 
geometric mean fluorescence intensity of CD1d expression 
in the gated populations.  
 
 
CD1d expression by mouse T and B cells of the spleen and lymph nodes has been 
extensively studied (Brossay et al., 1997; Makowska et al., 1999; Park et al., 1998; 
Roark et al., 1998). CD1d surface expression was found to be lower on T cells than on 
B cells and among T cells, was higher on CD4 T cells than on CD8 T cells. Using the 
35 and 233 antibodies we reproduced the findings obtained in mice, and observed that 
rat B cells also express higher CD1d levels than T cells (Fig. 9). Nonetheless, in rats the 
pattern of CD1d distribution among T cell subpopulations is different than in mice. Rat 
CD1d levels on CD4 T cells are not higher than those on CD8 T cells, as it was 
demonstrated by different staining and gating strategies (Fig. 10). 
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Figure 9. CD1d expression by B and T cells analyzed by multicolor flow cytometry. T and B cells 
were identified using antibodies visualized with APCy in order to avoid unspecific signal due to 
fluorescence spectral overlap in the PE channel, which was used for CD1d expression detection. 
Therefore, CD1d was analyzed on separate multicolor experiments with same CD1d staining intensity 
(Number 2 histograms: gray and black lines correspond to B and T cell stainings, respectively). Number 1 
dot plots show gates on total splenocytes which were further analyzed. For CD1d detection in C57BL/6 
mice, biotinylated 35 mAb followed by SA-PE was used. In rats, CD1d was detected with unconjugated 
35 mAb followed by PE-labeled donkey anti-mouse IgG secondary antibody. Number 4 dot plots indicate 
co-expression of CD1d and T or B cell markers. Number 3 dot plots represent isotype control stainings 
for anti-CD1d mAbs. Gray and black dot plots correspond to B and T cell stainings, respectively. In 
mouse, B cells were stained with anti-CD19 (1D3-APCy) mAb and T cells with anti-TCRβ chain mAb 
(H57-597-APCy). In rat, B cells were defined as CD45RA (OX-33-biotin + SA-APCy) positive cells and 
for the identification of T cells, anti-TCRβ chain (R73-biotin + SA-APCy) antibody was used. Boxes 
indicate gated cells shown in number 5 histograms and numbers inside the plots correspond to the 
percentage of gated cells. Data shown is one representative experiment out of three. 
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Figure 10. Relative CD1d expression by CD4 and CD8 positive T cells analyzed by multicolor flow 
cytometry. Dot plots on the left show the gated splenocytes which were studied. CD4 and CD8 positive T 
cell gating strategies are illustrated with the histograms and dot plots of the columns in the middle. Two 
different antibody combinations were used to stain LEW cells: one with biotinylated 35 visualized with 
SA-PE (upper row) and other with unconjugated 35 mAb detected with PE-labeled donkey anti-mouse 
IgG (DαM-PE, lower row). Numbers in the plots indicate percentages of gated cells. The antibodies used 
for each staining appear in the axes of the figures. Fluorescence 2 geometric MFI of CD4- and CD8-gated 
T cells in stainings where instead of the anti-CD1d mAb, an isotype control Ab was used were: in the 
staining of C57BL/6 cells, 5.98 and 4.58 in CD4- and CD8-gated cells, respectively; in the upper LEW 
staining: 10.2 and 10.6 for CD4 and CD8 T cells, respectively, and in the lower rat staining: 5.32 for 
CD4, and 5.09 for CD8 positive T cells. In the histograms on the right, gray and black lines correspond to 
CD4 and CD8 positive T cells respectively. Filled histograms are control stainings.  
 
In the mouse, in addition to MZ B cells also antigen presenting cells show very high 
CD1d levels (Roark et al., 1998). Analysis of mouse MZ B cells (CD21high/CD23low) 
with the mAbs reported here confirmed their high CD1d expression levels (Fig. 11). Rat 
MZ B cells defined either by combinations of the B cell marker CD45RA (OX-33) and 
the MZ B marker HIS57 or by gating on IgM high/IgD low cells (Fig. 11) (Kroese et 
al., 1990) are CD1d high as well.  
CD1d expression on rat dendritic cells (OX-62+) and macrophages (CD11b/c+) was also 
analyzed and compared to that of MZ B cells, identified as HIS57+ in this case. The 
stainings of figures 11 b and c show that, similar to what has been reported for mouse 
antigen presenting cells, CD1d levels on rat dendritic cells and macrophages are as high 
as those of MZ B cells.  
Last, we also analyzed CD1d expression on natural killer cells from the spleen which 
were defined as NK1.1 or NKR-P1 positive TCR negative cells in mice and rats, 
respectively. In C57BL/6 mice, NK1.1 positive cells express lower CD1d levels 
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compared to the rest of splenocytes, whereas in rats NKR-P1 positive cells and T cells 
express CD1d at similar levels (data not shown). 
 
Figure 11. CD1d and CD4 expression by MZ B cells, dendritic cells and macrophages from the 
spleen. One representative experiment out of three is shown. Dot plots illustrate the followed gating 
strategies and numbers in them indicate the percentage of gated cells. Histograms show CD1d and CD4 
expression levels. (A) MZ B cells analysis. In C57BL/6 mice, CD1d was stained with biotinylated 35 
mAb + SA-Cy5-PE and CD4 with RM4-APCy. In LEW, CD1d was detected with unconjugated 35 mAb 
followed by PE-labeled secondary antibody and CD4 with OX-35 labeled with PE-Cy5 unless otherwise 
indicated. Upper row histograms show gated MZ B cells, whereas, lower row histograms show total 
lymphocytes. MZ B cells in C57BL/6 mice were identified by gating on CD21 hi (7G6-FITC) and CD23 
low/negative (B3B4-PE) cells. In LEW rats, MZ B cells were stained with two different marker 
combinations: CD45RA (OX-33-FITC) / HIS57-biotin + SA-APCy and IgM (G53-238-FITC)/IgD 
(MARD-3-biotin + SA-APCy), respectively. Analysis of CD1d and CD4 in MZ B cells defined as HIS57- 
and CD45RA positive cells was carried out with one single multicolor experiment. Expression of CD1d 
and CD4 in MZ B cells defined as IgD-low and IgM-high cells was determined in separated multicolor 
experiments as both, the anti-CD1d and the anti-CD4 mAbs were visualized with the PE fluorochrome 
(CD1d: 35 mAb + PE-secondary Ab, CD4: OX-35-PE). (B) CD1d and CD4 expression by LEW dendritic 
cells (OX-62 detected with anti-mouse IgG PE secondary antibody) and MZ B cells (HIS57-biotin and 
SA-APCy). CD1d was detected with 35-FITC mAb and CD4 with OX-35-PE-Cy5. (C) CD1d and CD4 
expression by LEW macrophages – defined as CD11b/c+ cells (OX-42-PE) – and MZ B cells (HIS57-
biotin + SA-APCy). CD1d was stained with unconjugated 35 mAb followed by FITC-labeled anti-mouse 
IgG Ab. For CD4 detection, OX-35-PE-Cy5 antibody was used.  
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3.2.1.4 CD4 expression by rat MZ B cells  
Surprisingly, while analyses of CD1d among different cell populations in the spleen 
were carried out, it was observed that MZ B also expressed CD4 and nearly half of them 
as much as other splenocytes (e.g. CD4 T cells) (Fig. 11). These findings were 
confirmed with a different anti-CD4 mAb (OX-38) and in another inbred rat strain 
(F344) (data not shown). The multicolor stainings of MZ B cells and antigen presenting 
cells also demonstrate that the expression of CD4 by rat MZ B cells was not the result 
of some CD4 positive macrophages or dendritic cells included in the gate of MZ B 
cells. Moreover, immunohistochemical analysis carried out in the laboratory of Prof. 
Steiniger, Institute of Anatomy and Cell Biology, Philipps-University of Marburg, 
Marburg, with another anti-CD4 mAb (W3/24) also showed that CD4 expression in the 
white pulp was not only restricted to the T cell area and to some dendritic cells but also 
to the marginal zone of the spleen (data not shown).  
 
3.2.1.5 CD1d expression in rat and mouse non-lymphatic organs 
In collaboration with Prof. Steiniger, Institute of Anatomy and Cell Biology, Philipps-
University of Marburg, Marburg, CD1d was analyzed outside the hematopoietic system 
by immunohistochemistry. Figure 12 shows stainings with the 233 mAb of LEW heart, 
liver, pancreas and small intestine.  
In rat liver, all hepatocytes are stained and their reactivity increases in direction to the 
central vein of the lobule (Fig. 12 a). Sinusoidal endothelia express higher CD1d levels 
than hepatocytes and the most strongly stained cells may correspond to Kupffer cells or 
stellate cells scattered among the hepatocytes. However, these cells are difficult to 
diagnose due to the strong staining of the sinusoidal endothelia. In the heart (Fig. 12 b), 
233 stains the interior and surface of cardiomyocytes and the intercalated discs are also 
clearly visible. Capillary endothelia between the muscle cells and, in addition, the 
endocardium are also CD1d positive.  
When CD1d expression was addressed in the rat ileum, the distribution pattern turned 
out to be as diverse as the cellular components of this organ (Fig. 12 c). Enterocytes are 
clearly detected by the 233 mAb with crypt cells staining more strongly than cells 
covering the villi. Enteroendocrine cells are most probably also positive, but this is 
difficult to distinguish. Remarkably, Paneth cells at the base of the crypts show very 
strong staining intensity. Beneath the epithelium many different cells lodge in the 
lamina propria, such as lymphocytes, myeloid cells, smooth muscle cells, fibroblasts 
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and endothelial cells forming capillaries and lymphatic vessels. A large number of these 
cells are also positive. Smooth muscle cells forming the gut wall are almost CD1d 
negative, but there are some elongated CD1d positive cells in the lamina muscularis 
mucosae and in the circular layer of the tunica muscularis, some of which may be 
endothelia.  
Staining of the rat pancreas (Fig. 12 f) with 233 and 35 revealed massive CD1d 
expression in the apical granules of exocrine acinar cells, being detected even at 
extremely high dilution (1:100.000). Interacinar capillary endothelial cells and/or 
intercalated duct epithelia also express CD1d. The epithelium in larger interlobular 
ducts and the endothelium in arteries and veins are CD1d positive as well. mAb 35 
tends to produce a somewhat reduced staining reaction in these cells compared to mAb 
233 (data not shown). Interestingly, in many islets of Langerhans central endocrine cells 
stain with variable intensity, while the peripherally situated glucagon-containing islet 
cells appear almost non-reactive. Whether nerve fibers are CD1d positive is difficult to 
recognize, because endothelia and certain connective tissue cells surrounding larger 
vessels react with mAb 233. The strong CD1d expression in the rat pancreas was 
verified by ELISA and Western Blot analyses (figures 2 c and 4 b). 
Because reactivity of the 233 and 35 mAbs against mouse CD1d in histochemistry is 
not as high as against rat CD1d, immunohistology of mouse ileum and pancreas was 
performed using the more sensitive tyramide amplification procedure including organs 
from CD1d-/- mice as negative controls (Fig. 12 d, e, g and h and data not shown for 35 
mAb). This analysis revealed a considerable species-specific difference of CD1d 
expression intensity and, at least with respect to the pancreas, also of expression pattern 
among mouse and rat. In mouse ileum the expression of CD1d is reduced in comparison 
to rats. The reduction is especially evident in parenchymal cells such as epithelia. It is 
less pronounced in the lamina propria and in the muscle layers, where the staining 
pattern corresponds to that of rats (Fig. 12 c-e). Even with the tyramide amplification 
technique, enterocytes of the ileum do not react with any of the antibodies. A 
subpopulation of Paneth cell apical granules is, however, reliably visualized in the small 
intestine. It is not clear whether the apical cell membrane of Paneth cells is also slightly 
stained. In addition, enteroendocrine cells in the epithelial layer of the ileum are CD1d 
positive. These cells are especially numerous in the crypts. In contrast to rats, in mouse 
pancreas the highest CD1d levels are found in the epithelium of larger ducts and in 
interacinar capillary endothelia, while the exocrine granules of acinar cells appear very 
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faintly stained and are only prominent in few single cells in spite of tyramide 
amplification (Fig. 12 f-h). Whether epithelial cells of the intercalated ducts are also 
positive cannot be clearly distinguished. Moreover, endocrine islet cells appear only 
very faintly stained and the endothelium in arteries and veins does not react at all, 
although vessel-associated nerve fibers appear positive. With the exception of some 
epithelial cells in larger ducts, mAb 35 is nearly unreactive with the pancreas. To 
address the question whether in contrast to C57BL/6 mice, CD1d expression in the 
pancreas of other strains is comparable to that observed in rats due to the expression of 
CD1d2, we also studied BALB/c and CBA/N mice with both mAbs and found that this 
 
Figure 12. CD1d distribution in non-lymphatic tissues. Experiments performed by Prof. Steininger, 
Phillipps-University of Marburg. ABC technique with unconjugated mAb 233 was applied unless 
otherwise stated. (a) LEW liver. Bar = 250 µm. (b) LEW heart. Hemalum counterstain was included. 
Bar = 250 µm. (c) LEW ileum. The epithelium at the tips of the villi (left rim of picture) is not 
preserved. Analysis was carried out with biotinylated 233 and hemalum counterstain. Bar = 100 µm. 
(d) C57BL/6 ileum. Arrows indicate CD1d positive enteroendocrine cells in the epithelium. Biotin-
conjugated primary antibody, tyramide-amplified ABC technique and hemalum counterstain were 
used. Bar = 50 µm. (e) C57BL/6 CD1d-/- ileum. Biotin-conjugated primary antibody, tyramide-
amplified ABC technique and hemalum counterstain were applied. Bar = 50 µm. (f) LEW pancreas. 
Biotinylated 233 was used. Bar = 50 µm. (g) C57BL/6 pancreas. Biotin-conjugated primary antibody 
and tyramide-amplified ABC technique were used. Hemalum counterstain was included as well. Bar = 
50 µm. (h) C57BL/6 CD1d-/- pancreas. Biotin-conjugated primary antibody and tyramide-amplified 
ABC technique were applied and hemalum counterstain was also carried out. Bar = 50 µm. 
Abbreviations used: c, crypts; lp, lamina propria; m, smooth muscle cells of the gut wall; i, islet of 
Langerhans and d, interlobular duct. 
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is not the case because very similar results were obtained for the pancreas of all 
analyzed mouse strains (data not shown).    
 
3.3 Analysis of CD1d-restricted immune response with the 233 and 35 
mAbs 
Upon stimulation with the potent antigen α-Gal, iNKT cells secrete Th1 and Th2 
cytokines very rapidly being the only lymphocytes described to date that can secrete 
large amounts of IL-4 within few hours after primary antigen contact. CD1d restriction 
of α-Gal responsiveness has been extensively demonstrated by the use of CD1d-
deficient mice and the use of monoclonal antibodies. However in the rat, although an α-
Gal response of intrahepatic lymphocytes and splenocytes has been previously been 
shown by E. Pyz et al. (Pyz et al., 2006), direct demonstration of the role of CD1d as an 
antigen presenting molecule had not been shown yet. Thus, in order to investigate 
whether the 233 and 35 mAbs interfere with the presentation of α-Gal by CD1d to 
primary iNKT cells, C57BL/6 and F344 splenocytes were cultured with α-Gal in the 
presence or absence of the anti-CD1d mAbs. After 24 hours of culture, supernatants 
were harvested and IL-4 and IFN-γ amounts were measured by ELISA. As controls, 
cells were also incubated with β-Gal, ConA or culture medium only. As it is shown in 
figure 13, regardless of the species origin, addition of the antibodies blocked cytokine 
release. A toxic or unspecific effect of the antibodies could be ruled out as they did not 
inhibit cytokine production after ConA stimulation and the isotype control did not affect 
α-Gal-dependent cytokine release (figure 13).  
 
Figure 13. Effects of mAbs 233 
and 35 on CD1d antigen 
presentation to iNKT cells. IL-4 
and IFN-γ production was analyzed 
by measuring cytokine release into 
the culture supernatant by ELISA 
after 24 hours. 107 splenocytes per 
ml from C57BL/6 mice or F344 rats 
were cultured with various stimuli: 
α-Gal (10 ng/ml), β-Gal (10 ng/ml) 
or ConA (3 µg/ml) or media alone, 
in the presence or absence of 233, 
35 or isotype control antibodies 
(with a final saturating 
concentration of 3,6 µg/ml). Bars 
show mean values + SD of cytokine concentrations obtained in three independent experiments.  
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3.4 Rat iNKT cell identification  
TCRs bind to peptides loaded on MHC molecules or to glycolypids loaded on CD1d 
with rather low affinity, resulting in complexes which have a very fast on-off 
dissociation rate (Matsui et al., 1994). For this reason it is not possible to visualize 
antigen-specific T cells with soluble monomeric peptide-MHC complexes, but they can 
be stained and analyzed by flow cytometry using multimerized complexes which have a 
much higher avidity for the TCR (Altman et al., 1996). In the same way, iNKT cells can 
also be identified with α-Gal-loaded CD1d oligomers. As mentioned in the introduction, 
this enables to distinguish these cells from other T cells expressing NK receptors and 
from other CD1d-restricted T cells, which do not bear the semi-invariant TCR reactive 
to α-Gal (Godfrey et al., 2004). 
Cross-species recognition of α-Gal presented by CD1d has been described (Benlagha et 
al., 2000; Karadimitris et al., 2001; Matsuda et al., 2000; Schumann et al., 2003). An 
example of this cross-reactivity are mice and humans: The human semi-invariant TCRs 
recognize α-Gal presented by mouse CD1d and vice versa, mouse T cells with semi-
invariant TCRs recognize α-Gal presented by human CD1d. Nonetheless, despite that 
iNKT cells can be stained with CD1d oligomers from the other species, the affinity with 
which the semi-invariant TCR of one species recognizes CD1d from the other species is 
lower than when both molecules are from the same species (Schumann et al., 2003). 
Moreover, this cross-species reactivity is not universally conserved, being lost or 
impaired between closer species than mouse and human. One example is the loss of 
reactivity of human semi-invariant TCR against α-Gal-loaded tree shrew (Tupaia 
belangeri) CD1d (Zhang et al., 2009). Another example is that of mouse and rat. As it 
was described by E. Pyz et al. in our laboratory, whereas the mouse semi-invariant TCR 
recognizes α-Gal-loaded rat CD1d almost to the same extent as it recognizes mouse α-
Gal presented by the syngenic CD1d, the rat semi-invariant TCR response to α-Gal 
presented by mouse CD1d is severely impaired (Pyz et al., 2006). Furthermore, staining 
of rat IHLs with mouse α-Gal-loaded CD1d tetramers did not lead to the clear 
identification of a tetramer positive cell population, despite the reactivity of rat primary 
cells to α-Gal. Based on this data, the most simple explanation for the impossibility to 
reliably detect rat iNKT cells using α-Gal mouse CD1d tetramers is a poor binding of 
semi-invariant rat TCR to α-Gal/mouse CD1d complexes although it still might be 
possible that the numbers of iNKT cells in the rat are below the detection limit of flow 
cytometry. To address these questions, rat CD1d oligomers were produced. Different 
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strategies were followed, since each of them has advantages or disadvantages over the 
others (Fig. 14). First, divalent oligomers were produced with CD1d-IgG fusion 
proteins. Second, to avoid the difficulties which can result from using mouse IgG1 
comprising molecules to stain primary cells from rats and mice, dimers were also 
produced with CD1d human IgG Fc fusion proteins and third, three different approaches 
were taken to produce tetramers, in order to generate a reagent with higher avidity than 
that of dimers. In two of the three strategies, directly targeted biotinylation of the 
soluble CD1d molecules was required for tetramerization. In the other one, a strep-tag 
which can be directly bound without biotinylation to a modified streptavidin (Strep-
Tactin) was used. 
Figure 14. CD1d recombinant proteins. a Illustration of the different produced CD1d recombinant 
proteins. b Purified CD1d recombinant proteins analyzed by SDS-PAGE (15%) under reducing 
conditions. Proteins were stained with Coomassie Blue R250. Different amounts of each recombinant 
protein were loaded. Protein concentrations were calculated after photometric analysis as described in the 
methods section 2.2.3.7. 1: mouse CD1d-IgG dimers (2 µg); 2: rat CD1d-IgG dimers (2 µg); 3: rat β2m-
CD1d-hFc dimers (4µg); 4: biotinylated mouse CD1d, kindly provided by M. Schiemann (2 µg); 5: 
biotinylated rat CD1d-biotag produced in S2 cells (2,6 µg); 6: rat β2m-CD1d-biotag produced in 293T 
cells (10 µg) and 7: rat β2m-CD1d-streptag (10 µg). Commercially purchased mouse IgG2b (2 µg) was 
loaded as control. The real amount of CD1d recombinant protein in lanes 6 and 7 is about 5 times less 
than the calculated one after photometric analysis. c Purified CD1d recombinant proteins analyzed by 
SDS-PAGE (10%) under non-reducing conditions. Lanes are the same as in b. The used molecular weight 
marker was peqGOLD Protein Marker (Peqlab). 
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3.4.1 Production of CD1d oligomers 
3.4.1.1 Mouse and rat CD1d-IgG dimers  
Dimer production of MHC-I, -II, as well as mouse and human CD1d molecules using 
IgG antibodies as platform for the creation of divalent molecules has previously been 
described (Dal Porto et al., 1993; Greten et al., 1998; Hamad et al., 1998; Lebowitz et 
al., 1999; Schumann et al., 2003). In order to produce mouse and rat CD1d dimers in 
this way, fusion proteins containing the α1-α3 domains of CD1d and the mouse IgG1 
heavy chain were created as previously described by cloning rat or mouse CD1d cDNAs 
into the pXIg vector and expressing the recombinant proteins into the J558L murine 
plasmocytoma cell line (Dal Porto et al., 1993; Schumann et al., 2003). The J588L cells 
producing rat CD1d-IgG dimers were additionally transduced with rat β2-
microglobulin. In the figure 14, the different subunits which form the mouse or rat 
CD1d-IgG recombinant proteins can be appreciated when analyzed under reducing 
conditions: the CD1d-IgG1 heavy fusion protein of about 100 kDa, the λ light chain of 
27 kDa and the β2-microglobulin at approximately 12 kDa.  
E. Pyz and I. Müller generated the plasmids encoding CD1d-IgG1 fusion proteins and 
did the first transfections into J558L cells. Cloning of rat β2-microglobulin into the 
retroviral expression vector pczCFG5 IZ was carried out by P. Neuhöfer.  
 
3.4.1.2 Rat β2m-CD1d-hFc dimers  
Rat CD1d extracellular domains (α1-α3) were fused to the human IgG1 Fc region 
encoded in the pFUSE-hIgG1-Fc2 vector. As previously described for human CD1d 
molecules (Li et al., 2008), the N-terminus of the α1 domain of CD1d of this fusion 
molecule was then connected to rat β2m by a glycine-serine linker. This assures 
constant binding of rat CD1d to rat β2-microglobulin and not to β2-microglobulin of the 
dimer producing human 293T cells or of the fetal calf serum present in the culture 
medium. The final fusion construct was abbreviated as: β2m-CD1d-hFc. The 
recombinant dimer should be formed by two identical rat β2-microglobulin CD1d 
human IgG1 Fc fusion heavy chains with a molecular weight about 90-95 kDa. Western 
blot analysis using the biotinylated 233 mAb demonstrated that among all the bands 
which appeared in the purified extracts, the band running at approximately 95 kDa 
under reducing conditions was the rat β2m-CD1d-hFc fusion protein (Fig. 14, and data 
not shown for the Western blot). Most likely, the bands observed at 55 and 25 kDa are 
heavy and light Ig chains since they were also detected by the HRP-conjugated 
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secondary polyclonal anti-mouse Ig antibody used in the Western blot (data not shown). 
These Ig chains are probably traces comprised in the serum containing media, which 
remained in the cultures after having exchanged it by serum free media and which also 
bound to the protein G.  
 
3.4.1.3 Rat CD1d constructs for streptavidin based multimerization 
Two different approaches were taken in order to produce rat CD1d monomers 
containing a specific peptide sequence (bio-tag) recognized by the enzyme BirA, which 
adds one single biotin molecule to the lysine contained in such amino acidic sequence 
(Schatz, 1993). The first approach was originally designed for production of mouse 
CD1d in the Drosophila derived cell line SC2 (Benlagha et al., 2000) and it was carried 
out in collaboration with M. Schiemann and D. Busch, Institute of Medical 
Microbiology, Dept. of Medicine, Technical University Munich. The second approach 
was conceived to produce rat CD1d in the mammal cell line 293T.  
Production of rat CD1d fused to bio- and polyhistidine-tags in insect cells was 
performed as described in Materials and Methods (Methods section 2.2.3.3). Soluble 
biotinylated mouse CD1d was loaded onto the gel as control (line 4). The lane of the 
mouse CD1d comprises three clear bands: Two prominent bands appear at 38 and 12 
kDa and are likely mouse CD1d and β2-microglobulin, respectively. Another band with 
a more reduced intensity appears at 33 kDa and is probably the BirA enzyme used for 
biotinylation, since that is exactly its molecular weight (Schatz, 1993). In contrast, in 
the lane where rat CD1d (line 5) was loaded, no prominent bands appear at 38 or at 12 
kDa, but one at 33 kDa.  
For production of rat CD1d in the mammal cell line 293T (second strategy) rat β2-
microglobulin was attached to CD1d by a glycine-serine linker, as described above for 
the human Fc dimers, resulting in a fusion protein formed by rat β2-microglobulin, rat 
CD1d extracellular domains, bio- and polyhistidine-tags. In figure 14 b and c it can be 
appreciated as this fusion protein is highly glycosylated in the 293T cells, appearing as a 
broad band of approximately 60 kDa under reducing conditions and of about 50-55 kDa 
under non-reducing conditions. Unfortunately, specific biotinylation of rat CD1d tested 
as described in the methods section 2.2.3.9 was not efficient. 
These recombinant proteins were not further used to produce rat CD1d oligomers due to 
the reported inconveniences: Not enough protein amounts and inefficient biotinylation. 
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3.4.1.4 Rat β2m-CD1d-streptag  
In order to avoid problems of inefficient biotinylation and in addition, to produce a 
reagent whose oligomerization can be reversed (Knabel et al., 2002), also in 
collaboration with M. Schiemann and D. Busch, a rat CD1d soluble molecule 
containing a strep-tag and a polyhistidine-tag was produced in the SC2 fly cell line. This 
soluble CD1d molecule also contained the rat β2-microgloubulin fused by a glycine-
serine linker. SDS-PAGE and Coomassie Blue R250 staining shows the purified protein 
as a sharp band running at the expected molecular weight of non N-glycosylated CD1d 
and β2-microglobulin, approximately 43 and 36 kDa under reducing and non-reducing 
conditions, respectively (Fig. 14).  
 
3.4.1.5 Efficient loading of CD1d with α-Gal  
Loading of glycolypids with long fatty acid chains as α-Gal into CD1d in vivo is 
facilitated by proteins belonging to the saposine family, GM2 activator proteins, and 
Niemann-Pick type C1 and C2 proteins (Sagiv et al., 2006; Schrantz et al., 2007; Yuan 
et al., 2007; Zhou et al., 2004a), which contribute to the solubilisation and transport of 
these glycolipids from hydrophobic membranes or micelles to the antigen binding 
groove of CD1d. Such biological conditions can be simulated in vitro for example by 
adding recombinant saposine B or detergent (TRITON X-100 at a final concentration of 
0.05%) to the CD1d/lipid mixtures (Im et al., 2009). As shown in figure 15, only when 
α-Gal loading was carried out in the presence of 0.05% of TRITON X-100 staining of 
rat semi-invariant TCR transductants with the dimers correlated with the TCR levels 
and all cells could be visualized. In contrast, without TRITON X-100 not all cells bound 
to the dimers. Moreover, the binding of the dimers did not correlate directly with the 
TCR levels expressed at the cell surface of the transductants. Thus, proper loading of α-
Gal into rat CD1d was only achieved when TRITON X-100 was also added to the 
lipid/CD1d mixture. Nonetheless it is very important to take into account the 
detrimental effects that the use of detergents can cause to living cells. Indeed, after 
staining with dimers containing TRITON X-100 the size of BWs cells was smaller. 
These damaging effects were even more pronounced with primary cells which were 
lysed to a substantial proportion if the final concentration of TRITON X-100 reached 
0.0063% and/or the incubation times were longer than one hour during the staining with 
the dimers (data not shown). For these reasons stainings were usually carried out during 
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one hour at room temperature and at a final concentration of 0.0037% TRITON X-100, 
conditions which most of the cells resisted.  
 
Figure 15. Efficient glycolipid loading of CD1d dimers. BW r/mCD28 rAV14S6 + CDR2+4 cells were 
stained with dimers loaded with either α-Gal or β-Gal in the presence or absence of 0.05% TRITON X-
100 detergent. Dimers were visualized with DαM-PE, and TCR levels were analyzed with R73-bio + SA-
APC. Two independent experiments are shown. Numbers in the density plots correspond to the 
percentages of cells in each quadrant.   
 
3.4.2 Binding of diverse CD1d oligomers to rat semi-invariant TCR 
At first, the capability of the newly generated rat CD1d oligomers to bind to rat semi-
invariant TCRs was tested with transductants expressing a rat semi-invariant TCR 
(AV14S6FAJ18 α chain and BV8 β chain) (Pyz et al., 2006). In this experiment, the 
newly generated rat CD1d oligomers were compared to mouse and human CD1d 
oligomers (figure 16). β-Gal-loaded controls were included to assess unspecific binding.  
As previously shown by E. Pyz, these cells were stained by α-Gal-loaded mouse CD1d 
tetramers to some extent. Similarly, α-Gal-loaded mouse CD1d-IgG dimers also stained 
this cell line very weakly. α-Gal-loaded human CD1d tetramers did not bind to the 
transductants. Importantly, staining of these cells with α-Gal-loaded rat CD1d-IgG 
dimers was much better than with mouse CD1d-IgG dimers. α-Gal-loaded rat CD1d 
human Fc dimers also bound this rat semi invariant TCR, although not as efficiently as 
rat CD1d-IgG dimers. Unfortunately, and even though oligomerization was carried out 
in one single experiment, the differences observed between α-Gal- and β-Gal-loaded rat 
CD1d streptamer stainings were very modest. Moreover, this reagent gave a very high 
unspecific signal shown by the β-Gal-loaded control staining. This unspecific binding 
was independent from TCR recognition since it also appeared when untrasduced BWs 
were stained (data not shown).  
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Figure 16. Reactivity of CD1d oligomers from different species against rat semi-invariant TCR. BW 
r/mCD28 rAV14S6 + CDR2+4 transductants were stained with various α-Gal- or β-Gal-loaded CD1d 
oligomers. 1 Human CD1d tetramers: 105 cells were stained for 40 min at room temperature with 0.025 
µg of α-Gal- or β-Gal-loaded human CD1d-PE tetramers (black and gray lines, respectively) in a final 
volume of 50 µl of FACS buffer. Filled histograms correspond to unstained BW cells. 2 Mouse CD1d 
tetramers: Staining of BW transductants with mouse CD1d-PE tetramers was carried out as with human 
CD1d tetramers. Human and mouse CD1d tetramers were kindly provided by S. A. Porcelli. 3 Mouse 
CD1d-IgG dimers: 2x105 cells were stained with 2 µg of α-Gal- or β-Gal-loaded mouse CD1d-IgG dimers 
during 1 hour at room temperature in a final volume of 100 µl, where the final concentration of TRITON 
X-100 was 0.0037%. After washing, dimers were detected with DαM-PE. Filled histograms show BW 
cells which were stained with DαM-PE in the absence of CD1d-IgG dimers. Rat CD1d-IgG dimers: 
Staining of BW transductants with rat CD1d-IgG dimers was carried out as with mouse CD1d-IgG 
dimers. 5 Rat β2m-CD1d-hFc dimers: 2x105 cells were stained with 2 µg of α-Gal- or β-Gal-loaded rat 
β2m-CD1d-hFc dimers for one hour at room temperature in a final volume of 100 µl, where the 
concentration of TRITON X-100 was 0.0063%. Rat β2m-CD1d-hFc dimers were detected, after washing, 
with PE labeled goat F(ab’)2 anti-human IgG Fc fragment. Filled histograms represent non-stained cells. 
6 Rat CD1d streptamers: 105 cells were stained with rat CD1d streptamers (50 µl containing 1 µg α-Gal- 
or β-Gal-loaded rat β2m-CD1d-streptag + 0.75 µg Strep-Tactin-PE, which had previously been pre-
incubated for 45 min at 4ºC in a final volume of 50 µl). The final concentration of TRITON X-100 was 
0.01%. Filled histograms represent non-stained BW cells. 
 
3.4.3 Binding of mouse and rat CD1d dimers to iNKT cells of either species  
From all rat CD1d oligomers produced and tested, rat CD1d-IgG dimers were chosen to 
analyze rat primary cells, firstly, because they were the best reagent to stain a cell line 
expressing a rat semi invariant TCR (Fig. 16) and secondly, because the production of 
mouse CD1d-IgG dimers had also been established in our laboratory, allowing a direct 
comparison of rat and mouse primary cells with the same CD1d reagent from each 
species. 
The following results were obtained when mouse (C57BL/6) and rat (F344) intrahepatic 
lymphocytes were stained with rat and mouse CD1d-IgG dimers (Fig. 17): i) mouse 
CD1d-IgG α-Gal-loaded dimers stained mouse iNKT cells, which as previously 
reported were the major proportion of T cells in the liver (45%) (Hammond et al., 
2001). ii) α-Gal-loaded rat CD1d-IgG dimers, stained also mouse iNKT cells, although 
the proportion of iNKT cells stained by rat the rat oligomers (29% of the intrahepatic T 
cells) was smaller than the proportion stained by mouse CD1d dimers (45%). iii) Rat 
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iNKT cells could be identified with rat CD1d-IgG α-Gal-loaded dimers, revealing that 
compared to mouse, iNKT cell numbers in the rat are a much lower: only a 1.4% 
(±0.37, SD) of all rat intrahepatic T cells are iNKT cells. Moreover, in line with CD4 
and CD8 expression by mouse and human iNKT cells (Bendelac et al., 2007) these α-
Gal-loaded rat CD1d-IgG dimer positive T cells are mostly CD4 or DN cells, and only a 
very small proportion expresses CD8β (4.58% ±1.43). In contrast, the few T cells which 
are included in the gate of rat CD1d-IgG β-Gal-loaded positive cells have a completely 
different CD4/CD8 distribution: Many of them CD8β and double positive and very few 
DN. In a single experiment binding of mouse CD1d-IgG α-Gal-loaded dimers to rat 
iNKT cells was also tested. In this experiment the proportion of TCR positive cells 
stained by the CD1d-IgG α-Gal-loaded dimers was less than half of that stained by rat 
dimers, while the number of cells stained by the β-Gal-loaded control was slightly 
higher. Nevertheless, much of this staining was probably specific for iNKT cells given 
Figure 17. Interspecies cross-reactivity of mouse and rat CD1d-IgG dimers. C57BL/6 and F344 
intrahepatic lymphocytes were stained with rat and mouse CD1d-IgG dimers loaded with either α-Gal 
or β-Gal. Dimers were detected with DαM-PE. To assure specific dimer staining of T cells, mouse and 
rat T cells were identified with H57-597 or R73 FITC-labeled mAbs, respectively. FCS/SCC dot plots 
depict the gated populations among total isolated cells, which are shown in the dimers/TCR plots. In 
mouse IHLs stainings, B cells, defined as CD19-positive cells stained with the 1D3-APCy mAb, were 
excluded and are not shown in the dimers/TCR plots. In rat cells, CD8β (341-bio + SA-APCy) and 
CD4 (OX-35-Cy5PE) expression was also analyzed. CD4/CD8 plots show F344 IHLs-gated cells 
which were double positive for the different dimers and TCR. Numbers in the plots indicate the 
percentages of gated cells.  
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the increased number of DN cells in this population. However, the lower staining 
efficacy and the rather high degree of staining of non-T cells underscore that mouse 
CD1d-IgG dimers are not suitable for the analysis of rat primary iNKT cells. A point 
which is underlined by results obtained with cultured iNKT cells later in this section 
(Results 3.7.4).     
 
3.4.4 Phenotype of rat iNKT cells 
Once rat iNKT cells could be identified by flow cytometry its phenotype was analyzed. 
First, based on their FCS and SCC properties, iNKT cells were relatively big and fairly 
granular (Fig. 18 a). These properties allowed the reduction of the gate set on total 
lymphocytes in such a way that unspecific staining was reduced while the proportion of 
iNKT cells among the gated cells was increased (Fig. 18 a). Second, approximately the 
half of F344 iNKT cells bear a TCRβ chain which contains the BV8S4 gene segment, 
whereas among the other intrahepatic T cells only a 6.5 ±0.5% have this particular BV 
gene segment (Fig. 18 b). Third, almost all α-Gal-loaded rat CD1d-IgG dimer positive T 
cells expressed NKR-P1A/B receptors detected by the mAb 10/78, hereafter referred 
simply as NKR-P1. Nonetheless, from all T cells expressing NKR-P1 only a very small 
proportion were iNKT cells (5%, Fig. 18 c) and fourth, as shown in the previous section 
of the results, most of rat iNKT cells were CD4 or DN (Fig. 17).  
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3.5 iNKT cell frequencies in various rat strains 
In human and mouse iNKT cell numbers are under strict genetic control, as shown by 
very similar frequencies in genetically identical individuals but varying up to 100 fold 
among different genetic backgrounds (Lee et al., 2002b). These differences are also well 
illustrated in studies where different mouse strains were investigated (Hammond et al., 
2001; Rymarchyk et al., 2008). Therefore, apart from the direct identification of iNKT 
cells in the rat, the analysis of iNKT cell frequencies and function among different rat 
strains was one of the aims of this study. Prior results from E. Pyz investigating α-Gal 
responsiveness in F344 and LEW rats, showed that whereas F344 splenocytes secreted 
cytokines in an antigen-dose dependent manner, cytokine release by LEW splenocytes 
was absent (IL-4) or very low (IFN-γ) even at high concentrations of α-Gal. Based on 
Figure 18. Phenotype of rat iNKT cells. F344 intrahepatic lymphocytes were stained with rat CD1d-
IgG dimers loaded with either α-Gal or β-Gal, which were detected with DαM-PE. To assure specific 
dimer staining of T cells, after blocking of free binding sites of DαM-PE with mouse IgG, anti-TCR 
mAb (R73-FITC) was included in the analysis. a Size and granularity of iNKT cells. To determine the 
size and granularity of rat iNKT cells compared to other intrahepatic lymphocytes first, dimer and 
TCR co-staining was analyzed among all lymphocytes. The FCS/SSC plot on the left, illustrates how 
total lymphocytes were gated. Subsequently, iNKT cells (in blue), defined as shown in the plot in the 
center of the figure (α-Gal-loaded rat CD1d-IgG dimer+ TCR+), were superimposed to the gate of all 
lymphocytes (red). In such a way a new gate was defined where iNKT are mostly localized (black 
gate in the overlay of iNKT cells and total lymphocytes). As expected, the proportion of iNKT cells 
increased among the cells contained in this narrower gate (dimers/TCR plots on the right). b BV8S4 
usage by F344 iNKT cells compared to αβ T cells. Multicolor flow cytometry allowed to assess the 
proportion of BV8S4+ cells among iNKT cells (α-Gal-loaded rat CD1d-IgG dimer+ and TCR+ cells) by 
including the biotinylated R78 mAb (visualized with SA-APCy) in the staining. The dimer/TCR plot 
illustrates which cells were analyzed for their BV8S4 usage. In the histogram overlay the percentages 
of R78+ among iNKT cells (black) or αβ T cells (gray) are shown. c NKR-P1 expression. Similar to b, 
NKR-P1 (10/78-Bio + SA-APCy) analysis was included into the iNKT cell staining. The NKR-
P1/TCR dot plot shows total lymphocytes in red (gated as shown in a, big FCS/SSC gate) and iNKT 
cells in blue (α-Gal-loaded rat CD1d-IgG dimer+ TCR+ cells, density blot shown in a). In the 
experiment shown, iNKT cells constitute a 5% of NKR-P1 intermediate TCR+ lymphocytes (black 
gate).  
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these findings both strains were chosen as representative of α-Gal responder and non-
responder inbred rat strains and were tested for the presence of iNKT cells.  
 
3.5.1 iNKT cells in F344 and LEW rats 
Using rat CD1d-IgG α-Gal-loaded dimers, iNKT cell frequencies were analyzed in 
different compartments of F344 and LEW rats. The particular CD4/CD8 distribution of 
these cells helps to identify false positive cells when the frequencies of cells stained 
with the dimers are very low. Therefore, CD4 and CD8β expression was also addressed 
(Fig. 19).  
As shown in a previous section (Results 3.4.3) iNKT cell frequencies in F344 rats are, 
when calculated as proportion of hepatic T cells, 10 fold lower than that of C57BL/6 
mice and at least 50 fold lower when the frequencies among total hepatic lymphocytes 
were compared. Nonetheless, the distribution of these cells in liver, spleen and blood 
correlate with the data obtained in mice: rat iNKT cell numbers were also much higher 
in the liver than in the spleen and than in the blood: 3.5, 0.4 and 0.05% of the T cells 
which were included in the electronically-set gate as shown in figure 18 (Fig. 19, FSC-
SCC dot plots). This gate contained only big-sized lymphocytes and it was necessary to 
reduce unspecific staining. However, this gate does not include the small-sized 
lymphocytes and therefore the frequencies which are shown in the dot plots are not 
representative for all lymphocytes. Among F344 IHLs the mean values of the 
frequencies of iNKT cells among total intrahepatic lymphocytes and among total T cells 
analyzed in four animals are 0.25 (±0.1 SD) and 1.4 (±0.37 SD), respectively. 
Importantly, although sometimes only very few iNKT cells were stained with the α-Gal-
loaded CD1d-IgG dimers (for example in the blood where 1 only of 2300 cells was 
stained, Fig. 19), the constantly reduced numbers positive for β-Gal-loaded CD1d-IgG 
dimers, and the nearly absolute lack of DN cells among cells stained with β-Gal-loaded 
CD1d-IgG dimers indicate a large specific staining of iNKTs. 
In agreement with the functional data obtained by E. Pyz, iNKT cell numbers were 
much more reduced in LEW compared to F344. Indeed, whereas iNKT cells appear as a 
clearly distinct population among F344 intrahepatic lymphocytes, the results obtained 
with LEW rats were close to the detection limit.  
iNKT cell development has been extensively studied in the mouse. In this species iNKT 
cells are selected in the thymus by DP thymocyes, after AV14-AJ18 rearrangements. In 
the early stages of its development iNKT cells express CD4, which will be lost later on. 
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This loss of CD4 already occurs in the thymus (Bendelac et al., 2007; Godfrey et al., 
2010). Therefore, it was surprising when no differences were observed between the 
frequencies of α-Gal- or β-Gal-loaded CD1d-IgG dimer positive cells in thymocytes 
from both strains (Fig. 19) and when no more DN cells were found among the cells 
stained with α-Gal CD1d-IgG dimers. To which extent the observed increased 
proportion of CD4 single positive among α-Gal-loaded CD1d-IgG positive cells 
compared to β-Gal-loaded CD1d-IgG positive cells in F344 but not in LEW thymocytes 
relates to iNKT cells remains to be elucidated.  
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Figure 19. iNKT cell frequencies in F344 and LEW rats. Frequencies of iNKT cells were analyzed 
among intrahepatic lymphocytes (IHLs), splenocytes, peripheral blood cells (PBCs) and thymocytes by 
flow cytometry after having stained the cells with either α-Gal- or β-Gal-loaded rat CD1d-IgG dimers 
(visualized with DαM-PE) and anti-TCRβ (R73-FITC), anti-CD4 (OX-35-CyPE) and anti-CD8β (341-bio 
+ SA-APCy) mAbs. Based on the size and granularity of iNKT cells (FIG phenotype a), the FCS/SSC 
plots on the left depict which cells are shown in the dimer/TCR plots. CD4/CD8 plots show either α-Gal- 
or β-Gal-loaded rat CD1d-IgG dimer+ TCR+ gated cells. Numbers in black indicate the percentages of 
gated cells in each plot. Numbers in blue above each plot correspond to the total events which are shown. 
Blue numbers with brackets in the plots indicate the total events of the dimer+ TCR+ gated cells.    
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3.5.2 Expression of AV14-AJ18 rearrangements in F344 and LEW rats 
The fact that iNKT cells express an invariant TCRα chain formed by rearranged AV14-
AJ18 gene segments can be exploited to detect iNKT cells by amplifying such invariant 
α chains by PCR. Such rearrangements were analyzed in F344 and LEW thymocytes, 
splenocytes and IHLs by RT-PCR using AV14 and AJ18 primers. All AV14-containing 
TCRα chains were amplified as well with AV14 and AC primers (Fig. 20). Figure 20 a 
depicts the positions of these primers. Moreover, TCRβ chains containing BV8 gene 
segments and β-actin were also analyzed as controls of a specific product expressed by 
T cells and of the general quality of the cDNA, respectively.  
In line with iNKT cell frequencies detected by flow cytometry using rat CD1d dimers, 
the highest signal intensity of AV14-AJ18 products was obtained with F344 IHLs-
derived mRNA and it was followed by spleen and thymus. The signal of AV14-AC 
products was also higher in F344 IHLs than splenocytes and thymocytes. In LEW, 
signals for BV8-BC and β-actin controls were the same or even higher than for F344 but 
AV14-AJ18 rearrangements were hardly detected regardless of the tissue origin. 
Moreover, intensity of AV14-AC PCR products was also lower than in F344.  
As mentioned in the introduction, LEW rats have one functional BV8S2 like gene 
segment (BV8S2l) and F344 rats have two (BV8S2a and BV8S4a) (Asmuss et al., 1996). 
The forward primer used to amplify TCRβ chains bind to both, BV8S2 and BV8S4 
genes. 
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A real time PCR was also established to detect iTCRα chains. In addition of being a 
more quantitative approach, it also allowed the confirmation of the results obtained by 
RT-PCR, because the primers used in each PCR lay in different regions (Fig. 20 a and 
21 a). Relative quantification of iTCRα mRNA among the different tissues of F344 and 
LEW rats was based in the delta delta cycle threshold method (∆∆Ct), but interpretation 
of the results is rather limited since efficiencies for iTCRα (iTCR) and total TCRα (AC) 
PCR products were not determined, final concentrations of each primer pair were 
different (iTCR 100 nM and AC 300 nM) and serial dilutions of the cDNA were not 
routinely included. Moreover, for the detection of the iTCRα chain one primer had to 
anneal to AV14 and the other to AJ18. However, since the size of the PCR product 
should not be bigger than 300 bp for detection with SYBR Green, the forward primer 
had to anneal to the exon encoding the variable region (Fig. 21a). Therefore it was not 
possible to discriminate between amplicons of genomic or complemetary DNA as it was 
Figure 20. β-actin, iTCRα, AV14 TCRα and BV8 TCRβ mRNA expression by F344 and LEW 
thymocytes, splenocytes and IHLs. a Schematic representation of the position of the primers used to 
amplify iTCRα (AV14-AJ18) or AV14-containing TCRα (AV14-CA) chain mRNA by RT-PCR. b 
iTCRα (AV14-AJ18), AV14 TCRα (AV14-CA), BV8 TCRβ (BV8-BC) and β-actin mRNA 
expression was analyzed by RT-PCR in two independent experiments: exp1 and exp2, respectively. 
The products obtained after PCR amplification using cDNA derived from F344 or LEW thymocytes 
(thy), splenocytes (spl) and intrahepatic lymphocytes (IHLs) are show. - lanes are water controls. 
Numbers indicate the size of the bands of the DNA marker (m). Black arrows point out the expected 
size of each RT-PCR product: β-actin: 300 bp; AV14-AJ18: 420 bp; AV14-AC: 500 bp; BV8-BC: 
484 bp. Gray arrows in the BV8-BC products indicate the expected size of amplified DNA containing 
the intron between the signal peptide and the variable gene segment: 582 bp. n.d. non determined.   
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possible when the forward primer anneals to the exon encoding the signal peptide (Fig. 
20). For all these reasons, instead of only showing the relative values obtained after 
∆∆Ct calculations (Fig. 21 c and d), all Ct values obtained for iTCR and AC products 
are shown (Fig. 21 b). Despite the mentioned limitations, it is clear that the ratio of 
iTCRα to total TCRα mRNA is much higher in IHLs than in other compartments of 
F344 rats or in any of the tissues analyzed in LEW.  
 
Figure 21. Relative quantification of iTCRα mRNA among total TCRα chain mRNA. a Schematic 
representation of the position of the primers used to analyze iTCR (AV14-AJ18) mRNA expression 
among total TCRα (AC) chain mRNA by real time PCR. b Mean values of the cycle thresholds obtained 
for iTCRα and total TCRα mRNA in triplicate samples ± SD and ∆Ct calculation, except for LEW iTCR 
in splenocytes and IHLs, where only in 1 of 3 and 2 of 3 replicated samples, respectively, a PCR product 
appeared. Relative iTCRα mRNA expression was analyzed in different F344 and LEW compartments: 
thymocytes (Thy), splenocytes (Spl), intrahepatic lymphocytes (IHLs), lymph nodes (LN) and peripheral 
blood mononuclear cells (PBMCs). n.d. non determined. c Relative iTCRα mRNA expression in F344 
rats calculated by the ∆∆Ct method. In order to allow such a graphical representation, the relative iTCRα 
mRNA expression in the thymus was set as 1. The ∆∆Ct values were obtained from the results shown in 
c. d Relative iTCRα expression among F344 and LEW thymocytes (Thy), splenocytes (spl) and 
intrahepatic lymphocytes (IHLs) calculated by the ∆∆Ct method from the values shown in c. LEW 
relative iTCRα mRNA expression. Values were set as 1.   
 
3.6 Analysis of AV14 gene family in the rat 
The size of the AV14 gene family varies considerably between species: Humans 
possess one AV14 gene whereas mice one or two and rats up to ten (Kinebuchi and 
Matsuura, 2004; Koseki et al., 1991; Lefranc, 2001; Matsuura et al., 2000; Pyz et al., 
2006). In a previous report based on an obsolete supercontig sequence (NW_042969), it 
was reported that BN rats have ten AV14 gene segments, which based on their 
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localization in this contig were designated as TRAV11-1 to TRAV11-10 (Kinebuchi 
and Matsuura, 2004). The designation of AV14 as AV11 is based on the IMGT 
nomenclature. This nomenclature is maintained in this study to distinguish them from 
the actual BN genomic sequence (NW_047454.2, April 15th, 2005). All these gene 
segments were expected to be functional and some of them (i. e. TRAV11-5 and -6, as 
well as, TRAV11-2 and -8) had identical sequences. Blasting of these ten AV14s 
(TRAV11-1 to -10) with the most recent NCBI release (NW_047454.2) reveals a 
change in the order of the AV14 gene segments (Fig. 22). In the actual version, all the 
gene segments have unique sequences expected to encode different polypeptides (Fig. 
23 a). Consequently, two segments were absent in the former report: AV14S1 and 
AV14S3 (Fig. 22). AV14S3 is expected to produce a non-functional TCRα chain due to 
the deletion of two nucleotides resulting in a reading frame shift and a premature stop 
codon (Fig. 23 a).  
Currently, there are no mAbs which recognize and/or distinguish the predicted products 
of these AV14 gene segments (shown in Fig. 23 a) therefore analysis of expression of a 
specific AV14 is restricted to the mRNA level. In F344 rats five different AV14 gene 
segments and one pseudogene have been identified by cloning AV14 comprising TCRs 
from cDNA and genomic DNA, respectively (Matsuura et al., 2000; Pyz et al., 2006). In 
this study we propose a new nomenclature for some of these F344 AV14 gene segments 
based on their homology degree with BN AV14 gene segments in order to simplify the 
comparisons between these two species (Fig. 22). All the F344 AV14 gene segments are 
found in the BN rat genome with 100% homology for the exon encoding the mature 
polypeptide, except the pseudogene AV14S4PF which shows only 98% homology 
compared to AV14S4B. Consequently, its predicted amino acid sequence is not present 
in BN (Fig. 22 and 23). In the exons encoding the signal peptide, some of the F344 gene 
segments have a nucleotide substitution when compared to BN, which would encode a 
glutamine (Q, F344 allele) at position 4 instead of a histidine (H, BN allele) (Fig. 24).  
AV14 gene segments from F344 rats have been divided into two different types based 
on their CDR2 sequence similarity: AV14S6F, AV14S7F, AV14S8F and the pseudogene 
AV14S4PF belong to type I and AV14S2F is the only type II representative (Matsuura et 
al., 2000). Among all BN AV14 gene segments only 2 belong to the type II (AV14S2B 
and AV14S9B, figure 22 and 23 a and b). Interestingly, in the work published by 
Matsuura et al. a specific tissue distribution of these types was proposed: Type II 
 99 
bearing rearrangements were more frequent in the spleen, whereas type I containing 
invariant TCRs were slightly more abundant in the liver (Matsuura et al., 2000).  
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             b 
 
 BN actual genome  BN obsolete sequence NW_042969  F344 AV14 gene segments identified up to date 
CDR2 
Type  Gene Name 
Positions at 
NW_047454.2  
Gene Name 
(Kinebuchi et al. 
2004)  
Homology   New gene name Previous gene 
name 
Homology with 
BN genome Reference 
I  AV14S1  390863-391393         
II  AV14S2B 583401-583932  TRAV11-10 99%  AV14S2F AV14S3 98% s.p. 100% v.  
(Matsuura et 
al., 2000) and 
this study 
(I)  AV14S3PB 759841-760370         
I  AV14S4B 762278-762809  TRAV11-3 100%  AV14S4PF AV14S4 98% s.p. 98% v. 
(Matsuura 
et al., 2000) 
I  AV14S5B 1154998-1155529  TRAV11-7 100%  AV14S5F  98% s.p. 100% v. 
Identified in 
this study 
 I  AV14S6B 1418612-1419143  TRAV11-1 100%  AV14S6F AV14S1 100% s.p. 100% v. 
(Matsuura et 
al., 2000) 
I  AV14S7B 1659363-1659894  TRAV11-5 TRAV11-6 
100% 
100%  AV14S7
F
 AV14S2 100% s.p. 100% v. 
(Matsuura et 
al., 2000) 
I  AV14S8B 1834544-1835071  TRAV11-2 TRAV11-8 
100% 
100%  AV14S8
F
 AV14S8 100% s.p. 100% v. 
(Pyz et al., 
2006)  and 
this study 
II  AV14S9B 2181139-2181670  TRAV11-4 100%      
I  AV14S10B 2760694-2761225  TRAV11-9 100%      
Figure 22. Nomenclature of rat AV14 gene segments. According to their position in the most actual version of the rat genome at the NCBI (NW_047454.2, April 15th, 
2005) (a), we have named the AV14 gene segments of the BN inbred rat strain according to their position in the rat genome (b). In the table are also listed the AV14 gene 
segments reported by Kinebuchi and colleagues in 2004, based in the obsolete supercontig sequence and all AV14 gene segments reported up to date for F344 inbred rat 
strains with their new nomenclature based in their homology to the BN AV14 gene segments.   
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Figure 23. AV14 gene segments. a Alignment of the predicted amino acidic sequence of all VA14 gene 
segments. The only F344 gene segment identified to date which is different (without considering the 
signal peptide exon) from those of BN rats, is AV14S4PF (Accession Nr. AB036697.1) therefore it is the 
only F344 derived sequence included in this alignment. CDR regions are illustrated with bold letters. The 
box indicates the peptide region containing the CDR2 whose nucleotide sequences are shown in b. b 
Nucleotide sequence (nt) of regions encoding the CDR2 region. Above and below the alignment, the 
amino acidic (aa) sequences of representative type I (BN AV14S1) and type II AV14 (BN AV14S9) gene 
segments are shown. The CDR2 region is highlighted in bold. 
 
 
Figure 24. Cloned AV14 TCRα chains. The predicted amino acid sequences of various AV14-
containing TCRα chains which were coned after amplification by PCR using F344 splenocytes (Fs) or 
ihntrahepatic lymphocytes (Fl) derived cDNA as template are shown. The obtained clones are compared 
to a previously described type I iTCRα chain (AV14S6F (previously named AV14S1, Pyz E. et al., 2006)) 
and to a type II AV14 gene segment AV14S2F (previous AV14S3, Matsuura, H. et al. 2000)). Dots 
indicate same amino acid residue as the first sequence. CDR regions are highlighted with bold letters.  
 
3.6.1 Analysis of AV14 TCRα chains in F344 rats 
At first, in order to analyze AV14 and AJ gene segment usage in F344 rats as in the 
previous study of Matsuura et al. (Matsuura et al., 2000), AV14-containing TCRs from 
F344 IHLs or splenocytes derived cDNA were cloned (Methods section 2.2.2.10). Three 
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clones selected randomly from each tissue were sequenced. Their predicted amino acid 
sequences are shown in Fig. 24.  
All the clones isolated from IHLs contained the AJ18 gene segment. In two of them, the 
amino acid encoded in the junction region was an alanine whereas in the other one was 
a glycine. In contrast, none of the splenocytes derived AV14 TCRs comprises the AJ18 
segment. Instead, based on sequence similarity with mouse AJ gene segments, the Fs18 
and Fs19 clones encode the AJ47 and AJ21 rat homologues, respectively. The Fs14 also 
used a different AJ segment (the rat homologue of the mouse AJ38) but a stop codon 
appears in the cDNA resulting in a non-functional TCRα chain. In the BN genome, 
identical sequences were found for all these rat AJ genes.  
All clones generated from IHLs cDNA used the type II AV14 gene segment AV14S2. 
On the contrary, TCRα chains isolated from the spleen contained different AV14 gene 
segments: One was again AV14S2, but the other two were AV14S8 (type II), previously 
identified by E. Pyz (Pyz et al., 2006), and AV14S5 (type I) which had not yet been 
described for F344 (Fig. 22).  
 
3.6.2 AV14 and AJ18 gene segment usage in F344 and LEW rats 
In order to study the usage of AV14 and AJ gene segments in the thymus, the spleen 
and the liver of F344 and LEW rats, the products obtained in the RT-PCR experiments: 
AV14-AJ18 and AV14-AC (Fig. 20) were directly sequenced. This approach does not 
provide information about single TCRα chains but it gives a relative quantification of 
which are the gene segments used in each compartment of each strain. On the one hand, 
sequences of the AV14-AJ18 products show which AV14 gene segments are 
exclusively rearranged with AJ18. On the other hand, sequences from AV14-AC 
products indicate the AV14 gene segments used, in principle, by any AV14-positive 
TCR and in addition also reveal which AJ gene segments are contained in these AV14 
positive TCRs. 
Sequencing of the AV14-AC products from F344 and LEW thymocytes, splenocytes 
and IHLs in the AV14 forward direction, showed an AJ18 dominance only among F344 
IHLs (Fig. 25). In the product obtained from F344 splenocytes, AJ18 is not the only AJ 
gene segment comprised among AV14 TCRs but still AJ18 nucleotides stand out in 
such a way that parts of this gene segment can be read. In contrast, in AV14-AC 
products from F344 thymocytes or from any of the analyzed compartments of LEW 
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inbred rats, AJ18 is neither preferentially used by the AV14 TCRs nor a unique reading 
frame was identified (Fig. 25).  
Sequencing was also carried out in the 3´ to 5´ direction using AC binding primers. 
These sequences confirmed the results of the forward sequences: only where the AJ18 
gene segment stood out in one unique reading frame a complete reverse sequence was 
achieved i.e. F344 IHLs, which reached the AV14 gene segment. On the contrary, in the 
organs where no AJ18 was legible, the readable sequence ended as soon as the AJ 
segment started and a mixture of many sequences appeared (F344 thymus) or a 
sequence with no homology to any AJ gene segment was found (LEW thymus and 
spleen, analyzed by blasting the sequences to the rat genome and GeneBank at the 
NCBI). The intermediate situation is perfectly illustrated by F344 spleen sequences: the 
AJ18 gene segment can still be detected and parts of the AV14 as well, but other AJ 
segments interfere with AJ18 (Fig. 25).    
In line with the conserved CDR3 region of mouse and human iTCRα chains, whose 
joining region contains three nucleotides encoding a single amino acid, (Koseki et al., 
1991; Lantz and Bendelac, 1994), the joining region of the AV14 TCRs (AV14-AC 
products) of F344 IHLs, most of which contained the AJ18 segment, also contains a 
three-nucleotide stretch encoding alanine (GCx, where x is any nucleotide) and glycine 
(GGx) are detected (Fig. 25) – being even more evident in the reverse sequence – 
whereas all AV14 gene segments of the BN genome bear GCC at these positions. 
Alanine and glycine are also the joining amino acids described for cloned iTCRα chains 
by Matsuura et al. (Matsuura et al., 2000).  
Among TCRs formed by AV14 and AJ18 gene segments in F344 splenocytes and IHLs, 
the same three-nucleotide joining region containing various nucleotides encoding 
alanine or glycine was consistently found (Fig. 26). In contrast, among F344 
thymocytes the AV14-AJ18 transition contained junctional regions of various sizes 
resulting in different reading frames and illustrated by the appearance of various 
nucleotides at the same positions of the AJ18 gene segment (Fig. 26) although the 
intensity of the AV14-AJ18 RT-PCR products was approximately the same as in 
splenocytes (Fig. 20). In LEW rats the analysis of such AV14-AJ18 products was not 
always possible due to the very low amount of amplified material which, as described 
above, may reflect the small numbers or absence of iNKT cells in this strain (Fig. 19 
and 20). Indeed, from three analyzed animals no IHL-derived sequence could be 
obtained; in the spleen, two sequences were achieved, but AJ18 was legible only in one 
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of them, indicating that not all AV14AJ18-rearranged TCRs contained the same reading 
frame; and at last, in thymocytes in one single case a sequence was obtained whose VJ 
transitions differed in size.  
Fig. 27 a illustrates how we evaluated the usage of AV14 gene segments. A type I to II 
ranking was established depending on which dideoxynucleotides and with which 
intensity appeared in the CDR2 region. In such a way, I >>> II was assigned when only 
nucleotides were observed which correspond to type I CDR2s and I ~ II when 
nucleotides of both types were detected with the same intensity. In order to exclude 
sequencing artifacts reverse sequencing was generally carried out. The table in Fig. 27 b 
summarizes all the data obtained. Three different rats were analyzed (except for F344 
thymus) but sequencing often failed in the cases where the obtained RT-PCR product 
was difficult to detect (Fig. 20 and 27 b). First of all, there were no differences on the 
types of AV14 gene segments used by invariant TCRs (AV14-AJ18) and AV14 positive 
TCRs with various AJ segments. Second, in the periphery of F344 rats (spleen and 
IHLs) both types of AV14 gene segments seem to be equally used. Third, in the thymus 
however, a preference towards type II can be appreciated and fourth, LEW TCRs in 
contrast show a general bias to type I AV14 gene segments in all the tissues.  
 
 
 
 105 
Figure 25. AJ gene segment usage by AV14-comprising TCRα chains. AJ gene segment usage by 
AV14-containing TCRα chains was analyzed in F344 and LEW thymocytes (thy), splenocytes (spl) or 
IHLs derived mRNA by RT-PCR and subsequent sequencing of the obtained AV14-AC products (as in 
Fig. 20). RT-PCR products were sequenced in both, forward and reverse directions. When possible, a 
representative example is shown. Below each example, it is specified how many rats were analyzed, how 
many sequencings were carried out and how many legible sequences were obtained. R: junctional region. 
n.d.: non determined. 
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Figure 26. Analysis of nucleotides contained in the junctional regions of AV14-AJ18 TCRα chains. 
TCRα chains containing AV14 and AJ18 gene segments were analyzed in F344 and LEW thymocytes 
(thy), splenocytes (spl) or IHLs derived mRNA by RT-PCR and subsequent sequencing of the obtained 
products (as in Fig. 20). RT-PCR products were sequenced in both forward and reverse directions. When 
possible, a representative example is shown. Below the representative example, how many rats were 
analyzed, as well as how many sequences were carried out and how many legible sequences were 
obtained is specified. R: junctional region. n.d.: non determined. 
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Figure 27. AV14 gene segments usage by AV14 and AV14-AJ18-containing TCRα chains. a 
Illustration of the relative quantification of the AV14 usage. AV14-JA18 as well as AV14-AC RT-PCR 
products (Fig. 20) were sequenced to analyze the usage of the different AV14 segments by invariant and 
AV14-containing TCRα chains. Three representative examples are shown where the usage of either type I 
and type II or both (type I ~ II) AV14 genes predominated. RT-PCR products were generally sequenced 
in both, forward (Fow) and reverse (Rev), directions demonstrating that when in one particular position 
more than one nucleotide was detected the reason behind was not a sequencing artifact. b AV14 gene 
segment usage by invariant and AV14-containing TCRα chains of F344 and LEW thymocytes (Thy), 
splenocytes (Spl) and intrahepatic lymphocytes (IHLs) obtained in three independent experiments (e 1 to 
3). Abundance of one or the other AV14 gene types in each particular case, when a successful sequence 
was obtained, was summarized with > symbols. The examples shown in a for type I and type II would 
correspond to I>>>II and II>>>I, respectively, whereas I~II was used when the signals observed were 
nearly equal for both AV14 types. “Failed” appears when sequencing of RT-PCR products failed.  
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3.7 α-Gal responsiveness in the rat 
KRN7000 is a synthetic analogue of α-Galactosylceramide (α-Gal), a compound 
isolated from the marine sponge Agelas mauritiauns. Due to its origin, KRN7000 is 
usually referred simply as α-Gal and, as mentioned in the introduction, is the first 
glycolipid antigen described to be presented by CD1d and to be recognized by the semi-
invariant TCR of iNKT cells (Kawano et al., 1997). α-Gal is still one of the most potent 
iNKT cell agonists described up to date (Venkataswamy and Porcelli, 2010). Therefore, 
it was used in this study to analyze iNKT cell presence among different rat strains.  
 
3.7.1 Cytokine release in ex vivo cultures: Comparison of 5 different inbred rat 
strains  
As mentioned before, a particular characteristic of iNKT cells is the very fast secretion 
of various cytokines. We used this property as test system for the occurrence of 
functional iNKT cells in 5 different inbred rat strains including F344 and LEW. Primary 
cultures of IHLs and splenocytes in presence or absence of α-Gal were carried out and 
IL-4 and IFN-γ released into the supernatants were measured after 24 hours by ELISA. 
In order to demonstrate that the cytokine release was due to the presentation of α-Gal by 
CD1d, cultures with mAb 233 were included in the assay. In addition to cultures with 
medium only, β-Gal was also used as negative control. Furthermore, to asses the general 
capacity of the cultured cells to secrete IL-4 or IFN-γ, ConA was also added to the 
cultures (Fig. 28). 
Splenocytes and IHLs derived from F344 rats secreted IL-4 and IFN-γ in an α-Gal dose-
and CD1d-dependent manner. Considering the different cell densities of splenocyte-  
and IHL-cultures, 107 and 2.5*106 cells/ml, respectively, cytokine release by IHLs was 
much higher than by splenocytes, as expected from the different frequencies of iNKT 
cells detected in these organs (Results section 3.5.1). Remarkably, the IL-4 amounts 
secreted by splenocytes after α-Gal stimulation were approximately the same as after 
ConA stimulation.  
In cultures of BN- and DA-derived cells, IL-4 secretion also appeared in an α-Gal dose-
dependent manner and was inhibited by the anti-CD1d mAb 233, although ConA 
induced IL-4 production by DA cells was also partially inhibited when the mAb was 
added to the culture. LEW and PVG splenocytes completely lacked an α-Gal-induced 
IL-4 production despite the presence of cells with IL-4 secreting potential demonstrated 
by ConA stimulation. IL-4 production by PVG IHLs seemed to be largely α-Gal-
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independent and partially inhibited by 233. Apparently, this mAb also inhibited IL-4 
release by PVG IHLs after ConA stimulation.  
An α-Gal-induced and CD1d-specific IFN-γ production can be clearly stated for IHL 
and splenocytes of F344 rats while the results for BN rats were less clear. The other 
inbred rat strains showed only a varying spontaneous IFN-γ production, which may 
have obscured an α-Gal-specific response. For all these strains spontaneous IFN-γ 
secretion by IHLs was at least as high as the maximum of the α-Gal-induced production 
by F344 IHL. The spontaneous IFN-γ release by PVG IHLs was even higher than after 
ConA stimulation of all the other inbred strains, except DA where it was at least as 
high.  
Despite the strict attachment to experimental protocols, results varied considerably as 
indicated by the high standard deviations obtained in five independent experiments, in 
the case of cells without addition of the 233 mAb (Figure 28).  
Cytokine release by thymocytes was also addressed at least for one rat of each strain 
with the same conditions as indicated above. An α-Gal response was never observed 
even at high cell density cultures (2*107 cells/ml), where after ConA stimulation at least 
some IL-4 production (1-10 pg/ml) was detected.   
Even in F344, which is the inbred rat strain in which the highest α-Gal responsiveness 
was observed, iNKT cell frequencies are very low (Results section 3.5.1). Thus single-
cell based techniques, which facilitate the detection of low frequencies of cytokine 
producing cells, were also used and IL-4 secretion after α-Gal simulation of splenocytes 
and IHLs (106 and 2.5*105 cells per well, respectively) was analyzed by ELISPOT (Fig. 
29). In addition to the detection of the number of IL-4 producing cells, ELISPOT results 
also allow the analysis of the relative levels of IL-4 secretion by determining the size of 
the spots. The intensity and size of the spots vary depending on the settings used to read 
the plate and on the duration of the incubation with the substrate reagent in the 
experimental procedure. Hence, the wells and the quantification of the spots according 
to their size are shown only for one representative experiment of each strain. The 
general variability between experiments is illustrated by the high SD of the total spot 
numbers obtained in two or more independent experiments. Moreover, the non 
standardized sensitivity of the method, surely contributes to this variability.  
With the IL-4 ELISPOT, basically, the same α-Gal responsiveness pattern was observed 
as in the ELISA experiments with the exception of DA rats. A comparable size of the 
spots after ConA and α-Gal-induced activation was only found in F344. In this strain 
 110 
the number of large spots (above -1.6 and -1.8 Log mm2 for spleen and IHLs, 
respectively) was even higher after α-Gal than after ConA stimulation. Importantly, the 
233 mAb inhibited the formation of these large spots in α-Gal but not ConA cultures. In 
the experiment shown 270 and 117 big-sized spots (above -2.2 Log mm2) were found 
among α-Gal-stimulated IHLs and splenocytes, respectively. Emphasizing the 
importance of the size of the spots, the total number of the spots was higher in 
splenocytes but not in IHLs cultures after α-Gal stimulation compared to β-Gal or 
medium only. Thus the graphics showing only the number of the spots but not the size 
are not sufficient to interpret the results in these assays (Fig. 29).  
A response such as that of F344 rats was not observed among any of the other inbred rat 
strains. Only cell cultures from BN rats showed an increase above the background 
(obtained with β-Gal or only media) in the number of relatively-big spots after α-Gal 
stimulation which disappeared when the 233 mAb was added. In contrast, in LEW and 
PVG cultures, the spots obtained after α-Gal stimulation were not more abundant or 
bigger than the spots observed in cultures where β-Gal or no antigen was added. 
Nonetheless ConA-stimulated splenocytes cultures contained a considerable amount of 
IL-4 secreting cells. Among IHLs, a high number of cells producing IL-4 was observed 
in a non-specific manner.   
In DA-derived ELISPOT assays, in contrast to the results obtained by ELISA, the 
number of IL-4-secreting cells and sizes of the spots after α-Gal stimulation were not 
higher than in β-Gal or only media cultures. Moreover, IL-4 secretion of IHLs was in 
one case even reduced when the cells were incubated with α-Gal compared to β-Gal or 
only media (Fig. 29), while in another experiment the response of all three culture 
conditions was similar (not shown). In BN cultures the number of cells producing small 
amounts of IL-4 appearing in ConA stimulations was reduced when the 233 mAb was 
added. This mAb also inhibited the ConA response of DA splenocytes.  
Thymocytes (1.5*106 cells / well) derived from F344 and LEW rats were also analyzed 
in ELISPOT assays. IL-4 secreting cells were completely absent in α-Gal stimulations. 
Nonetheless a very low but constant number of spots were observed in both strains after 
ConA stimulation: 4 and 13 in F344 and 12 and 8 in LEW thymocytes. The secretion of 
IL-4 by these cells was not inhibited by the 233 mAb (data not shown). 
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Figure 28. IL-4 and IFN-γ release by splenocytes and IHLs. 2*106 splenocytes or 5*105 IHLs from five different inbred rat strains were cultured in 96 well plates with α-
Gal, β-Gal or ConA at the indicated final concentrations for 24 hours (gray bars). Moreover, also the 233 mAb was added to each culture condition (white bars). IL-4 and 
IFN-γ release into the supernatant was analyzed by ELISA. The mean values obtained in three independent experiments + SD, except for PVG rats where only two 
experiments were performed, are shown. Duplicates were carried out when sufficient cells were isolated. The 233 mAb was included in two of three experiments. 
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Figure 29. IL-4 ELISPOT analyses of primary splenocytes and IHLs cultures of five different inbred rat strains. 106 splenocytes or 2.5*105 IHLs from five different rat 
strains were cultured for 24 hours with α-Gal (10 ng/ml), β-Gal (10 ng/ml), ConA (3 µg/ml) or only media in the presence or absence of the 233 mAb. The wells of one single 
experiment for each tissue and each rat strain are shown. The first row of graphs shows the number of counted spots according to their size (X axis Log mm2) in one single 
experiment. In addition, the mean values + SD of the total spots detected in at least two independent experiments are shown in the second graph-row (bar graphs). The number 
of conducted experiments is two for BN, DA and PVG; three for F344; three for LEW IHLs and five for LEW splenocytes.  
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3.7.2 Analysis of F344 x LEW F1 generation 
Analysis of supernatants harvested from cultures of primary splenocytes and IHLs 
derived from F1 generations between F344 and LEW rats (2 male rats from 
F344xLEW, and 1 male rat from LEWxF344) revealed an α-Gal dose-dependent release 
of IL-4 which was CD1d-restricted (Fig. 30). A codominant, no sex-linked inheritance 
of the alleles controlling iNKT cell frequencies and cytokine release after α-Gal 
stimulations is expected because cytokine amounts were approximately half of those 
observed in F344 cultures and because there was no difference between the two F1 
generations, regardless of the strain origin of the Y chromosome.  
Figure 30. IL-4 release by splenocytes 
and IHLs ex vivo cultures of F344 and 
LEW F1 generation. 2*106 splenocytes or 
5*105 IHLs were cultured in 96 well plates 
with α-Gal, β-Gal or ConA at the indicated 
final concentrations for 24 hours and IL-4 
release into the supernatant was analyzed 
by ELISA (gray bars). Moreover, the 233 
mAb was also added into each culture 
condition (white bars). The mean values 
obtained in three independent experiments 
+ SD are shown. Duplicates were carried 
out when sufficient cells were isolated.  
 
3.7.3 Analysis of C57BL/6 
In order to compare rat α-Gal responsiveness to mouse, similar cultures with C57BL/6 
splenocytes and IHLs (107 and 5*105 cells/ml, respectively) were carried out. Figure 31 
shows that C57BL/6 derived primary cells produce much more cytokine amounts after 
α-Gal stimulation than rat primary cells. Having in consideration that five times less 
C57BL/6 IHLs than rat IHLs were used, α-Gal-dependent cytokine release by mouse 
IHLs is about 50 fold higher than that of F344 IHLs. C57BL/6 splenocytes produce also 
much more IFN-γ than F344 splenocytes.  
 
 
Figure 31. Cytokine production in ex vivo 
cultures of splenocytes and IHLs from 
C57BL/6 mice. 2*106 splenocytes or 105 IHLs 
were cultured in 96 well plates with α-Gal, β-Gal 
or ConA at the indicated final concentrations for 
24 hours. IL-4 and IFN-γ release into the 
supernatant was analyzed by ELISA (gray bars). 
Moreover, the 233 was also added into each 
culture condition (white bars). The values 
obtained in one single experiment are shown. 
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3.7.4 iNKT cell expansion in F344 but not in LEW and C57BL/6 IHL-cultures 
IHLs derived from F344 and LEW rats or from C57BL/6 mice were cultured with 
different stimuli (ConA, α-Gal, β-Gal or no stimulus) for 7 days. After this time, apart 
from ConA cultures, a clear population of large, granular cells appeared exclusively in 
F344-derived IHLs incubated with α-Gal (Fig. 32). These cells express NKR-P1 and 
low TCR levels in contrast to the small-sized T cells that are also present in these 
cultures and in the cultures with β-Gal or without stimulus. Cultures with 3 µg / ml 
ConA were used as positive control for activated T cells.   
NKR-P1+ and TCR-low cells are stained with α-Gal-loaded rat CD1d-IgG dimers, as 
shown in figure 33, but not by α-Gal-loaded mouse CD1d-IgG dimers. As illustrated in 
the histogram of Fig. 33, most of the cells are stained by α-Gal-loaded rat CD1d-IgG 
dimers, although the staining intensity of many cells is not very high. Therefore, in 
contrast to primary cells (Results section 3.4.4), TCR and NKR-P1 are suitable markers 
for the identification of rat iNKT cells in rat IHLs cultures.  
About 50 percent of F344-cultured iNKT cells express the BV8S4a gene segment, 
whereas none of them expresses BV16 (Fig. 34). Moreover, most of them are CD4 and 
CD8β negative in contrast to the T cells present among the gate of small-sized cells, 
whose CD4 and CD8β distribution is the same as in primary T cells (Fig. 34 and 37).  
The presence of iNKT cells after seven days of culture with α-Gal is due to an 
expansion because the initial number of iNKT cells added to the cultures was about 
3000 cells per well (0.03 % of the total IHLs) and the number of living cells recovered 
at the end of the culture was 30000 to 300000 and about half of them were iNKT cells.  
Although it is not shown, the AV14 gene segment usage of F344 expanded iNKT cells 
was also addressed in the same way as described in the results section 3.6.2. 
Interestingly, both types of AV14 gene segments were found after 7 days of culture with 
α-Gal.                           
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Figure 32. Primary F344, LEW and C57BL/6 IHLs cultures. IHLs derived from C57BL/6 mice, F344 
or LEW rats were cultured for 7 days in the presence of α-Gal (20 ng/ml), β-Gal (20 ng/ml), ConA (3 
µg/ml) or only media and were analyzed by flow cytometry. Numbers indicate percentages of gated cells. 
FCS/SSC plots, show characteristics of the cultured cells and depict the gated cells for which TCR and 
NKR-P1 expression was analyzed. Gray arrows indicate gated cells shown in the subsequent TCR/NKR-
P1 plots. Cells were stained with anti αβ TCR (R73) visualized with DαM-FITC and with anti NKR-P1 
(10/78-PE). Isotype control stainings were included.  
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Figure 33. After culture in the presence of α-Gal iNKT cells are expanded when primary IHLs are 
derived from F344 but not from LEW rats. After 7 days of culture with 20 ng/ml α-Gal, intrahepatic 
lymphocytes from F344 and LEW rats were analyzed by flow cytometry. Cells were stained with anti-
TCRβ mAb (R73-FITC) and α-Gal- or β-Gal-loaded rat CD1d-IgG dimers, which were visualized with 
DαM-PE. F344 cells were also stained with mouse CD1d-IgG dimers. In F344, but not in LEW cultures 
two different populations based on their FSC/SSC properties were clearly distinguished (FSC/SSC plots). 
Dimer and TCR stainings are shown separately in the density plots for each population, as it is pointed 
out by the arrows coming out of the FSC/SCC plots. The histogram on the upper right shows all the dimer 
stainings of the big-sized cells observed in the F344 cultures.  
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Figure 34. BV usage and CD4/CD8β distribution among cultured iNKT cells. Cultured F344 iNKT 
cells were analyzed by flow cytometry. Numbers indicate percentages of gated cells depicted in the dot 
plots. Gray arrows indicate gated cells shown in the subsequent dimer/BV8 (b) or CD4/CD8β (c) plots. a 
The FCS/SSC plot depicts the gating strategy followed to analyze BV usage by the two different cell 
populations - labeled as small and big cells - which appeared in 7 day α-Gal F344 IHLs cultures. b 
Analysis of BV8S4a usage. Cultured cells were stained with α-Gal-loaded rat CD1d-IgG dimers (detected 
with DαM-PE) followed by anti-TCRβ (R73-FITC) and biotinylated anti-BV8S4a (R78, visualized with 
SA-APCy) mAbs. c Analysis of BV usage. Cells were stained with unconjugated antibodies against 
TCRβ (R73), BV8S4a (R78) or BV16 (HIS42) which were visualized with DαM-FITC and with anti-
NKR-P1 (10/78-PE), anti-CD4 (OX-35-Cy5PE) and anti-CD8β (341-bio + SA-APC) mAbs. Isotype 
control stainings were included.  
 
 
3.8 Analysis of NKR-P1 and TCR expression in different rat strains  
In the results section 3.4.4 it is shown as in contrast to some mouse strains (e. g. 
C57BL/6), where most of NK1.1+ T cells are iNKT cells (Hammond et al., 2001; 
Matsuda et al., 2000), in the rat only a minor part of all NKR-P1+ TCR+ cells are iNKT 
cells, what is similar to the situation found in humans. Indeed in F344, the strain with 
the strongest α-Gal-induced cytokine secretion and therefore the strain where the 
highest number of iNKT cells is expected, only 3% NKR-P1+ TCR+ splenocytes and 5 
to 10% of NKR-P1+ TCR+ IHLs are iNKT cells (Fig. 35). From all the strains in which 
the response to α-Gal was investigated (Results section 3.7.1), iNKT cell frequencies 
were only addressed in F344 and LEW. This results section summarizes our analysis of 
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NKR-P1 expression as well as the frequencies of certain BV gene segments used by 
different T cell subsets. This analysis also served to gain more information about the 
cells added to the cultures described in the results section 3.7.   
 
Figure 35. iNKT cells are a very small population compared to NKR-P1+ T cells. iNKT cells and 
NKR-P1 expressing T cells were analyzed by FACS among splenic and intrahepatic lymphocytes from 
F344 and LEW rats. iNKT cells were identified as α-Gal-loaded rat CD1d-IgG dimer+ TCR+ cells (control 
stainings are shown in Fig. 17). Dimer staining was revealed with DαM-PE. TCR was stained with the 
FITC conjugated mAb R73 and NKR-P1 was visualized with 10/78-PE labeled mAb.  
 
3.8.1 Analysis of NKR-P1 expression among T and non-T cells  
In line with the low numbers of iNKT cells among NKR-P1+ TCR+ cells in the rat, no 
correlation was found between the frequencies of T cells expressing NKR-P1 and the 
observed α-Gal response pattern (Fig. 36 and Fig. 28). These frequencies are very 
similar among all the strains, with the only exception of DA splenocytes. In general, the 
frequencies of NKR-P1 positive T cells in the liver are higher than in the spleen.     
In contrast, the percentages of NKR-P1 expressing cells which are not T cells differ 
between these five inbred strains in the thymus and in the liver. Apart from NK cells, 
monocytes and some dendritic cells also express NKR-P1 at intermediate levels (Josien 
et al., 1997; Scriba et al., 1997). Among thymocytes, a small population expressing high 
levels of NKR-P1 was clearly detected in F344, DA and PVG rats. This population was 
much more reduced in BN and LEW (Fig. 36 and table 6). Within the isolated IHLs, 
F344, BN, DA and LEW have similar frequencies of cells expressing intermediate 
NKR-P1 levels but in PVG these cells are absent. Noteworthy, the numbers of cells 
expressing NKR-P1 at high levels vary between all the strains from almost 50% of all 
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IHLs in DA to 14% in BN rats. These differences reflect variations on the frequencies 
of the other cell types (Fig. 36 and table 6). Moreover, NKR-P1 expression by the cells 
with the highest levels also differs between the strains in the liver and in the spleen, 
being more reduced in BN and PVG compared to F344, LEW and DA (Fig. 36 and 
means of geometric MFI ±SD in four to five independent experiments in spleen: BN: 
871 ±203; PVG: 935 ±404; F344: 2087 ±230; DA: 1602 ±208 and LEW: 1926 ±203 
and in IHLs: BN: 807 ±162; PVG: 542 ±208; F344: 1560 ±85; DA: 1208 ±415 and 
LEW: 1252 ±202).  
 
Figure 36. NKR-P1 and TCR expression by thymocytes, splenocytes and intrahepatic lymphocytes 
in five different inbred rat strains. a NKR-P1 (10/78-PE mAb) and TCR (unconjugated R73 mAb 
followed by DαM-FITC) expression was analyzed by FACS. Isotype controls were included, although 
they are only shown for F344 stainings. Different gates were set according to the various NKR-P1/TCR 
levels observed. Numbers indicate the percentages of the gated cells. b Percentages of αβ T cells 
expressing NKR-P1 were obtained as illustrated in a by dividing the percentage of NKR-P1+ TCR+ cells 
among the total percentage of TCR+ cells. c Percentages of NKR-P1+ TCR+ thymocytes. In the bar graphs 
the means + SD of four to five independent experiments are shown. Unspecific stainings, determined as 
in a for F344 with isotype control antibodies, were subtracted.  
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   F344  BN  DA  LEW  PVG 
Thymus  0.2516 ± 0.0994  
0.0404 ± 
0.0500  
0,1220 ± 
0,0277   
0.0037 ± 
0.0054  
0.0667 ± 
0.0191 
high 
 
4.86 ± 0.60  1.92 ± 0.09  3.68 ± 0.46  3.41 ± 0.53  3.86 ±0.77 
int 
 
1.17 ± 0.24  1.56 ± 0.16  0.82 ± 0.19  1.00 ± 0.10  0.90 ± 0.07 Spleen  
low 
 
1.29 ± 0.33  1.28 ± 0.26  1.12 ± 0.51  2.21 ± 0.42  0.46 ± 0.1 
high 
 
25.40 ± 2.19  14.72 ± 2.58  46.54 ±8.12  27.26 ± 4.93  40.11 ± 5.01 
int 
 
6.00 ± 2.58  3.84 ± 1.89  3.03 ± 1.05  6.56 ± 3.16  IHLs 
low 
 
4.56 ± 1.26  5.25 ± 1.78  3.47 ± 1.39  5.77 ± 2.35  
1.03 ± 0.43 
 
Table 6. TCR- cells expressing various levels of NKR-P1 in the thymus, spleen and IHLs of five 
different inbred rat strains. The means of the percentages obtained as illustrated in figure 36 a in four 
or five independent experiments ±SD are shown. Among splenic and intrahepatic lymphocytes of all the 
strains, except in PVG, three TCR- populations with high, intermediate (int) and low NKR-P1 levels were 
observed. In PVG the intermediate and low NKR-P1+ populations could not be distinguished (Fig. 36 a); 
therefore, one gate containing intermediate and low NKR-P1 expressing cells was established. 
 
3.8.2 CD4 and CD8 distribution among NKR-P1+ TCR+ cells 
Rat iNKT cells are mostly CD4 or DN (Fig. 19). As previously described (Knudsen et 
al., 1997; Li et al., 2003; Matsuura et al., 2000; Pyz et al., 2006; Ru and Peijie, 2009), 
most NKR-P1+ TCR+ rat cells express CD8β in the spleen and in the liver of all the 
strains (Fig. 37 and Table 7). In F344, changes on the relative frequencies of CD4 and 
DN positive cells among NKR-P1+ TCR+ cells due to the presence of iNKT cells can 
only be expected within IHLs, where iNKT cells are about a 10% of all NKR-P1+ TCR+ 
cells, but not in splenocytes, where the frequency of iNKT cells is only 2% 
approximately of all NKR-P1+ TCR+ cells (Fig. 35). Indeed, more DN and less CD8β+ 
appear in F344 IHLs compared to splenocytes (Table 7). A significant increase of the 
DN NKR-P1+ TCR+ cells in IHLs compared to splenocytes was also found in BN and 
DA, the two other α-Gal responding inbred strains. Nevertheless, it remains to be shown 
whether this increase is due to augmented iNKT cell numbers. In fact in PVG rats, 
which did not show a clear response to α-Gal, the frequency of DN NKR-P1+ T cells in 
IHLs was also higher compared to splenocytes (although the differences are not 
statistically significant) (Table 7). CD4+ frequencies among NKR-P1+ TCR+ cells are 
not augmented in IHLs of any strain compared to splenocytes. Remarkably, the 
CD4/CD8 distribution in NKR-P1 negative T cells differs little (i. e. LEW CD8+ T cells 
and PVG CD4+ T cells) if at all between splenocytes and IHL from the same strain 
whereas the inter-strain differences can be high (Table 7).  
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Figure 37. CD4 and CD8β expression by NKR-P1 positive and negative F344 T cells. Lymphocytes 
from the spleen and the liver were analyzed by flow cytometry. CD4 (OX-35-Cy5PE) and CD8β (341-bio 
+ SA-APCy) expression by NKR-P1 (10/78-PE) positive or negative T cells (R73 and DαM-FITC) was 
analyzed by flow cytometry. Numbers inside the dot plots indicate the percentages of gated cells. Gray 
arrows indicate which T cell subpopulations are shown in the CD4/CD8β plots.  
 
 
  F344 BN DA LEW PVG 
  Spl IHLs Spl IHLs Spl IHLs Spl IHLs Spl IHLs 
CD8β 71.9 
±3.9 
54.5 
±4.9** 
60.2 
±3.8 
51.3 
±6.4 
69.5 
±5.8 
65.8 
±5.5 
71.2 
±7.4 
68.1 
±10.7 
77.5 
±2.1 
63.3 
±1.3* 
CD4 11.1 
±2.5 
13.5 
±3.6 
12.1 
±3.4 
15.0 
±3.2 
17.5 
±6.7 
12.6 
±3.7 
11.5 
±5.4 
12.3 
±5.6 
8.4    
±3.0 
16.4 
±2.8 
NKR-P1+ 
TCR+ 
DN 14.8 
±2.1 
30.7 
±6.9* 
26.4 
±1.2 
33.0 
±5.0* 
10.7 
±2.8 
20.3 
±3.0** 
15.1 
±5.6 
 17.7 
±5.6 
12.0 
±2.3 
18.7 
±2.5 
CD8β 34.2 
±2.3 
31.7 
±1.7 
6.4  
±0.8 
6.0  
±1.5 
19.9 
±1.3 
20.9 
±3.7 
24.1 
±0.5 
22.0 
±1.2* 
13.7 
±1.3 
10.2 
±2.5 
CD4 63.5 
±2.0 
65.8 
±2.0 
91.1 
±0.6 
91.8 
±1.6 
78.4 
±1.2 
77.1 
±4.1 
73.7 
±0.9 
75.3 
±1.2 
84.5 
±1.6 
88.2 
±2.5* 
NKR-P1- 
TCR+ 
DN 1.3  
±0.3 
1.8 
 ±0.5 
1.8  
±0.5 
1.7  
±0.5 
1.3  
±0.8 
1.7  
±0.6 
1.7  
±0.7 
2.0 
±1.0 
1.3 
 ±0.7 
1.0 
 ±0.5 
 
Table 7. CD4 and CD8β distribution among NKR-P1 positive and negative T cells. Percentages of 
CD4, CD8β or DN cells among NKR-P1+ TCR+ or NKR-P1- TCR+ cells were obtained after analysis of 
splenic (Spl) and intrahepatic (IHLs) lymphocytes as shown in figure 37 by flow cytometry. Numbers 
indicate the mean of three to five independent experiments ±SD. Two-tailed paired t-test was conducted 
to determine significant differences in the distribution of the subpopulations in the spleen compared to the 
liver of each rat strain. P values *< 0.05 and ** < 0.005.  
 
3.8.3 BV chain usage among NKR-P1+ TCR+ cells 
Similar to mouse, rat iNKT cells show a bias in their BV gene segment usage, with 50% 
of iNKT cells being BV8S4 positive (Fig. 18). With this in mind, expression of BV8S2l 
and BV8S4a (detected by the mAb R78 (Asmuss et al., 1996) and of BV16 (detected by 
the mAb HIS42 (Kampinga et al., 1989)) gene segments was analyzed among NKR-P1 
positive and negative T cells in the liver and the spleen of the five studied rat inbred 
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strains (Fig. 38 and table 8). Only in F344 IHLs the frequency of BV8S4a + cells is 
increased in NKR-P1A+ T cells compared to NKR-P1A- T cells, being also the highest 
frequency found among all the tissues and strains.   
 
 
Figure 38. BV usage by NKR-P1 positive and negative F344 T cells. Lymphocytes from the spleen 
(Spl) and liver (IHLs) were analyzed by flow cytometry. All αβ T cells were detected with the mAb R73, 
BV8S4a+ T cells were stained with the mAb R78 and BV16+ T cells were visualized with the mAb HIS42. 
The antibodies recognizing various TCRs were unconjugated and therefore were detected with DαM-
FITC. NKR-P1 was analyzed with the PE labeled mAb 10/78. Isotype control stainings were included to 
determine unspecific binding of the antibodies. Numbers in the dot plots indicate the percentage of gated 
cells.  
 
  
  F344a  BNl DAa  LEWl PVGl  
  Spl IHLs Spl IHLs Spl IHLs Spl IHLs Spl IHLs 
R78+  among  
NKR-P1+ TCR+ 
6.0  
±1.3 
13.2 
±2.8** 
4.9 
±0.6 
5.6 
±2.2 
4.6 
±1.1** 
7.0 
±1.1 
4.6 
±0.5 
4.9 
±1.8 
4.3 
±0.7 
8.4 
±4.4 
HIS42+ among  
NKR-P1+ TCR+ 
8.0 
±0.6 
6.6 
±3.7 
6.4 
±1.0*** 
7.5 
±2.5 
7.4 
±1.2 
8.2 
±0.9 
7.0 
±1.6* 
7.9 
±1.5 
10.5 
±1.0* 
11.7 
±1.5 
R78+ among  
NKR-P1- TCR+ 
6.3 
±0.6 
6.5 
±0.5 
5.1 
±0.5 
4.8 
±1.4 
6.3 
±0.6 
6.0 
±1.2 
4.6 
±0.5 
5.0 
±0.3 
4.1 
±0.8 
9.1 
±2.0 
HIS42+ among  
NKR-P1-  TCR+ 
9.0 
±0.5 
8.7 
±0.4 
10.0 
±0.7 
9.5 
±1.4 
8.2 
±0.2 
7.8 
±0.7 
9.1 
±0.4 
9.2 
±0.5 
8.9 
±0.1 
9.0 
±0.6 
 
Table 8. R78+ and HIS42+ cells among NKR-P1 positive and negative T cells. The Tcrb haplotype of 
each inbred rat strain is indicated in their name. The mAb R78 stains BV8S4 TCRβ chains of the 
haplotype a and BV8S2 TCRβ chains of the haplotype l (Asmuss et al., 1996). The mAb HIS42 detects 
BV16-containing TCRβ chains. Splenic and intrahepatic lymphocytes from five different rat strains were 
analyzed by flow cytometry as shown in figure 38 for F344 rats. Numbers indicate the mean of the 
percentages obtained from three to five independent experiments ±SD. Specific staining was determined 
after subtraction of the unspecific binding of the antibodies obtained with isotype control stainings as 
illustrated in figure 38. Two-tailed paired t-test was carried out to determine differences between NKR-
P1+ T cells and NKR-P1- T cells for their BV usage in each organ and each inbred rat strain. P values: * < 
0.05, ** < 0.005 and *** <0.0005  
 
The majority of rat iNKT cells are CD4 or DN (Fig. 19), whereas conventional T cells 
express either CD4 or CD8β. Therefore, the frequencies of BV8 or BV16 positive cells 
were also compared between NKR-P1+ and NKR-P1- CD4 or CD8β T cell subsets 
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(Table 9). Often, the frequency of BV8 positive cells among NKR-P1+ CD4 T cells was 
higher than among NKR-P1- CD4 T cells. However, this increase is not restricted to 
subsets, tissues or strains were iNKT cells are expected to be found.  
Moreover, also an increase of BV8 positive cells was found among NKR-P1+ CD8β T 
cells compared to NKR-P1- CD8β T cells and the frequencies of T cells using the BV16 
gene segment, which is not expected to be present in iNKT cells, were also higher in 
NKR-P1+ CD4 T cells than in NKR-P1+ CD4 T cells. 
 
  F344a BNl DAa  LEWl PVGl  
  Spl IHLs Spl IHLs Spl IHLs Spl IHLs Spl IHLs 
R78+  among  
NKR-P1+ TCR+ CD8β+ 
4.9 
±0.9* 
6.0  
±1.7* 
3.1  
±0.3 
2.0 
±0.7 
3.3 
±0.7 
3.4 
±0.8 
3.5 
±0.6 
2.6 
±0.9* 
3.6 
±0.3 
3.2 
±0.2* 
R78+  among  
 NKR-P1- TCR+ CD8β+ 
3.8 
±0.2 
4.4 
±0.6 
4.3 
±2.0 
5.2 
±4.7 
3.4 
±0.6 
2.6 
±0.5 
3.9 
±0.3 
4.1 
±0.1 
3.2 
±0.7 
7.0 
±0.7 
R78+  among  
NKR-P1+ TCR+ CD4+ 
14.1 
±4.7* 
27.6 
±12.2* 
13.7 
±2.7** 
19.1 
±13.2 
8.4 
±3.2 
23.7 
±5.6** 
11.4 
±3.0* 
19.5 
±11.2 
11.2 
±1.2** 
15.2 
±7.2 
R78+  among  
NKR-P1- TCR+ CD4+ 
7.4 
±0.8 
7.5 
±0.9 
4.9 
±0.4 
4.6 
±1.2 
7.1 
±1.2 
6.9 
±1.6 
4.8 
±0.5 
5.1 
±0.2 
4.1 
±0.7 
8.5 
±2.1 
HIS42+ among   
NKR-P1+ TCR+ CD8β+ 
7.6 
±0.9 
7.0 
±2.7 
4.9 
±1.0* 
4.6 
±1.7* 
6.8 
±1.4 
6.6 
±1.4 
6.3 
±1.5 
6.3 
±1.6 
9.7 
±1.0 
9.0 
±0.8 
HIS42+ among  
NKR-P1- TCR+ CD8β+ 
7.2 
±0.6 
7.4 
±0.4 
6.5 
±0.8 
6.9 
±1.7 
 7.4 
±0.3 
6.6 
±0.8  
7.2 
±0.4 
7.0 
±0.9 
9.5 
±0.7 
10.7 
±0.7 
HIS42+ among   
NKR-P1+ TCR+ CD4+ 
13.4 
±1.2** 
14.0 
±7.7 
13.6 
±6.1 
22.5 
±12.1 
11.6 
±5.4 
17.7 
±5.0* 
13.0 
±7.9 
15.7 
±4.6 
16.1 
±1.9** 
21.1 
±9.2 
HIS42+ among  
NKR-P1- TCR+ CD4+ 
9.8 
±0.5 
9.2 
±0.6 
10.1 
±0.8 
9.7 
±1.3 
8.3 
±0.2 
8.0 
±1.0 
9.7 
±0.5 
9.8 
±0.9 
8.7 
±0.2 
8.9 
±0.7 
            
R78+  among  
NKR-P1+ TCR+ DN 
5.5 
±2.3 
21.5 
±4.4 
4.5 
±1.0 
3.7 
±2.4 
4.8 
±1.1 
8.5 
±5.0 
4.2 
±2.0 
6.3 
±5.4 
3.5 
±1.5 
6.9 
±3.9 
HIS42+ among  
NKR-P1+ TCR+ DN 
6.3 
±1.9 
4.2 
±4.4 
5.0 
±1.0 
5.4 
±1.1 
6.7 
±2.6 
7.4 
±1.8 
6.6 
±2.9 
9.1 
±2.7 
10.3 
±1.8 
10.5 
±3.3 
 
Table 9. Frequencies of R78+ or HIS42+ cells among the indicated T cell subsets in the spleen (Spl) 
or liver (IHLs). The Tcrb haplotype of each rat inbred strain is indicated in their name. The mAb R78 
stain cells bearing BV8S4 β chains of the a haplotype and BV8S2 β chains of the l haplotype (Asmuss et 
al., 1996). Splenic or intrahepatic lymphocytes were analyzed by flow cytometry. Four-colour analysis 
and two independent probes were needed to obtain the frequencies of R78+ or HIS42+ cells among each T 
cell subset. In one probe, CD4 and CD8β distribution among NKR-P1 positive and negative T cells was 
determined as shown in Fig 37. In the other probe, the frequencies of R78+ or HIS42+ NKR-P1 positive 
and negative T cells were calculated as illustrated in figure 38. Numbers shown are the means obtained in 
three to five independent experiments ±SD. Variations in the frequencies of R78 and His42 positive cells 
between NKR-P1 positive and negative T cell subsets (CD4 and CD8β) were analyzed conducting the 
two-tailed paired t-test. P values: *<0.05, **<0.005 and ***<0.0005.  
 
3.8.4 CD4 and CD8 distribution among BV8 or BV16 expressing NKR-P1+ T cells 
CD4 and CD8β expression by the BV8 and BV16 positive T cell subsets was also 
studied (Table 10). In F344 rats, BV8S4 iNKT cells constitute approximately 0.15% of 
all IHLs, while the percentage of BV8S4+ NKR-P1+ T cells among total IHLs is 0.44% 
±0.08 SD. In the spleen, only a 0.025% of all lymphocytes are expected to be BV8S4+ 
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iNKT cells, whereas a 0.22% ±0.05 are BV8S4+ NKR-P1+ T cells. Having this in mind, 
if changes in the CD4/CD8 distribution of BV8S4+ NKR-P1+ T cells are due to the 
presence of iNKT cells, those should be more evident in IHLs than in splenocytes. In 
line with this hypothesis, the percentage of BV8S4+ NKR-P1+ T cells isolated from 
F344 livers which are DN is markedly increased compared to the percentage of DN 
cells among BV16+ NKR-P1+ T cells. In the spleen both CD4 and DN cells are slightly 
augmented (Table 10). Nonetheless, in all the other strains, regardless of whether they 
secreted cytokines in response to α-Gal ex vivo stimulation, also less CD8β positive, and 
therefore more CD4 and/or DN, cells were found among NKR-P1+ T cells bearing BV8 
than among BV16+ NKR-P1+ T cells.  
 
  F344a BNl DAa LEWl PVGl 
  Spl IHLs Spl IHLs Spl IHLs Spl IHLs Spl IHLs 
CD8β 56.5 
±7.9* 
22.4 
±6.8** 
39.2 
±8.6 
23.2 
±8.7* 
52.3 
±13.2 
32.0 
±6.7* 
52.4 
±6.6* 
35.8 
±3.1** 
66.6 
±6.5 
33.2 
±3.6** 
CD4 25.9 
±8.0 
26.3 
±5.6 
33.2 
±7.6 
52.0 
±17.7 
30.6 
±10.5 
41.5 
±11.8 
31.0 
±9.0 
43.1 
±7.5** 
21.3 
±4.5** 
38.1 
±12.4 
R78+  
NKR-P1+ 
DN 14.5 
±3.1 
49.5 
±6.9*** 
24.3 
±3.6* 
23.8 
±9.1 
11.1 
±1.4 
22.7 
±7.5  
12.8  
±4.7 
18.3 
±4.4 
9.1 
±1.9 
21.1 
±11.5 
CD8β 65.3 
±4.3 
55.8 
±12 
47.6 
±8.1 
32.4 
±10.9 
63.6 
±3.3 
52.7 
±8.2 
64.7 
±7.6 
54.4 
±8.7 
72.1 
±5.0 
50.8 
±1.1 
CD4 18.4 
±2.4 
27.6 
±8.6 
27.6 
±6.1 
40.8 
±10.4 
23.8 
±4.0 
26.2 
±8.7 
18.2 
±6.0 
22.6 
±4.4 
13.0 
±5.4 
29.3 
±7.1 
HIS42+ 
NKR-P1+ 
DN 12.5 
±1.6 
14.0 
±4.7 
22.2 
±2.3 
24.6 
±7.5 
9.5 
 ±3.2 
18.0 
±3.0 
13.2 
±2.1 
20.1 
±6.1 
11.9 
±2.4 
17.5 
±5.3 
CD8β 20.8 
±2.8*** 
21.3 
±3.0* 
5.2  
±1.0  
6.3  
±4.9  
10.6 
±1.0*** 
9.1 
±2.0*** 
20.3 
±0.7 
17.6 
±1.5 
10.6 
±1.2** 
8.4  
±1.7 
CD4 74.6 
±3.0** 
75.5 
±3.5 
88.5 
±1.5* 
88.5 
±5.7 
86.6 
±06*** 
87.5 
±3.2** 
76.3 
±1.5* 
77.1 
±0.9 
85.2 
±2.7 
88.9 
±0.4 
R78+ 
NKR-P1- 
DN 2.8  
±0.2 
2.6  
±1.1 
5.3 
±0.9* 
4.5 
±1.0* 
1.7  
±1.0 
2.7  
±1.5 
3.0 
±1.6* 
4.8  
±2.4 
3.4  
±2.2 
1.8  
±0.8 
CD8β 27.7 
±2.9 
27.0 
±2.6 
4.2  
±0.6 
4.3  
±1.1 
18.1 
±1.6 
17.6 
±2.6 
19.1 
±0.9 
16.8 
±2.5 
14.6 
±1.2 
12.0 
±3.3 
CD4 69.3 
±2.4 
69.9 
±3.3 
91.7 
±2.6 
93.5 
±1.6 
80.1 
±1.4 
79.0 
±1.5 
78.9 
±0.9 
79.6 
±3.4 
82.6 
±2.4 
85.9 
±3.3 
HIS42+ 
NKR-P1- 
DN 2.0  
±0.9 
2.2 
±1.1 
3.1  
±1.3 
1.7  
±0.7 
1.2  
±0.5 
2.9  
±1.3 
1.4  
±0.6 
3.0  
± 3.0 
1.8  
±1.1 
1.3  
±0.4 
 
Table 10. CD4 and CD8β distribution in R78+ or HIS42+ NKR-P1 positive and negative T cells. 
Splenic (Spl) and intrahepatic (IHLs) lymphocytes were analyzed by flow cytometry as shown in figure C 
but with R78 (anti-BV8S4a and anti- BV8S2l) or HIS42 (anti-BV16) unconjugated mAbs instead of R73. 
Shown are the means obtained in three to five independent experiments ±SD. Changes in the CD4/CD8β 
distribution between BV8 and BV16 T cell subsets were analyzed using the two-tailed paired t-test. P 
values: *<0.05, **<0.005 and ***<0.0005. 
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4 DISCUSSION 
4.1 Further characterization of CD1d monoclonal antibodies  
Previous knowledge about rat CD1d expression was based on experiments using RT-
PCR, in situ hybridization or polyclonal antiserum, but the analysis of rat CD1d protein 
with specific monoclonal antibodies was still pending (Ichimiya et al., 1994; Kasai et 
al., 1997). To this end, five hybridomas (232, 233, 244, 35 and 58) derived from CD1d-/- 
mice immunized with rat CD1d transductants had been generated which produced such 
monoclonal antibodies (Pyz, 2004). These antibodies have been characterized in greater 
detail in this study.   
The analysis of the variable regions of the IgG2a heavy and kappa light chains (when 
possible) revealed that on the one hand, the 232 and 233, and on the other hand, the 244 
and 58 hybridomas secreted antibodies encoded by the same rearranged Ig genes. Since 
all hybridomas were generated in the same fusion and single cell cloning of the 
hybridomas was carried out, it seems likely that those with the same rearranged Ig genes 
arose from an expanded B-cell clone. Nonetheless, descendance from the same 
hybridoma cannot formerly be ruled out. 
Unfortunately, although the 232 and 233 antibodies comprised kappa light chains, as 
demonstrated with the kit used to determine their isotype, no PCR product was obtained 
for the light chain of these hybridomas with the universal primers used to amplify the 
kappa light chains of the other hybridomas. These forward universal primers contained 
a mixture of sequences of the FR1 regions of the IGLKV gene segments most 
commonly used in the mouse based on the Kabat-Wu database book (Wang et al., 
2000). Nonetheless, it is still possible that a sequence which anneals to the particular V 
gene segment comprised in the 232 and 233 light chains is not present among the 
degenerated primers, and that therefore, no PCR product was obtained.  
As mentioned in the results section 1.1, in flow cytometry experiments the mAbs 233 
and 35 recognized mouse CD1d1 on transduced cells or thymocytes with the same 
efficacy as rat CD1d while, the mAb 58 only showed such cross-reactivity for mouse 
CD1d-expressed by transduced cells but not for CD1d positive primary mouse cells. In 
accordance with their CD1d specificity, both 233 and 35 mAbs precipitated two chains 
of molecular weight corresponding to the heavily glycosylated mature CD1d molecule 
and the non-covalently bound β2-microglobulin, respectively, from primary rat and 
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mouse thymocytes as well as from rat and mouse CD1d-transduded Raji cells. mAb 58, 
in line with the results obtained by flow cytometry, precipitated rat CD1d from 
transduced and primary cells but mouse CD1d1 only from transduced cells. The reduced 
ratio of precipitated β2-microglobulin to CD1d heavy chain found for 58 compared to 
the other two mAbs, might reflect a preferential binding to a β2m independent form of 
CD1d. Such β2m-independent forms have been previously described in mouse and 
humans (Amano et al., 1998; Blumberg et al., 1991; Kim et al., 1999). However, 
another possibility is that the interaction of the 58 mAb with CD1d somehow displaces 
the bound β2-microglobulin, resulting in the preferential precipitation of single CD1d 
heavy chains.  
The different reactivity of the 58 mAb depending of which cell type expresses mouse 
CD1d is not yet understood. In contrast to 233 and 35 mAbs, the epitope recognized by 
mAb 58 was disrupted under denaturating conditions in Western blot experiments, 
indicating that this mAb is more sensitive to changes in the tertiary structure of CD1d 
than the other two mAbs. Thus, subtle differences in the tertiary structure between 
transduced and primary cells could be the cause of the distinct reactivity of mAb 58. 
The binding of the 233 and 35 mAbs to CD1d in Western blot demonstrated the 
localization of both epitopes to the heavy CD1d chain. Both mAbs bound much more 
efficiently to CD1d molecules which had been separated by SDS-PAGE under non-
reducing compared to reducing conditions, probably reflecting the importance of the 
intramolecular disulfide bridges in the conservation of the epitopes. The slightly higher 
mobility of the CD1d heavy chain separated by SDS-PAGE under non-reducing 
compared to reducing conditions is probably a consequence of the more compact 
structure maintained by the intact intramolecular disulfide bridges. Both mAbs 
recognized only mature forms of the CD1d molecules, since no bands were observed 
where immature CD1d proteins are expected (as it has been shown for human CD1d at 
37 or 30-35 kDa under reducing and non-reducing conditions, respectively (Kim et al., 
1999)). To our knowledge this is the first demonstration of IgG mAbs binding to mouse 
or rat CD1d heavy chain in a Western blot. 
Titration of the antibodies in flow cytometry experiments revealed that the avidity of 
mAb 35 was 3- to 5-fold higher than that of 233 and that both mAbs bound rat CD1d 
and mouse CD1d1 to the same extent (data not shown generated by S. Schweigle and L. 
Starick). This was in contrast to the results observed in Western blot (Fig. 2), 
immunohistology (not shown) and sometimes also immunoprecipitation where 233 was 
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superior to 35 and where binding to rat CD1d was more efficient than to mouse CD1d1. 
These findings suggest that the 233 epitope is more resistant to denaturation than the 35 
epitope and also that denaturation affects more the epitopes recognized in mouse CD1d1 
than in rat CD1d. Nonetheless, it remains to be investigated, whether these differential 
binding efficacies result from protein denaturation and/or effects of detergents or 
alcohols on CD1d-bound lipid-containing antigens.  
Analysis of 233 and 35 mAb reactivities against various CD1d transductants allowed a 
partial mapping of the epitopes as discussed in the results section. The mAb 233 is 
likely to bind to an area above the β2-microglobulin where the ends of the α1 and α2 
helices meet, as demonstrated by the lack of binding of the mCD1dD93A mutant. Thus 
it was surprising that mCD1d2 staining by 233 was also severely impaired, since the 
aspartic acid at position 93 is conserved. This loss of the 233 epitope in mCD1d2 could 
be due to several unique substitutions but it is worth noting that the positively charged 
arginine at position 21 (indicated as blue spheres in Fig. 3), close to the negatively 
charged aspartic acid 93, is substituted by a hydrophobic isoleucine in mCD1d2. This 
substitution may either directly induce a conformational change of the aspartic acid at 
position 93 thereby disrupting the 233 epitope or directly affect the contact with the 
antibody. The epitope recognized by the 35 mAb could only be mapped to the α1 
domain and the first 26 amino acids of the α2 domain of mouse CD1d1 because it is 
conserved in mouse-human CD1d chimeras but it is lost in human-mouse CD1d 
chimeras. The binding of 35 mAb to the mouse/human chimera was reduced compared 
to complete mCD1d1 molecule but this reduction was also observed with other mAbs 
(233 and 1B1, Fig. 3). These findings together with the fact that EGFP levels are very 
similar between the cell lines expressing these CD1d variants suggest that the lower 
binding of the 35 mAb to the m/h chimera is the result of a reduced cell-surface 
expression of the m/h chimera compared to the intact molecule rather than from a 
contribution to the 35 epitope of the non-conserved residues of the mouse CD1d1 C-
terminal part. Nevertheless, the aspartic acid 93 can be excluded to be part of the 35 
epitope since this mAb stained sCD1d- and mCD1d1D93A-transduced cells (Fig. 3).   
233 and 35 binding to distinct non-overlapping epitopes allowed the establishment of a 
Sandwich ELISA which was routinely used to monitor concentrations of CD1d during 
preparation and purification of recombinant CD1d molecules. Similar to Western blot 
and immunohistochemistry analyses, the detection of mouse CD1d was less efficient 
than the detection of rat CD1d in this Sandwich ELISA. The samples analyzed with this 
 128 
technique contained CD1d molecules which were either secreted forms of CD1d (e.g. 
CD1d-IgG dimers) or cell lysates where cell membranes had been disrupted by the use 
of detergents. The binding capacities of the antibodies may differ depending on whether 
the CD1d molecules have a soluble or a membrane-bound form. Thus it is possible that 
the recognition of mouse CD1d in such a soluble form by these mAbs is more affected 
compared to rat CD1d.  
 
4.2 CD1d in the hematopoietic system  
The 233 and 35 mAb allowed not only the analysis of CD1d protein expression in the 
rat but also the direct comparison to mouse, where CD1d expression in the 
hematopoietic system has been largely studied (Brossay et al., 1997; Park et al., 1998; 
Roark et al., 1998). Moreover, binding of both mAbs to different epitopes further 
validated results, e.g. determination of tissue distribution, where a cross-reactivity of 
both mAbs with an unknown tissue antigen would be most unlikely. 
Among different inbred rat strains, CD1d expression levels at the cell surface of 
splenocytes, thymocytes and PBMCs were nearly the same, demonstrating that the two 
rat CD1d alleles identified in this study did not show different expression patterns at the 
cell surface. Only among IHLs from DA and PVG, more cells with elevated CD1d 
levels appeared compared to the other inbred rat strains. It remains to be determined 
whether this is due to an increase in the frequency of a particular cell type with high 
CD1d levels. 
CD1d expression at the cell surface of hematopoietic cells is also remarkably similar 
between rat and mouse. The only notable difference between these species was found 
among CD4 and CD8 peripheral T cells. In the rat, both subsets express similar CD1d 
levels whereas in the mouse, CD4 T cells express higher CD1d levels than CD8 T cells. 
Nonetheless, the difference is rather small and a physiological role for CD1d on mature 
T cells still has to be described.  
The nearly identical expression among thymocytes, where CD1d selects iNKT cells 
(Wei et al., 2005) is of special interest because their level of CD1d considerably affect 
NKT cell frequency and state of activation (Zimmer et al., 2006). Since CD1d levels are 
also practically the same between the rat and mouse in other cells for which a role for 
CD1d has been established in the mouse i. e. APCs, B cells and MZ B cells (Brigl and 
Brenner, 2004), no qualitative differences are expected between the CD1d-restricted 
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immune responses of these two species. If in contrast differences appear, those should 
not be intrinsic to variations in CD1d expression on hematopoietic cells.  
Apart from being used to identify MZ B cells in the mouse, CD1d serves also as a 
marker to distinguish between other B cell subsets (Mizoguchi et al., 2002; Yanaba et 
al., 2008). With 233 and 35 mAbs we can investigate now whether these distinct B cell 
populations are also present in the rat with the same CD1d expression patterns.  
 
4.3 CD1d in non-lymphatic tissues 
Similar to previous studies using polyclonal antiserum, in situ hybridization and RT-
PCR in the rat (Ichimiya et al., 1994; Kasai et al., 1997), CD1d protein was also found 
with the 233 and 35 mAbs in non-lymphatic organs as the liver, heart, intestine and 
pancreas. Here, in contrast to the hematopoietic system, CD1d distribution varies 
enormously between different cell types and in some cases also between mice and rats.  
CD1d present at the cell surface of any cell may display endogenous or exogenous 
lipids. Endogenous lipids vary between different cells as well as between different 
activation states of the same cells, as shown for example by the production of charged 
β-linked glycosphingolipids (which will activate iNKT cells) by dendritic cells which 
sense danger signals through TLR-9 (Paget et al., 2007). Thus in a similar way, CD1d 
present in non-hematopoietic cells may warn the immune system of changes by 
presenting certain lipids which activate CD1d-restricted T cells.  
CD1d protein was detected in the serum of different inbred rat strains by CD1d 
Sandwich ELISA. To assure the specificity of these measurements, further controls are 
necessary, as for example the analysis of serum of CD1d knockout mice. Assuming that 
the presence of CD1d in the serum is indeed specific, it would be interesting to learn 
about its source and whether it is soluble and/or it is contained in lipidic membranes of 
vesicles such as exosomes. 
The vast expression of CD1d in rat exocrine cells in the pancreas and small intestine 
and its biological implications are intriguing, therefore these tissues were also analyzed 
in the mouse. Several studies addressing CD1d expression in the mouse small intestine 
with different mAbs have not lead to a general consensus about its cellular distribution 
(Brigl and Brenner, 2004). Terhorst and colleagues detected CD1d protein expression in 
epithelial cells such as enterocytes was with a rat IgM antibody (1H1); in contrast, 
Kronenberg et al. found these cells to be negative for the staining with the rat anti-
mouse CD1d IgG mAb 1B1 (Bleicher et al., 1990; Brossay et al., 1997). In spite of 
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these opposite findings, a recent study by Blumberg and colleagues has demonstrated 
the importance of CD1d expression for gut function since intestinal colonization with 
pathogenic and non-pathogenic bacteria was increased in CD1d-deficient mice 
compared to wild type mice (Nieuwenhuis et al., 2009). An essential cell type in 
controlling intestinal homeostasis are Paneth cells, in which CD1d mRNA has been 
detected by in situ hybridization in mice and rats (Kasai et al., 1997; Lacasse and 
Martin, 1992). Localized at the bottom of the crypts of Lieberkühn, these specialized 
cells control the microbiota content by secreting antimicrobial peptides (defensins) to 
the intestinal lumen. Interestingly, Blumberg and colleagues also showed that in CD1d 
knockout mice, compared to wild type, the morphology and content of the secretory 
granules of the Paneth cells were altered, and more importantly, that the degranulation 
activity of these cells was defective (Nieuwenhuis et al., 2009).  
Using the 233 and 35 mAbs we found that among the different types of epithelial cells 
in the mouse none of our antibodies stained CD1d in enterocytes, although detection of 
CD1d in other epithelial (e.g. enteroendocrine cells) and non-epithelial (e.g. cells of the 
lamina propria) cells was possible. Therefore, if there is any expression of CD1d by 
mouse enterocytes its level must be very low. Importantly however, the mAbs served to 
detect CD1d protein in mouse Paneth cells for the first time. 
In contrast, in the rat ileum CD1d was broadly detected being expressed by most of the 
different cell types including all intestinal epithelial cell types; among which, the 
outstanding levels found in Paneth cells are remarkable. As mentioned above, CD1d 
expression in the rat ileum had previously been addressed using a polyclonal antiserum 
and in situ hybridization (Ichimiya et al., 1994; Kasai et al., 1997). In this study high 
levels of CD1d mRNA were found in Paneth cells as well, but the polyclonal antiserum 
failed to detect protein in this cell type.  
The physiological function of CD1d in Paneth cells remains unclear, but there are 
several possible biological processes in which it might be involved. On the one hand, 
since it also has been shown that degranulation of Paneth cells could be triggered in vivo 
after injection of α-Gal and in vitro after stimulation with α-Gal and iNKT cells 
(Nieuwenhuis et al., 2009), it is tempting to speculate that CD1d on Paneth cells may 
present activating antigens to CD1d-restricted T cells, which in turn could trigger 
directly or indirectly the degranulation and secretion of antimicrobial peptides to the 
intestinal lumen by the antigen presenting Paneth cells.  
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On the other hand, a T cell-independent function of CD1d in the secretion process of 
this specialized cell type appears also possible. Two observations support the latter 
view: first, as mentioned before, CD1d-deficient Paneth cells show an altered content 
and morphology of their granules compared to wild type cells (Nieuwenhuis et al., 
2009), indicating a contribution of CD1d to the formation of the exocrine granules of 
Paneth cells, and second, CD1d was mainly detected in apical granules (Fig. 12 d) but 
not in basolateral membranes where it would be more accessible to T cells. In addition, 
it has been shown that cross-linking of human CD1d with mAbs induce intracellular 
signals and provoke cytokine production (Colgan et al., 1999; Yue et al., 2005), 
implying that clustering of CD1d molecules either by reactive TCRs or by other yet 
unidentified molecules can result in intracellular signaling events.   
The histological finding of an unexpected vast CD1d expression in rat pancreatic 
exocrine acinar cells is not only supported by Western blot and ELISA analyses of 
pancreatic extracts, but also by two independent proteomic analyses which also 
identified CD1d in rat pancreatic exocrine granules (Chen et al., 2006; Rindler et al., 
2007). Surprisingly, such expression was not found in mouse pancreas. The slightly 
lower apparent molecular weight of the rat pancreatic CD1d compared to that from 
extracts of spleen or thymus could indicate a different processing during intracellular 
maturation e.g. proteolytic cleavage of membrane bound material or the generation of a 
truncated form. Since the staining observed in the acinar cells was localized to the 
mature exocrine granules, it is tempting to speculate about a soluble CD1d which might 
be secreted into the intestinal lumen together with other pancreatic products. A potential 
function of this soluble CD1d might be the sampling of microbial glycolipids in the 
intestinal lumen - helped by the low pH of the duodenum - and the transport to various 
cells of the intestine. Another option inspired by the human CD1e, which is cleaved 
resulting in a soluble form that facilitates glycolipid processing by α-mannosidase 
(Angenieux et al., 2000; de la Salle et al., 2005) and by other proteins secreted by the 
pancreas (e.g. lipase) could be the participation in intestinal lipid processing and 
absorption. Since CD1d was also found in some endocrine cells and in exocrine 
granules of rat parotid glands (Steiniger, Monzon-Casanova, Herrmann; data not 
shown), this repeated localization of CD1d in secretory granules might indicate, as 
mentioned before for Paneth cells, a role of CD1d in the exocytosis process of certain 
cell types.  
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A functional specialization of the different CD1 isoforms is indicated by their 
differential intracellular localization and specificity in antigen-binding, or as in the case 
of CD1e, by the identification of functions distinct from direct presentation of antigens 
to TCRs. Interestingly, although a substantial variability has been found between 
number and types of CD1 isoforms in different clades of placental mammals, complete 
CD1 deficiency has not been reported yet (Kasmar et al., 2009). This, not only supports 
the idea that CD1 molecules fulfill essential biological functions, but also implies that 
the function of CD1 isoforms may vary between species and that to some extent CD1 
isoforms could substitute each other. In muridae CD1d is the only CD1 isoform. 
Therefore, one may speculate a need for “multitasking” of CD1d in these species. Such 
a requirement may explain the – in comparison to humans – less restricted intracellular 
distribution and tissue expression (Brigl and Brenner, 2004).  
 
4.4 Rat CD1d as antigen presenting molecule  
An α-Gal response of rat primary cells has previously been shown in our laboratory by 
E. Pyz and colleagues (Pyz et al., 2006). Here we have demonstrated the CD1d 
dependence of such a response, since the 233 and 35 monoclonal antibodies efficiently 
inhibited cytokine release after α-Gal activation of rat and mouse primary cells. These 
results are consistent with mapping the 233 epitope to the loop connecting the α1 and α2 
domains of the CD1d at the side of the F’ pocket, because it is this side of the CD1d 
molecule where in the three dimensional structure, the semi-invariant NKT TCR 
contacts α-Gal/CD1d complexes (Borg et al., 2007).  
Now these mAbs provide also the tool to investigate in vivo CD1d-restricted responses 
in the rat, what in contrast to the mouse, cannot be done using CD1d-deficient animals. 
Furthermore, the antibodies enable the direct comparison of CD1d responses in the rat 
to the mouse and since they were generated in mice, are ideally suited for in vivo studies 
in this species as they will not provoke a response against xenogenic Ig. 
 
4.5 CD4 expression by MZ B cells 
A major surprise was the not yet described substantial CD4 expression on rat MZ B 
cells, which was shown to be specific using three different monoclonal antibodies which 
bind to two different domains of the CD4 molecule (van den Berg et al., 2001). It is 
retrospectively difficult to explain, why this observation has not been reported before. 
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The functional implications of this finding are unclear, but it is important to know that 
any experimental setting addressing CD4, e.g. in depletion studies with CD4 specific 
antibodies in the rat, can be expected to affect not only CD4 T cells and to some extent 
antigen presenting cells but MZ B cells as well. Since rats and humans are more similar 
to one another with respect to CD4, CD8 and MHC-II expression by immune cells than 
rats and mice (Broeren et al., 1995; Crocker et al., 1987; Kenny et al., 2004), it may be 
worthwhile to reinvestigate CD4 expression on human MZ B cells as well.  
 
4.6 Production of rat CD1d oligomers 
As mentioned in the results section 3.4, different approaches with different advantages, 
were taken to produce rat CD1d oligomers. From the three variants that were tested with 
a semi-invariant TCR-transduced cell line, rat CD1d-IgG dimers showed the best 
staining (Fig. 16). The weaker staining capacity of the rat β2m-CD1d-hFc dimers 
compared to the rat CD1d-IgG dimers, apart from intrinsic differences of the protein 
preparation and α-Gal loading efficiency (see Methods 2.2.3.10 and Results 3.4.1.5), 
could be explained by a reduced avidity of this bivalent molecule resulting form a 
different orientation or less flexibility of the CD1d molecules when they are bound to 
the constant domain of the Fc portion compared to the variable domain of an intact 
antibody. A different conformation of the CD1d molecule induced by the covalently 
linked β2-microglobulin, although it can not be excluded, seems unlikely since covalent 
linkage by glycine-serine polylinkers are commonly used to fuse protein subunits and 
have been used for the optimization of production of human CD1d tetramers (Li et al., 
2008).  
In principle, CD1d tetramers would be advantageous over CD1d-IgG dimers in so far 
that they should have a higher avidity for the semi-invariant TCR and that they lack the 
IgG molecule which can cause problems by Fc receptor binding and the use of 
secondary reagents when primary cells are stained. Nonetheless, the rat CD1d-IgG 
dimers where highly superior to the rat CD1d streptamers, since the latter gave a very 
high unspecific staining which was independent from TCR expression because 
untransduced BW cells were also stained. Additionally, these CD1d streptamers showed 
little differences between α-Gal- and β-Gal-loaded reagents. The most likely 
explanation for the small differences between α-Gal- and β-Gal-loaded streptamers is 
the inefficient multimerization of the reagent. Strep-Tag/Strep-Tactin based 
multimerization has been successfully used in the production MHC class I oligomers 
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(Knabel et al., 2002; Neudorfer et al., 2007), but to our knowledge, this is the first 
attempt with CD1d molecules. Antigen loading of CD1d, in contrast to that of MHC-I 
molecules, was carried out in the presence of DMSO and TRITON X-100, thus it might 
well be that solvents and detergents still present in the multimerization mixture affect 
the Strep-Tag/Strep-Tactin interactions.  
 
4.7 Species specificity of α-Gal-CD1d recognition by mouse and rat iNKT 
cells 
Functional data generated in our laboratory with transduced cell lines and primary 
antigen presenting cells by E. Pyz et al. showed that while mouse semi-invariant TCR 
bearing cells responded to α-Gal-presented by rat CD1d almost to the same extent as to 
α-Gal-presented by mouse CD1d, rat semi-invariant TCR reactivity to mouse CD1d-α-
Gal was severely impaired compared to rat CD1d-α-Gal (Pyz et al., 2006). This species 
specificity of CD1d-α-Gal recognition by rat semi-invariant TCR was now confirmed 
by flow cytometry since the fluorescence intensity of these rat semi-invariant TCR 
(AV14S6F + CDR2+4) transduced cells stained with rat α-Gal-loaded CD1d-IgG dimers 
was about 30-fold better than with mouse α-Gal-loaded CD1d-IgG dimers (Results 
section 3.4.2). Moreover, this cell line was not stained by human α-Gal CD1d tetramers 
at all. 
Flow cytometry analysis of rat and mouse primary intrahepatic lymphocytes with these 
newly generated IgG dimers showed the same species specificity in CD1d/α-Gal 
recognition: on the one hand, most mouse primary iNKTs, stained with mouse α-Gal-
loaded CD1d-IgG dimers, were also stained with rat CD1d-IgG α-Gal-loaded dimers; 
on the other hand, among rat intrahepatic lymphocytes the small but distinct population 
detected with rat CD1d-IgG α-Gal-loaded dimers was not observed when mouse CD1d-
IgG α-Gal-loaded dimers had been used (Fig.  17). These results were confirmed by 
staining in vitro expanded rat iNKT cells. This species specificity of α-Gal-CD1d 
recognition by iNKT cells of rats and mice was unexpected since human CD1d α-Gal-
loaded oligomers stain mouse iNKT cells and vice versa, mouse CD1d α-Gal-loaded 
oligomers stain human iNKT cells (Benlagha et al., 2000; Matsuda et al., 2000) and also 
because the predicted amino acid sequences of all the genes (CD1d, AV14, AJ18 and 
BV8) necessary for the generation of such CD1d-restricted T cells are highly conserved 
between mice and rats (Fig. 39 and (Kinebuchi and Matsuura, 2004; Matsuura et al., 
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2000; Pyz et al., 2006). Nonetheless, apart from the CDR2α region of the invariant 
TCRα chain, which differs considerably but does not contribute to the recognition of α-
Gal-CD1d with evident interactions (Borg et al., 2007; Pellicci et al., 2009), two amino 
acids, one in CD1d and the other one in AJ18, which are conserved between mouse and 
human and which make energetically important interactions and are not preserved in the 
rat (Fig. 39, (Borg et al., 2007; Pellicci et al., 2009)). Although these non-conserved 
residues are only two, one single amino acid substitution in tree shrew CD1d compared 
to human CD1d is enough to cause the loss of cross-reactivity between human semi-
invariant TCR and tree shrew CD1d (human CD1d contains a lysine (K) at position 86 
where the tree shrew CD1d contains a glutamine (Zhang et al., 2009)). Therefore these 
single substitutions in AJ18 or CD1d may be responsible for the described need of 
syngeneic CD1d as presenting element in the rat. More precisely, on the one hand, the 
human and mouse arginine (R) 103 present in the CDR3α loop (encoded by the AJ18 
gene segment) is substituted by a lysine (K) in the rat. R103 makes Van der Waal 
interactions with R at position 79. In addition, in the mouse BV8S2 (but not BV7) 
ternary complex, this R103 in the α chain contacts the glutamic acid (E) at position 83 
of the mouse CD1d. On the other hand, in human and mouse CD1d a valine at position 
147 and 150, respectively, is substituted by a methionine in the rat. This valine makes 
Van der Waal interactions with serine (S) 97 and leucine (L) 99, which are present in all 
three species (Fig. 39, (Borg et al., 2007; Pellicci et al., 2009)). 
In F344 inbred rats approximately half of iNKT cells bear BV8S4+ TCRs. The detection 
of BV8S2 comprising TCRs using mAbs in this strain is not possible at the moment, but 
it would be interesting to learn whether the other half of iNKT cells use BV8S2 TCRs 
or TCR with other BV gene segments. Similarly, once demonstrated that the double 
negative and CD4 positive rat intrahepatic lymphocytes stained with mouse CD1d-IgG 
α-Gal dimers are indeed iNKT cells, it would be worth to address the V-D-J gene 
segments of their TCRβ chains to see whether there is any particular bias in the BV 
usage. 
No evident interactions between CDR3β and α-Gal-CD1d appeared in the crystal 
structures (Borg et al., 2007; Pellicci et al., 2009), but they still play an important role as 
it has been recently described for mouse and humans: First in mouse, certain CDR3β 
amino acid sequences allowed the usage of BV gene segments which are rarely found 
among the iNKT cell pool and, second in humans, the CDR3β region controlled the 
affinity of the binding to CD1d independently of the presented ligand (Mallevaey et al., 
 136 
2009; Matulis et al., 2010). Thus it would be also interesting to analyze the CDR3β 
regions and BV usage of mouse iNKT cells which are stained with rat CD1d-IgG α-Gal-
loaded dimers to see whether there is any particular bias.  
The different usage of AV14 gene segments by iNKT cells in the rat is later discussed 
in the discussion section 4.9.  
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a CD1d:α1 domain 
        1         11        21        31        41        51        61        71        81        91       
hCD1d AEVPQRLFPLRCLQISSFANSSWTRTDGLAWLGELQTHSWSNDSDTVRSLKPWSQGTFSDQQWETLQHIFRVYRSSFTRDVKEFAKMLRLS  
mCD1d1 S.AQ.KNYTF....M.....R..S...SVV...D....R.....A.ISFT......KL.N....K...M.Q...V.....IQ.LV..MSPKED  
rCD1d S..Q.-NYTF..........R..S...SVV...D....R.......ISFT......K..N....K...M.Q...T.....I..IV..MSPKED  
 1         10        20        30        40        50        60        70        80        90 
 
   α2 domain 
      92        102       112       122       132       142        152       162       172       182       
hCD1d  YPLELQVSAGCEVHPGNASNNFFHVAFQGKDILSFQGTSWEPTQEAPLWVNLAIQVLNQDKWTRETVQWLLNGTCPQFVSGLLESGKSELKKQ 
mCD1d1  ..I.I.L.....MY.....ES.L.......YVVR.W....QTVPG..S.LD.P.K...A.QG.SA...M...D...L..R....A...D.E.. 
rCD1d  ..I.V.L.....MY.....ES.L......EYVVR.H....QKVP...S.LD.P.KM..A.EG......I...D......R....A..PD.E.. 
  93        103       113       123       133       143       153       163       173       183    
 
 
b TCRα chain:                             CDR1                   CDR2                                          CDR3      
                      10        20        30        40        50        60        70        80       90     95 98 103                   
hAV24/AJ18     -NQVEQSPQSLIILEGKNCTLQCNYTVSPFSNLRWYKQDTGRGPVSLTIMTFSENTKSNGRYTATLDADTKQSSLHITASQLSDSASYICVV/S/DRGSTLGRLYFGRGTQ 
mAV14S1A2/AJ18  KT.........VVRQ.E..V.....S.T.DNH...F.....K.L....VLVDQKDKT.....S....K.A.H.T.....TL.D.T.T...../A/....A....H..A... 
rAV14S6/AJ18   RT.........VVH..ES.V.......T..N........R..A.....VL.NK.EKT.R...S......A.H.T......L.D.A.T...../A/....A..K....I... 
     1         11        21        31        41        51        61        71        81        91    95    101         
           
 
c TCRβ chain:                      CDR1                  CDR2               HV4/CDR4                   CDR3  
  1         11        21        31        41        51        61        71        81        91         101               
hBV11BDJ2 EADIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLIHYSYGVNSTEKGDLSSESTVSRIRTEHFPLTLESARPSHTSQYLCASS/ENIGTAYEQYFGPGTR  
mBV8S2  ..AVT.S..NK.AV..G.V..S.N..NN.NN....R..T.HG.R.......AG......IPDGYKA..PSQ.N.S.I..L.T..Q..V.F...G/.GGLGGPT...-----   
rBV8S4  ............T.K........K.N............M.............N......V.N...V...NK...F.T..S.S...........S     
rBV8S2   -----------.......................................DV.........D.......SQGD.....................     
  1         11        21        31        41        51        61        71        81        91          
  
Figure 39. Amino acid sequences of human, mouse and rat CD1d, variable domains of invariant TCRα chains and various β chains. Alignments of mature amino acid 
sequences necessary or relevant for the development of iNKT cells. Dots represent same amino acid as the first amino acid sequence. Numbers above and below the 
sequences correspond to mature human and rat predicted amino acid sequences, respectively.  a Predicted amino acid sequences of human CD1d (GBN: NM_001766), mouse 
CD1d1 (GBN: X13170) and rat CD1d (AB029486) α1 and α2 domains. Bold letters indicate α-helical regions. b Predicted amino acid sequence of human AV24/AJ18 (GBN 
protein: 2CDE_A, IGMT nomenclature TRAV11-TRAVJ18), mouse AV14S1A2/AJ18 (GBN: DQ340292) IGMT nomenclature TRAV11*02 and TRAJ18) and rat 
AV14S6F344/AJ18 (GBN: DQ340293). CDRs are indicated with underlined letters. Numbers in bold and cursive are assigned as published for human and mouse invariant 
TCRα amino acid sequences (Wun et al., 2008) although the numbering of the arginine 103 should be 101. This numbering has been conserved to allow a direct comparison 
with the iTCR-α-Gal-CD1d crystal structures published to date (Borg et al., 2007; Pellicci et al., 2009). c Predicted amino acid sequence of human BV11 (GBN protein: 
2CDE_B), mouse BV8S2 (GBN: DQ340294), rat BV8S4 (EMBL-Bank: X77995) and rat BV8S2 (EMBL-Bank: X98251.1) both from the a haplotype (Asmuss et al., 1996). 
CDRs are indicated with underlined letters. 
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4.8 Distribution and phenotype of rat iNKT cells 
In mice iNKT cell frequencies are a stable phenotype under genetic control of at least 
two different recessive loci (Esteban et al., 2003; Rocha-Campos et al., 2006). In 
humans, iNKT cells numbers vary noticeably among different individuals but are also 
under strict genetic control since they are approximately the same between identical 
twins (Lee et al., 2002b). In this study we have analyzed iNKT cell frequencies in two 
different rat strains: F344 and LEW. In F344 rats iNKT cells were clearly detectable 
with α-Gal-loaded rat CD1d oligomers in the liver and the spleen. Similar to mice, the 
frequencies of iNKT cells found in the liver were higher than those in the spleen: 0.25 
and 0.05% of total lymphocytes or 1.65 and 0.16% among αβ T cells in the liver and the 
spleen, respectively. Nonetheless, these frequencies are much lower than in C57BL/6 or 
BALB/c mice, where 30 and 20% of the liver lymphocytes, respectively, are iNKT cells 
(Matsuda et al., 2000). Among F344 PBCs a very low number of cells were stained with 
α-Gal-loaded but not with β-Gal-loaded rat CD1d oligomers. Despite these low 
numbers, the fact that the cells stained with rat CD1d-IgG α-Gal-loaded dimers were 
mostly DN and CD4 positive supports the interpretation that these cells are indeed 
circulating iNKT cells. However, in order to exclude that the CD1d-IgG dimer positive 
cells were not other T cells which serendipitously contained a TCR reactive to α-Gal-
CD1d complexes, these results should be confirmed at least for spleen and PBCs first, 
with further stainings in which more events are acquired and second, with other 
supporting methods as for example by sorting the stained cells and analyzing the TCRα 
chains by RT-PCR and sequencing.  
In LEW rats, except in the liver, where very few cells were stained by the α-Gal-loaded 
rat CD1d-IgG dimers, no iNKT cells were detected in the spleen or in PBCs. Although 
the cells stained with α-Gal-loaded rat CD1d-IgG dimers in the liver were mostly DN 
and CD4 and did not appear with β-Gal-loaded dimers, further analyses are required to 
confirm that these are indeed iNKT cells.  
In the thymus of both inbred rat strains, staining with α-Gal- or β-Gal-loaded rat CD1d-
IgG dimers revealed no differences. Taken into consideration that in the thymus of 
C57BL/6 or BALB/c mice, the frequencies of iNKT cells are low: 0.7 and 1.5%, 
respectively (Matsuda et al., 2000) and that in the other organs in the rat the frequencies 
of iNKT cells were 10 to 100 fold lower than in the mouse, it is well possible that iNKT 
cells are below the detection limit with the staining protocol used in these analyses. 
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Taken all together, the numbers of iNKT cells observed among rats are strikingly lower 
than those of mice. In fact, LEW rats can, in principle, be considered as an iNKT cell 
deficient inbred rat strain. To find such low frequencies among rats was in part 
surprising because in all the “wild type” mouse inbred strains analyzed to date, no strain 
has been reported yet in which liver iNKT cells could not be stained with mouse CD1d 
oligomers, although some strains such as 129 and LG contained very low iNKT cell 
numbers (Rymarchyk et al., 2008).  
Interestingly, the frequencies of iNKT cells in the rat resemble much more the 
frequencies observed in humans. In two independent studies where human livers were 
analyzed, the observed iNKT cell numbers varied from 0.03 to 0.3% among total 
intrahepatic lymphocytes in patients with end-stage viral-induced liver cirrhosis 
(Karadimitris et al., 2001) and were about 0.5% of all CD3+ T cells in healthy 
individuals (Kenna et al., 2003). In another study where human thymocytes were 
analyzed, the frequencies observed were much lower than those of mice: The mean 
value for 30 individuals was 0.0016%. Importantly, in this study a very high number of 
thymocytes (30*107) had to be acquired to detect a reliable population by flow 
cytometry analyses. Moreover, this study also showed that the iNKT cell frequencies 
observed in the thymus have limited correlation with the frequencies found in the 
periphery (Berzins et al., 2005). Although this is not surprising in humans because adult 
individuals were analyzed and the only peripheral “organ” studied was the blood, this 
phenomenon is also observed in mice maintained under specific pathogen-free 
conditions (Matsuda et al., 2000)  and therefore, it could occur in the rat as well.  
All the data obtained by flow cytometry with α-Gal-loaded CD1d-IgG dimers are 
supported by RT-PCR and sequencing experiments described in the results sections 
3.5.2 and 3.6.2. Briefly, where a relative high number of iNKT cells were observed (i.e. 
F344 liver and spleen) the AJ18 gene segment was preferentially used among all the 
AV14-containing TCRα chains, AV14AJ18 rearrangements were easily detected by 
RT-PCR and the AV14-AJ18 rearrangement junction consisted of a stretch with three 
nucleotides encoding an alanine or a glycine. The predominance of the alanine codon 
(GCx) in the junction region can be explained by the germline nucleotides subsequent to 
all BN AV14 coding sequences which are GCC. The presence of glycine codons (GGx) 
can only be the result of the addition of N nucleotides since the adjacent nucleotides to 
the coding region of the AJ18 gene segment are two thymines. In mice and humans the 
predominant residue found in the junctional region of invariant α chains is also that 
 140 
encoded by the germline DNA: glycine (GGC) in mouse and serine (AGC) in humans 
(Dellabona et al., 1994; Koseki et al., 1990). Analysis of the influence of alanine and 
glycine in the recognition of α-Gal-CD1d by rat iTCRs is underway.   
Interestingly, among F344 thymocytes AV14-AJ18 rearrangements were easily detected 
by RT-PCR, but the size and the nucleotides of their junction regions were highly 
diverse, indicating that many thymocytes rearrange AV14 and AJ18 gene segments 
together in F344, but probably only in a low proportion of these rearrangements the 
junctional region is formed by three nucleotides encoding either alanine or glycine as 
observed in the invariant α chains of the periphery. These last results support the lack of 
the identification of a distinguishable population with rat α-Gal-loaded CD1d-IgG 
dimers in F344 thymocytes compared to splenocytes or intrahepatic lymphocytes. 
Among LEW thymocytes, AV14-AJ18 rearranged TCRα chain transcripts were hardly 
detected (Fig. 20). From three analyzed animals, only one successful sequence was 
obtained which also contained different junction regions. These results show that in 
comparison to F344, in LEW rats the proportion of thymocytes which rearrange these 
two particular gene segments is much lower. Rearrangement of TCR gene segments 
encoding the variable region occurs in an orderly manner: Proximal gene segments 
rearrange first and those which are distal require a prolonged lifespan of DP thymocytes 
(Guo et al., 2002). AJ18 is encoded close to the 3’ end of the AJ loci and therefore is 
distal to the AV14 gene segment. Thus, various mouse models which lack - or have 
defective - factors that prolong thymocyte lifespan and sustained rearrangement such as 
ROR-γt, BCL-XL and c-Myb, have reduced iNKT cell numbers (Bezbradica et al., 
2005; Egawa et al., 2005; Hu et al., 2010). Torres-Nagel and colleagues showed that in 
LEW rats, proximal AJ gene segments are also preferentially rearranged with the 
AV8S2 gene segment in comparison to distal AJ segments (Torres-Nagel et al., 1997). 
Moreover, direct comparison of the mouse and rat AJ loci by blasting the complete 
genomic region encoding the mouse AJ loci with the rat BN genome showed an overall 
conservation in the locations of the AJ gene segments in the rat (data not shown). Thus 
since both F344 and LEW rats have almost identical levels of CD1d at the cell surface 
of DP thymocytes and contain the genes (AV14-AJ18 rearrangements were found in 
both strains) necessary to form the invariant α chain, it may be possible that the reduced 
amounts of AV14-AJ18-containing TCRα transcripts in LEW thymocytes and also 
iNKT cells in the periphery are due to an decreased capacity to rearrange distal gene 
segments in comparison to F344 rats.  
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As previously mentioned, the much lower iNKT cell frequencies found in rats compared 
to mouse are close to the frequencies found in human. Among other reasons, this was 
surprising since rat and mouse DP thymocytes express very similar levels of CD1d at 
the cell surface. Nonetheless, rat and human thymocytes differ remarkably from their 
mouse counterparts least in one aspect: rat and human thymocytes express MHC class II 
molecules whereas mouse thymocytes do not (our own unpublished data and (Fukumoto 
et al., 1982; Li et al., 2005)). This difference is remarkable because Li et al. have 
recently shown that the expression of MHC-II molecules in mouse thymocytes suppress 
iNKT cell development in trans in a CD4-dependent manner (Li et al., 2009). More 
importantly, in mice whose thymocytes expressed MHC class II molecules, iNKT cells 
were not completely absent but their frequencies were dramatically reduced. The 
mechanism behind this phenomenon is not completely understood but the authors 
suggest that the reduction on iNKT cell numbers could be due an increased negative 
selection resulting from an augment in the strength of the TCR signalling caused by 
CD4 binding to MHC-II molecules. Another alternative which also should be 
considered for the unsuccessful detection of iNKT cells in the rat thymus is that rat 
iNKT cell development could take place in other site/sites other than the thymus. Thus 
it would be worth to analyze athymic nude rats as well as thymectomized animals. 
Nonetheless, unless iNKT cell biology in the rat differs very much from the mouse, this 
alternative hypothesis seems highly improbable.   
  
4.8.1 NKR-P1 expression   
iNKT cells own their name first, to the expression of the invariant AV14-AJ18 chain 
(AV24-AJ18 human homologues) and second, to the expression of NK1.1 (NKR-P1C) 
in C57BL/6 mice (Godfrey et al., 2004). As mentioned in the introduction, since not all 
iNKT cells express NK1.1 (NKR-P1C) in mice or CD161 (NKR-P1A) in humans and 
not all the NK1.1+/CD161+ T cells are iNKT cells, in order to unambiguously identify 
iNKT cells, α-Gal-loaded CD1d oligomers are needed (Godfrey et al., 2004; Gumperz 
et al., 2002; Hammond et al., 2001; Matsuda et al., 2000). Moreover, recent reports 
have shown that these receptors typical of NK cells used initially to identify iNKT cells 
are members of the same family but their orthology between mouse, rat and human is 
not clear due, in part, to the very high degree of polymorphism (Aust et al., 2009; 
Carlyle et al., 2008). As mentioned in the introduction, former attempts carried out to 
identify rat iNKT cells also relied in the co-expression of TCR/CD3 and two of these 
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NKR-P1 receptors (A and B) detected by the mAbs 3.2.3 or 10/78 (Knudsen et al., 
1997; Li et al., 2003; Matsuura et al., 2000; Pyz et al., 2006; Ru and Peijie, 2009). Now, 
the identification of rat iNKT cells using α-Gal-loaded rat CD1d-IgG dimers in this 
study demonstrated that the expression of NKR-P1 is certainly not a suitable marker to 
identify rat iNKT cells. Indeed the frequencies of NKR-P1+ T cells in LEW rats, where 
iNKT cells were hardly detected if at all, do not differ from those of F344. These 
findings beg the reinterpretation of studies where rat TCR+ NKR-P1+ cells have been 
regarded as iNKT cells (Chopra et al., 2009; Kattan et al., 2008; Shao et al., 2003). In 
the spleen from F344 rats, iNKT cells are only a 1-2% of the NKR-P1+ T cells and in 
the liver where these cells accumulate they do not constitute more than a 10% of the 
NKR-P1+ T cells. These frequencies are much more reduced in comparison to C57BL/6 
mice, where a 75% in the liver and thymus, and about 30% in the spleen of all NK1.1+ 
T cells are iNKTs (Matsuda et al., 2000). Frequencies of iNKT cells in humans are 
difficult to investigate due to the limited access to human samples other than blood and 
to the variations between individuals (Lee et al., 2002b). Nonetheless, the very low 
numbers of iNKT cells (1%) found among CD161+ T cells in PBMCs and the low 
frequencies of iNKT cells (~0.5%) compared to the high numbers of CD161+ CD3+ 
cells in the liver (40%) suggest, that also in this case, the frequencies observed in the rat 
resemble more those of humans than those of mice (Gumperz et al., 2002; Ishihara et 
al., 1999; Kenna et al., 2003).  
In mice and humans, NK1.1 and CD161 negative iNKT cells are easily detectable 
among cells stained with α-Gal-loaded CD1d oligomers (Benlagha et al., 2000; 
Hammond et al., 2001; Lee et al., 2002b; Matsuda et al., 2000; Pellicci et al., 2002). 
Mouse NK1.1 negative iNKT cells are found in the thymus and in the periphery. NK1.1 
negative NKT cells in the thymus are regarded as immature iNKT cells which 
nonetheless can secrete large amounts of cytokines (Coquet et al., 2008). These NK1.1+ 
and NK1.1- iNKT cells can be further subdivided based on CD4 expression at the cell 
surface. Interestingly, it has been shown as these subsets also differ in the cytokine 
secretion and in the NK receptors expressed at the cell surface: NK1.1- cells do not 
express NKG2D, NKG2A/C/E or Ly49C/I whereas NK1.1+ cells do (Coquet et al., 
2008; McNab et al., 2007). In the rat, most, if not all, iNKT cells expressed NKR-P1 at 
intermediate levels (Fig. 18). Thus, if a mature NKR-P1 negative iNKT cell subset 
exits, this is more reduced in comparison to mice and humans.  
 143 
In mice, cell surface NK1.1 is down modulated in iNKT cells after in vitro and in vivo 
activation (Crowe et al., 2003; Chen et al., 1997; Wilson et al., 2003) but all rat iNKT 
cells harvested after seven days of culture with the potent antigen α-Gal expressed 
considerable amounts of NKR-P1 at the cell surface (Fig. 34). Accordingly, it seems 
that rat iNKT cells do not down modulate NKR-P1 after activation.  
In order to avoid a misinterpretation of the results where the expression of NKR-P1 
receptors was analyzed, it should be considered that the receptors studied in each 
species are different molecules. Indeed, no orthologue of the mouse NKR-P1C (NK1.1) 
has been yet described in the rat (Kveberg et al., 2009). Therefore, the differences which 
are observed between species might result from the analysis of different NKR-P1 
receptors. 
 
4.8.2 CD4 and CD8 distribution  
Based on the expression of CD4 at the cell surface, human iNKT cells can be divided 
into CD4+ and CD4- cells. Most human CD4- cells express CD8αα homodimers at the 
cell surface, but only a small fraction expresses CD8αβ heterodimers (Gadola et al., 
2002; Gumperz et al., 2002; Takahashi et al., 2002). In contrast, whereas also CD4+ and 
CD4- iNKT cells are found in the mouse, the CD4- fraction expresses neither CD8αα 
nor CD8αβ at the cell surface. Due to the reduced iNKT cell numbers observed in mice 
in which all T cells expressed CD8 molecules as a transgene, it was formerly believed 
that expression of CD8 was incompatible with mouse iNKT cells due to CD8-mediated 
negative selection of iNKT cell precursors (Lantz and Bendelac, 1994) until Kronenberg 
and colleagues showed that the expression of CD8αβ at the cell surface does not drive 
negative selection of iNKT cells and is not incompatible with iNKT cell development 
and function. In contrast, the absence of CD8 at the cell surface of mouse iNKT cells is 
probably the result of the expression of the Th-POK transcription factor at the DP stage, 
which is necessary for the development of iNKT cells and which suppresses the 
expression of CD8 (Engel et al., 2010).  
In this study we also analyzed CD4 and CD8β distribution among rat iNKT cells. CD8α 
was not included in the analysis because rat activated T cells and NK cells express CD8 
αα homodimers at the cell surface (Kenny et al., 2004). Most rat iNKT cells are DN or 
CD4. Similar as it has been shown for mouse iNKT cells, CD4 expression levels at the 
cell surface of rat iNKT cells are notably lower in comparison to those of αβ T cells 
(Engel et al., 2010). Interestingly, in the rat, a small proportion of CD8β positive cells 
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was constantly detected. Thus once more, rat iNKT cells appear more similar to human 
than to mouse iNKT cells. 
Expansion of iNKT cells by seven days culture with α-Gal considerably reduced the 
proportion of CD4+ iNKT cells, whereas the percentage of CD8β was more or less the 
same. It remains to be investigated whether this reduction in the frequencies of CD4+ 
iNKT cells in the cultures is due to a selective loss of CD4+ cells or to a down 
modulation of CD4 at the cell surface.  
A lot of efforts have been made to distinguish between iNKT cell subsets with different 
effector functions to better understand how these cells with a semi-invariant TCR 
manage to enhance and also to suppress immune responses (Godfrey et al., 2010). In 
humans, CD4+ iNKT cells secrete both, Th1 and Th2, cytokines whereas CD4- iNKT 
cells mainly produce Th1 cytokines (Gumperz et al., 2002; Lee et al., 2002b). In the 
mouse, although ex vivo analyses have not shown such a clear division between CD4+ 
and CD4- iNKT cells, in an in vivo tumor model, transfer of liver CD4- iNKT cells 
mediated tumor rejection whereas their CD4+ counterparts or iNKT cells from other 
tissues did not (Crowe et al., 2003; Godfrey et al., 2010). Moreover, in a recent study 
where these cells were further subdivided based on the expression of NK1.1 and tissue 
origin and where other cytokines than IL-4 and IFN-γ were measured, major differences 
have been found between the different subsets (Coquet et al., 2008). In this study 
Godfrey and colleagues also identified a new NK1.1- CD4- iNKT cell subset which 
produced large amounts of IL-17. IL-17 production by mouse NK1.1- iNKT cells had 
been previously reported by Leite-de-Moreaes and colleagues (Michel et al., 2008); 
although in this case, in contrast to the subset described by Godfrey et al., the NK1.1- 
iNKT cells did not secrete high amounts of IL-4 or IFN-γ. 
Although not addressed in our study, analysis of cytokine profiles by different rat iNKT 
cells might help to understand the diverse functions of iNKT cells and it also may 
provide an animal model more similar to human than the mouse, beginning with the 
possibility to analyze cytokine secretion by CD8β+ iNKT cells.  
 
4.8.3 BV usage  
In humans and mice, iNKT cells show a marked bias in their BV repertoire. As 
previously mentioned, most human iNKT cells contain BV11 β chains, and among 
mouse iNKT cells the TCRβ chains are principally formed by BV8S2, BV7 or BV2 
comprising β chains (Dellabona et al., 1994; Lantz and Bendelac, 1994). The analysis of 
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F344 iNKT primary cells with the mAb R78, which in this strain binds to BV8S4 
variable segments (Asmuss et al., 1996), revealed that about one-half of iNKT cells 
contained this particular BV. Supporting these data, among culture-expanded iNKT 
cells, about 50% of the cells were also stained with the R78 mAb. 
The BV repertoire of the other half of rat iNKT cells still has to be analyzed in order to 
elucidate whether the rat iNKT cells which do not use BV8S4, use another member of 
the BV8 family, all BV8 members or other BVs than BV8. Nonetheless, in vitro 
experiments carried out by E. Pyz et al. demonstrated that BV8S2-containing invariant 
TCRs also recognize α-Gal presented by CD1d, although less efficiently than invariant 
TCRs with a β chain containing BV8S4 (with a L14V substitution) (Pyz et al., 2006). 
These results indicate that BV8S2 may form the rest or a part of the non-BV8S4 semi-
invariant TCRs. In addition, it is likely that BV16-containing β chains do not form 
semi-invariant rat TCRs because this BV was not detected in cultured iNKT cells.  
As shown by the crystal structures and mutagenesis analyses, the CDR2β of BV8+ 
TCRs contributes to the recognition of α-Gal presented by CD1d (Borg et al., 2007; 
Mallevaey et al., 2009; Pellicci et al., 2009; Pyz et al., 2006; Scott-Browne et al., 2007; 
Wun et al., 2008). Particularly, as demonstrated by E. Pyz et al. (Pyz et al., 2006), the 
CDR2β of BV8S4 is sufficient to enhance the reactivity to α-Gal-CD1d of a cell line 
expressing an AV14S8F invariant α chain. Since rats have many different AV14 gene 
segments, it would be interesting to learn whether the BV repertoire changes depending 
on which AV14 gene segment is comprised in the invariant α chain. Different AV14 
usage by rat iNKT cells is discussed in more detail in the discussion section 4.9.  
Furthermore, it would be also very interesting to analyze the BV repertoire of iNKT 
cells in inbred rat strains which lack a functional BV8S4 (Asmuss et al., 1996), but 
showed a response to α-Gal such as BN rats (Results section 3.7.1).   
 
4.8.4 Activation markers 
After first antigen encounter, MHC-restricted αβ T cells clonally expand and 
differentiate for several days before they can elicit their effector functions. In sharp 
contrast, iNKT cells after first antigen encounter are activated very rapidly and secrete 
large amounts of cytokines within hours. Moreover, iNKT cells have a phenotype that 
resembles activated or memory T cells. Mouse iNKT cells express cell surface 
molecules such of CD25, CD44, CD69 and CD122 (Matsuda et al., 2000; Park et al., 
2000), and although most human iNKT cells in the peripheral blood do not express 
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CD69 or CD44, the majority of them are CD25 and CD45RO positive (Berzins et al., 
2005; Gumperz et al., 2002). In contrast in the liver, human iNKT cells expressed CD69 
but only a minority were CD25 positive (Kenna et al., 2003).    
In addition, a considerable part of the iNKT pool also expresses other receptors typical 
of NK cells (apart from NKRP family members) such as CD94 or NKG2 family 
members or, in the mouse, Ly49 (Gumperz et al., 2002; Uldrich et al., 2005). Analysis 
of these activation markers and receptors typical of natural killer cells is still pending 
for rat iNKT cells.   
 
4.9 AV14 gene segment usage in the rat  
The intriguing expansion of the AV14 gene segments observed in the rat has not been 
described for any other mammal species in which AV14-AJ18 rearrangements have 
been detected (Kashiwase et al., 2003; Sim et al., 2003; Yasuda et al., 2009). As 
previously mentioned, the predicted amino acid sequences of all rat AV14 gene 
segments described up to date are highly similar with the exception of the CDR2α 
region. According to the different sequences of the CDR2α region, rat AV14 gene 
segments have been divided into two types ((Kinebuchi and Matsuura, 2004; Matsuura 
et al., 2000; Pyz et al., 2006) and this study). Interestingly, in the mouse two different 
genes differing exclusively in the CDR2α region have also been found (Koseki et al., 
1991). Nonetheless, most of the commonly used inbred mouse strains have only one of 
these two genes and probably therefore have been considered as alleles (Sim et al., 
2003).  
In contrast to the mode of recognition of peptide-MHC complexes, the CDR2α of semi-
invariant TCRs does not contribute with important interactions to the recognition of α-
Gal-CD1d complexes (Borg et al., 2007; Godfrey et al., 2008; Pellicci et al., 2009). 
Consequently, single substitutions of the residues of this region by alanines did not 
affect the interaction of the semi-invariant TCR with CD1d tetramers loaded with α-Gal 
or with other lipidic antigens (Mallevaey et al., 2009; Scott-Browne et al., 2007). On the 
one hand, the variability in the CDR2α region may reflect the lack of a selecting 
pressure in this region to maintain the semi-invariant TCR-CD1d interaction. In line 
with these findings, the two mouse AV14 alleles showed only minor differences in the 
binding kinetics to α-Gal-CD1d complexes (Sim et al., 2003). Nonetheless, on the other 
hand, it is also possible that the variability of the CDR2α reflects the opposite situation: 
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The need of this region to recognize a wider spectrum of antigens of lipidic and/or 
protein origin.  
We neither have studied the binding capacities of the different rat AV14s to α-Gal-
CD1d oligomers, nor have we analyzed the AV14 repertoire of rat primary cells stained 
with rat α-Gal-loaded CD1d dimers yet. Nonetheless, among iNKT cells expanded in 
culture with α-Gal both AV14 types were observed after RT-PCR and direct 
sequencing, predicting that both AV14 types can participate in the recognition of α-Gal 
presented by CD1d. Moreover, both types of AV14s appeared with similar frequencies 
among AV14-AJ18 rearrangements of primary mature F344 lymphocytes. However, the 
BN genome contains only two type II versus seven type I AV14 gene segments and to 
date only one type II but four type I AV14 gene segments have been cloned from F344 
rats (Fig. 22 and results section 3.6). Thus, the similar frequencies of both AV14 types 
in the periphery – of F344 rats – may indeed reflect the preferential usage of type II 
AV14s by iNKT cells. It would be worthwhile to analyze the usage of these diverse 
AV14 gene segments as well as the variable regions of the β chains which form α-Gal-
CD1d-reactive TCRs in primary single cells, as this will provide information necessary 
to understand the basis of this variability in the rat. Moreover, in humans α-Gal-CD1d-
reactive T cells with other AV and AJ gene segments than AV24 and AJ18 have been 
described (Gadola et al., 2002; Gadola et al., 2006a), therefore it also would be 
interesting to investigate whether such cells are also present among rat α-Gal-CD1d-
reactive T cells.  
In the first study where multiple AV14 genes were found in the rat, a tissue-specific 
distribution of the two different types was also proposed (Matsuura et al., 2000). After 
the analysis of several hundreds of clones pooled from three F344 rats, a preferential 
usage of type II AV14 gene segments was observed among invariant TCRα chains in 
the spleen and a bias in the usage of type I AV14 TCRs was detected in the thymus. In 
contrast, in the liver type II AV14 gene segments were more frequently found among 
invariant TCRα chains and in the bone marrow, a similar proportion of AV14 of either 
type was found to be rearranged with AJ18 (Matsuura et al., 2000). Although we also 
analyzed some cloned AV14-containing TCRα chains from F344 rats, in order to 
address the AV14 usage of invariant and any AV14-containing TCR in thymus, spleen 
and liver of F344 and LEW rats, we directly sequenced the pool of AV14-AJ18 
rearrangements and AV14-comprising TCRα chains after amplification by RT-PCR. 
After having analyzed three animals of each inbred strain, in F344 we did not found a 
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tissue-specific usage of these two different AV14 types among AV14-containing or 
invariant TCRs, except in the thymus. Nonetheless, when the animals were analyzed 
individually, occasionally one AV14 type was more frequently found than the other. 
Therefore, the results obtained by Matsuura and colleagues do not disagree with our 
data.  
In LEW rats, as previously pointed out (Results section 3.5.2), AV14-J18 
rearrangements were hardly detectable and as a consequence, analysis of AV14 gene 
segment usage was only possible among non-invariant AV14α chains. Interestingly, in 
contrast to F344 rats, where both AV14 types were detected with similar frequencies, in 
LEW, type I AV14 gene segments were preferentially used. Although the sequences of 
individual AV14 gene segments have not been determined yet in LEW rats, Southern 
blot analysis showed a pattern similar to that of BN rats (Matsuura et al., 2000), and 
despite at low frequencies, type II AV14 segments were also detected in LEW-derived 
RT-PCR sequences. Assuming, as discussed above, a bias towards type II AV14 
segments among iNKT cells, the reduced usage of type II AV14 in LEW rats might be 
related to the low/absent iNKT cell frequencies in this inbred strain.  
In this study only six cloned AV14-containing TCRα chains from F344 rats were 
analyzed (Results section 3.6.1). Nonetheless among these, a previously unidentified 
AV14 gene segment was detected. This AV14 gene segment was designed as AV14S5F 
since the V-exon is identical to AV14S5 of BN rats. A premature stop codon was 
encoded in the cloned TCRα chain containing this novel AV14 gene. Since the TCRα 
chain does not undergo allelic exclusion, it is possible that this AV14S5 α chain was 
isolated from a T cell expressing another functional TCRα chain. Since no AV14S5F or 
AV14S8F gene segments have been yet found to be rearranged with AJ18 in single 
TCRα chains, it remains to be demonstrated whether these two segments can form 
invariant α chains in F344 rats.   
 
4.10 α-Gal responsiveness in the rat 
In this study, iNKT cell activation of five different inbred rat strains was analyzed by 
measuring cytokine release after ex vivo α-Gal stimulation of primary cells. We 
measured the secretion of IL-4 and IFN-γ into the supernatant after 24-hour stimulation 
by ELISA and of IL-4 by ELISPOT. Anti-CD1d mAbs were added to the cultures to 
demonstrate the CD1d restriction of such response. Nearly all isolated primary cells 
used in the stimulations express CD1d at the cell surface (Fig. 6) thus no supplementary 
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antigen presenting cells were included in the cultures. Despite that internalization and 
lysosomal processing is not necessary for α-Gal presentation (Prigozy et al., 2001), it 
should be considered that some differences in the cytokine production between rat 
inbred strains and/or tissues may result from variations in the number and efficiency of 
cells presenting α-Gal. Often, especially in intrahepatic lymphocytes cultures, very high 
amounts of IFN-γ were released into the supernatants even in cultures where only 
culture media was added. In contrast, IL-4 release was only observed when cells were 
stimulated with α-Gal or ConA (with the exception of PVG IHLs). The types and 
numbers of cells which secret IL-4 within a few hours after activation are much more 
reduced compared to the cells which are able to secrete IFN-γ. Indeed, NK cells which 
were very abundant among the cultured cells (5 to 50%) respond very fast to IFN-γ 
released by iNKT cells by secreting more IFN-γ (Carnaud et al., 1999). In contrast, 
illustrating the more restricted sources of IL-4, the IL-4 levels reached after α-Gal 
stimulation were very similar to those reached after ConA stimulation. Thus IL-4 
secretion reflects better than IFN-γ the presence of iNKT cells.  
Among the inbred rat strains studied, a clear dose-dependent CD1d-restricted response 
to α-Gal was only observed among F344 and BN rats. In line with the homing of iNKT 
cells to the liver (Bendelac et al., 2007) among these inbred rat strains the amounts of 
cytokines released by IHLs were higher than by splenocytes. In contrast, no α-Gal-
dependent cytokine release was measured in PVG- and LEW-derived cultures. This lack 
of α-Gal-dependent cytokine secretion is in line with the failure of iNKT cell expansion 
in LEW IHLs cultures with α-Gal (Results section 3.7.4). The absence of α-Gal 
responsiveness in PVG rats was surprising because NKR-P1+ T cell clones which 
expressed BV8S2, were either DN or CD4+ and secreted various cytokines had been 
isolated from PVG spleens (Knudsen et al., 1997). Intriguingly, ELISA results indicated 
that DA splenocytes and IHLs also contained cells which secrete IL-4 after α-Gal 
stimulation in a dose-dependent and CD1d-restricted manner but ELISPOT analyses 
showed an unspecific IL-4 production. These different outcomes may be explained by 
the differences between these two methodologies: In ELISPOT analyses the IL-4 
secreted is continuously “captured” through the 24-hours of the culture whereas ELISA 
detect only the IL-4 contained in the supernatant at one specific time point, which in 
this case was after 24-hours of incubation.  
Thymocytes derived from any of the studied inbred rat strains did not produced IL-4 in 
response to α-Gal stimulation. In part this was not surprising because we were not able 
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to visualize thymic iNKT cells with α-Gal-loaded CD1d-IgG dimers in F344 rats. After 
ConA stimulation some IL-4 production was observed, nonetheless it remains to be 
demonstrated whether it is released by iNKT cells. Importantly, it has been shown as α-
Gal presented by dendritic cells is not the best stimulatory agent to induce cytokine 
production by thymic iNKT cells in the mouse (Coquet et al., 2008). Therefore, and 
since ConA may also not be sufficient to activate iNKT cells present in the thymus, 
cytokine secretion by rat thymocytes should be reinvestigated with stimulation 
protocols similar to those used in mice e.g. anti-CD3 and anti-CD28 stimulation 
(Coquet et al., 2008).  
iNKT cell frequencies using rat CD1d-IgG dimers were studied in only two of these 
five inbred rat strains: F344 and LEW (a more detailed discussion about iNKT cell 
frequencies can be found in the discussion section 4.8). These analyses demonstrated 
that the numbers of iNKT cells correlate very well with the observed α-Gal response. 
The analysis of the other inbred rat strains is still pending but it will surely help to 
clarify unresolved questions such as the results observed in DA cultures.  
As previously pointed out, iNKT cell frequencies are under genetic control (Esteban et 
al., 2003; Lee et al., 2002b; Rocha-Campos et al., 2006). Based on the α-Gal response 
pattern of these five inbred rat strains, at least we can say that in the rat iNKT cell 
frequencies neither correlate with Tcra nor with Tcrb haplotypes. Moreover, the CD1d 
allelism described in this study most likely does not affect iNKT cell numbers since BN 
rats responded to α-Gal and CD1d protein levels at the cell surface of thymocytes were 
the same regardless of the CD1d-allelic form. 
The analysis of the F1 generation of F344 and LEW rats indicated a co-dominant effect 
of the genes controlling iNKT cell frequencies. Studies with congenic NOD mice were 
crucial to determine the role SLAM proteins in the development of iNKT cells (Jordan 
et al., 2007). Hence, further analysis of F344/LEW F2 generations and congenic 
animals selected for elevated iNKT cell numbers may reveal other genes important for 
iNKT cell biology.  
iNKT cell frequencies and α-Gal response do not only correlate among the studied 
inbred rat strains but also between mice and rats. Hence, cytokine release by mouse 
primary cells after α-Gal stimulation was much more elevated that cytokine release by 
F344 rats. In the mouse, a role for iNKT cells in controlling autoimmune diseases and 
infection has been reported. Nonetheless, depending on the experimental model, iNKT 
cells can exert opposite functions (Godfrey and Kronenberg, 2004). For example, they 
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can control, aggravate or have no effect in experimental autoimmune encephalomyelitis 
(EAE) conducted in mice (Furlan et al., 2003; Jahng et al., 2001; Miyamoto et al., 2001; 
Pal et al., 2001; Singh et al., 2001). Among the inbred rat strains studied here, the 
strains which are commonly used in organ specific autoimmune disease models seem to 
have no or very few iNKT cells (LEW, PVG and DA). In contrast, F344 rats, which 
showed the most elevated response to α-Gal and where relatively high numbers of iNKT 
cells were detected, is a strain resistant to the induction of EAE (Sun et al., 1999). 
Nonetheless, this is a mere correlation between α-Gal responsiveness (in LEW and F344 
rats also iNKT cell numbers) and autoimmune disease models established in these 
strains. Obviously, adequate experiments should be carried out to investigate whether 
rat iNKT cells play a role in such situations. Bortell and colleagues found that α-Gal had 
no therapeutic effect in virus-inducible models of Type 1 diabetes carried out in BBDR 
and LEW.1WR1 rats (Chopra et al., 2009). The authors addressed IL-4 and IFN-γ 
cytokine release after 48 and 72 hours of α-Gal ex vivo stimulation only in splenoctytes, 
but they neither analyzed whether the observed response was CD1d-restricted nor 
stained iNKT cells appropriately (Chopra et al., 2009). Thus the presence of iNKT cells 
in these strains should be investigated in order to interpret the failure of α-Gal to alter 
the diabetes outcome in these experiments.     
Several similarities between rat and human iNKT cells which are not conserved in the 
mouse have been previously pointed out (Discussion section 4.8). In a similar way rat 
iNKT cells derived from F344 intrahepatic lymphocytes could be easily expanded after 
7 days in culture where only α-Gal, but not additional cytokines, was added similar as it 
has been described with human PBMC cultures. In contrast, the expansion of mouse 
iNKT cells in vitro is complicated and needs various cytokines apart from the addition 
of antigen presenting cells (Watarai et al., 2008). Therefore, the culture and expansion 
of rat iNKT cells is not only very important for the analysis of rat iNKT cell-specific 
features (as previously discussed) but also offers an animal model very similar to 
humans. Thus these cultures provide the possibility to simulate therapies in the rat 
which are currently being investigated such as the use of in vitro expanded human 
iNKT cells to treat various types of cancer (Kunii et al., 2009).  
 
4.11 NKR-P1+ T cells 
In this study we have demonstrated that in the rat the majority of NKR-P1+ T cells are 
not stained by α-Gal-loaded rat CD1d oligomers. Indeed, in LEW rats where iNKT cells 
 152 
were hardly detected if at all, the numbers of NKR-P1+ T cells observed in the spleen 
and in the liver were very similar to those of F344 rats (Fig. 35 and 36).  
The expression of NKR-P1 receptors by non α-Gal-CD1d-reactive T cells has 
extensively been reported in human and mice (Godfrey et al., 2004). These cells can be: 
i) CD1d-restricted T cells bearing TCRα chains with gene segments different than 
AV14 (AV24 in humans) and AJ18 which recognize glycolipid antigens other than α-
Gal (type II NKT cells) ii) a distinct T cell subset with a different invariant TCR 
restricted to another MHC-I like molecule: MR1 (Kawachi et al., 2006), and iii) also 
“conventional” MHC-restricted cells (Iwabuchi et al., 1998; Legendre et al., 1999; 
Slifka et al., 2000). Thus it will be interesting to learn which is the restriction element or 
elements of the T cells expressing NKR-P1 in the rat which are not reactive to α-Gal 
presented by CD1d. Among all the inbred rat strains analyzed in this study we observed 
very similar frequencies of NKR-P1-expressing T cells in the spleen and the liver, with 
the only exception of DA where the percentage of NKR-P1+ T cells expressing was 
reduced.  
The expression of CD4 and CD8 coreceptors by NKR-P1+ T cells differed form that of 
NKR-P1- T cells; in all the inbred rat strains the majority of these cells expressed CD8β, 
even in BN inbred rats, where most of the NKR-P1- T cells are CD4 positive cells. 
Moreover the proportion of DN cells among NKR-P1+ T cells was also higher 
compared to NKR-P1- T cells. This different phenotype may reflect a distinct T cell 
lineage.     
BV8 and BV16 usage by these NKR-P1 positive and negative T cell subsets was also 
addressed. Only small differences in the usage of these BV segments between the NKR-
P1+ and NKR-P1- T cells in the spleen and in the liver of all the inbred rat strains 
analyzed, except in the liver of F344 NKR-P1A+ T cells where, as discussed in the 
results section 3.8.3, the frequency of BV8S4+ T cells was increased. These results are 
in agreement with previous reports where these cells also have been analyzed 
(Badovinac et al., 1998; Brissette-Storkus et al., 1994; Knudsen et al., 1997; Matsuura 
et al., 2000; Pyz et al., 2006). Nonetheless, apart from this phenotypic characterization 
and from some additional in vitro analyses where a cytolytic activity was only observed 
after IL-2-mediated activation (Brissette-Storkus et al., 1994), little is know about the 
functions of these cells in vivo. Evidence for a role of rat NKR-P1+ T cells in promoting 
allograft acceptance has been provided in only one study by Kiyomoto and colleagues. 
In this study, liver irradiated allografts survived for a longer period when they were 
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reconstituted with total or Ig-depleted donor spleen cells than when they were 
reconstituted with NKR-P1 or TCR-depleted spleen cells (Kiyomoto et al., 2005). Other 
studies, without taking into account the misinterpretation of NKR-P1+ T cells being 
regarded as iNKT cells, have shown variations of NKR-P1+ T cell frequencies under 
different pathological conditions (Altomonte et al., 2009; Iwakoshi et al., 1999; Kattan 
et al., 2008; Shao et al., 2003). Nonetheless, none of these studies directly demonstrated 
the implication of these cells in the different pathological conditions. Thus in order to 
elucidate the functions and origin of these cells further analysis are required, beginning 
with the identification of the restriction element (or elements) of these cells. 
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ABBREVIATIONS 
Ab     Antibody 
α-Gal     α-Galactosylceramide 
APC    Antigen presenting cell 
APCy    Allophycocyanin 
β2m      β2-microglobulin 
β-Gal    β-Galactosylceramide 
BSA     Bovine serum albumin 
BSS     Balanced salt solution 
CD     Cluster of differentiation 
cDNA     Complementary DNA 
CDR     Complementary determining region 
ConA    Concanavalin A 
Ct    Cycle threshold 
cTECs    Cortical thymic epithelial cells  
DαM-PE   PE labeled donkey anti-mouse IgG F(ab’)2 fragment 
DαM-FITC    FITC labeled donkey anti-mouse IgG F(ab’)2 fragment 
ddNTP    Dideoxynucleotide 
DMSO    Dimethyl sulfoxide 
DN     Double negative 
DNA     Deoxyribonucleic acid 
dNTP    Deoxynucleotide    
DP     Double positive 
EAE    Experimental autoimmune encephalomyelitis  
FACS     Fluorescence activated cell scan 
FCS     Fetal calf serum 
FITC    Fluorescein Isothiocyanate 
FSC     Forward scatter 
GBN     GenBank accession number 
HRP    Horseradish peroxidase  
IFN     Interferon 
Ig     Immunoglobulin 
IHLs    Intrahepatic lymphocytes 
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IL     Interleukin 
kDa     Kilo dalton 
M     Molar 
mAb    Monoclonal antibody 
MFI    Mean fluorescence intensity  
MHC     Major histocompatibility complex 
min    Minutes  
mRNA    Messenger RNA 
NK cell   Natural killer cell 
PBCs    Peripheral blood cells 
PBS     Phosphate buffered saline 
PBMCs   Peripheral blood mononuclear cells 
PCR     Polymerase chain reaction 
PE     Phycoerythrin 
rcf    Relative centrifugal force 
RNA     Ribonucleic acid 
rpm    Revolutions per minute 
RT     Reverse transcriptase 
SA    Streptavidin 
SAP    SLAM adaptor protein 
SD    Standard deviation 
SLAM    Signaling lymphocytic activation molecules 
SSC     Side scatter 
TCR     T cell receptor 
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